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The synergistic interaction between CD20 monoclonal antibodies and 
Histone Deacetylase inhibitors in B Cell Non Hodgkin’s Lymphoma 
By David Francis Luke Nolan 
Recent improvements in molecular sub typing of Non Hodgkin’s lymphomas 
have resulted in targeted therapies becoming incorporated into treatment 
paradigms.  The anti-CD20 monoclonal antibody, Rituximab, has resulted in 
dramatic improvements in survival for patients with B cell Non Hodgkin’s 
lymphoma.  Histone deacetylase inhibitors are a novel class of anti cancer 
agents targeting epigenetic regulation.   
This thesis addresses the interaction between histone deacetylase inhibitors 
and anti-CD20 monoclonal antibodies, including Rituximab, both in vitro and 
in vivo.  The initial approach identified synergistic induction of apoptosis in a 
number of B cell lines.  In a Ramos xenograft model, combination treatment 
with suberoylanilide hydroxamic acid (SAHA) and Rituximab reduced tumour 
growth compared to either agent alone, without discernable toxicity.  This 
effect appears specific to CD20 since monoclonal antibodies directed to other 
surface molecules (CD32b, CD22, CD37) did not exhibit cooperative effect.  
Analysis of apoptotic pathways demonstrated that PARP cleavage and 
caspase processing is significantly higher in cells receiving both treatments.  
Co-treatment of Ramos cells with the pan caspase inhibitor QVD-OPH 
abolished the synergy observed with CD20 monoclonal antibodies, 
suggesting that caspase processing is necessary for synergy.  Treatment of 
Ramos cells stably transfected to overexpress Bcl-2 resulted in loss of 
synergy with Rituximab, but not with the type II CD20 mAb B1 
(Tositumomab). 
 
Gene expression array analysis of Ramos cells was performed. Geneset 
enrichment analysis identified significant regulation of NFқB target genes in 
some genesets (Rituximab Vs control, p<0.001) with a number associated 
with apoptosis and B cell activation (Bcl2A1, LTA, CD69) which were 
confirmed using RT-Q-PCR.   
 
This novel combination elicits the induction of apoptosis in vitro, potentially 
through regulation of Bcl-2 family proteins and should be tested in a phase 
I/II clinical trial.    
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1 Introduction 
 
1.1  Non Hodgkin’s lymphoma 
 
Non Hodgkin’s lymphoma (NHL) is a major cause of morbidity and mortality 
with an estimated 66,000 new cases in the US in 2008 [1] and 10,310 cases 
in the UK in 2005.  The incidence is still rising, partly due to its association 
with human immunodeficiency virus infection (HIV), but mainly due to an 
ageing population.  Classification of this disease is evolving as expression 
profiling facilitates a greater understanding of the molecular events 
responsible.  In the 1990’s the Revised European American Lymphoma 
(REAL) classification system superseded prior methods and was based on 
morphological, immunological and clinical characteristics. Evolution of this 
system has resulted in the most recent WHO classification system which was 
published in 2008 and this incorporates molecular profiling of diffuse large B 
cell NHL for the first time [Table 1-1].  B cell NHL makes up approximately 
80% of all cases with diffuse large B cell NHL responsible for between 34% 
and 44% of all cases, closely followed by follicular NHL in published series 
[2, 3].  It is within these two commonest subsets that recent therapeutic 
advances, especially the widespread use of the CD20 monoclonal antibody 
Rituximab, have resulted in improvements in survival [4, 5].  In parallel with 
these improvements, gene expression profiling has demonstrated that within 
currently classified subtypes there is further heterogeneity which has 
significant predictive value for both prognosis and response to targeted 
therapies.     
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B-cell neoplasms 
    Precursor B-cell neoplasm 
        Precursor B-lymphoblastic leukemia/lymphoma (precursor B-cell acute 
lymphoblastic leukemia) 
    Mature (peripheral) B-cell neoplasms 
        B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 
        B-cell prolymphocytic leukemia 
        Lymphoplasmacytic lymphoma 
        Splenic marginal zone B-cell lymphoma (with or without villous 
lymphocytes) 
        Hairy cell leukaemia 
        Plasma cell myeloma/plasmacytoma 
        Extranodal marginal zone B-cell lymphoma (with or without monocytoid B 
cells) 
        Nodal marginal zone B-cell lymphoma (with or without monocytoid B 
cells) 
        Follicular lymphoma 
        Mantle cell lymphoma 
        Diffuse large B-cell lymphoma 
        Burkitt lymphoma/Burkitt cell leukaemia 
T-cell and NK-cell neoplasms 
    Precursor T-cell neoplasm 
        Precursor T-lymphoblastic lymphoma/leukemia (precursor T-cell acute 
lymphoblastic leukemia) 
    Mature (peripheral) T/NK-cell neoplasms 
        T-cell prolymphocytic leukaemia 
        T-cell granular lymphocytic leukaemia 
        Aggressive NK-cell leukaemia 
        Adult T-cell lymphoma/leukemia (HTLV1+) 
        Extranodal NK/T-cell lymphoma, nasal type 
        Enteropathy-type T-cell lymphoma 
        Hepatosplenic gamma delta T-cell lymphoma 
        Subcutaneous panniculitis-like T-cell lymphoma 
        Mycosis fungoides/Sezary syndrome 
        Anaplastic large cell lymphoma, T/null cell, primary cutaneous type 
        Peripheral T-cell lymphoma, not otherwise characterized 
        Angioimmunoblastic T-cell lymphoma 
        Anaplastic large cell lymphoma, T/null cell, primary systemic type  
   
Table 1-1 WHO classification of Non Hodgkin’s Lymphoma:    
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1.2  B cell development and lymphomagenesis 
 
It is widely acknowledged that normal lymphocyte differentiation exposes 
developing cells to a multitude of potentially oncogenic events [Figure 1-1].  
Immunophenotyping, gene expression profiling and genomic analysis are 
now starting to demonstrate how these events link lymphoid malignancies to 
their underlying cell of origin.  B cell development occurs in two stages, the 
earliest committed B cell progenitors are pro B cells, these express CD10, 
CD34 and CD19.  Cells at this stage have commenced Ig heavy chain 
recombination. This is the first potentially oncogenic hurdle in normal B cell 
development and is critical to developing the necessary B cell repertoire for 
effective antibody specificity.  To achieve this diversity pro B cells undergo 
double strand DNA breaks and rearrangement of the V(D)J genes.  This 
event is initiated and controlled by recombination activating genes (RAG1, 
RAG2) [6].  Successful recombination results in μ heavy chain synthesis and 
association with two surrogate light chain proteins Vpre-B and λ5 [7], surface 
expression of this ‘pre B cell receptor (BCR)’ is a defining feature of the pre B 
cell stage.  The next critical transition is from pre B cell to mature B cell and 
is the result of Ig light chain rearrangement by similar mechanisms.  It is 
worth noting that at both these transitional stages approximately two thirds of 
cells develop non productive rearrangements and are eliminated by 
apoptosis.  Secondary B cell development occurs in the spleen and results in 
negative selection of B cells with self antigen again by apoptosis and positive 
selection of a small subset (1-2%) by antigen.  This process results in naïve 
B cells which are able to circulate and occupy lymphoid tissue.  In response 
to antigen, naïve cells can respond in a number of different ways, regulated 
by the micro environment in which the encounter occurs.  T independent 
responses have a low threshold for activation and occur as a result of 
polymeric antigens and usually occur in the splenic white pulp (marginal 
zone).  This results in the rapid production of low affinity IgM and IgG3 
antibodies.      
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Figure 1-1 Normal B cell development and lymphoma counterparts: 
 
Stages of normal B cell development are shown with counterpart B cell 
malignancies depicted.  Adapted from figure by Kuppers et al [8].    
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A more specific response occurs when antigen is presented to B cells by T 
cells in the germinal centre (GC).  This results in B cell activation with 
differentiation of some cells into plasma cells secreting low affinity antibody, 
with other cells undergoing affinity maturation due to repeated antigen 
exposure resulting in high specificity plasma cells and memory B cells. 
At all stages of B cell development there is selection pressure with only the 
cells that express a functional BCR selected for survival.  This mechanism 
depends on functional signalling through the BCR and in particular activation 
of NFқB to induce the expression of anti apoptotic Bcl-2 family proteins.   
It is becoming increasingly apparent that events occurring at these key 
stages in B cell development result in inappropriate survival of cells through 
evasion of this apoptotic elimination. 
V(D)J recombination requires double strand DNA breaks and can result in 
chromosomal translocations.  The t(14:18) seen in Follicular lymphoma (FL), 
is a defining example of this.  This translocation results in fusion of the Bcl-2 
gene to the immunoglobulin heavy chain locus.  This results in constitutive 
expression of Bcl-2 and this discovery was a key event in describing the 
function of this anti apoptotic protein [9].  A similar event is also seen in 
mantle cell lymphoma (MCL) where t(11:14) results in overexpression of 
cyclin D1 [10].  Interestingly these early oncogenic events do not arrest B cell 
differentiation. It has been well described that FL frequently displays GC 
features suggesting that the cell of origin has been exposed to antigen in the 
GC [8].   
Potentially as important are oncogenic events occurring in the germinal 
centre during affinity maturation.  As discussed earlier this process is 
involved in developing and potentiating antibody specificity following antigen 
presentation by T cells in the GC and is facilitated by two mechanisms;   
Class switch recombination (CSR) and somatic hypermutation (SHM).  CSR 
is implicated in the t(8:14) seen in sporadic Burkitt’s lymphoma (BL) which 
results in overexpression of the c-MYC oncoprotein [11]  and may also 
account for Bcl6 overexpression seen in GC NHL [12, 13].  These events 
again act to render cells independent of microenvironment growth signals 
and demonstrate how avoidance of apoptosis is fundamental to 
lymphomagenesis.        
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The advent of molecular profiling has offered a new approach for 
understanding the sequelae of these oncogenic events and specifically how 
they act to overcome the normal homeostatic mechanisms and drive 
lymphomagenesis.  In 2000 Alizadeh et al published results from DNA 
microarray analysis of 96 normal and malignant lymphocytes [14].  They 
observed clustering of samples from common lineages.  Chronic lymphocytic 
leukaemia (CLL) and FL samples clustered closely with normal B cells, 
where as diffuse large B cell lymphoma (DLBCL) clustered separately and 
were characterised by expression of genes associated with a high 
proliferative index.  When DLBCL cases were reclustered using only genes 
that defined the germinal centre B cells, two distinct groups appeared; these 
groups were defined as germinal centre B-like DLBCL (GC) and activated B-
like DLBCL (ABC).  Using the expression profiling data from these cases they 
were able to demonstrate differences in prognosis following multimodality 
treatment.  These data were reinforced by another study using a 100 gene 
signature to divide a larger case series between ABC and GC subtypes [15].  
Gene expression subtyping was again able to predict outcome following 
anthracycline based chemotherapy. 
More recent analysis has demonstrated that these subtypes harbour novel 
oncogenic events, for example an amplicon on chromosome 19 was seen in 
26% of ABC but in only 3% of GC subtypes.  Knockdown of a highly up-
regulated gene in this amplicon (SPIB) was toxic to ABC but not GC 
subtypes [16].  One of the other most consistant ABC characteristics is 
constitutive NFқB activation, resulting in activation of known NFқB target 
genes [17].  Use of a library of short hairpin RNA (shRNA) constructs 
representing 2,500 genes, demonstrated synthetic lethality of NFқB target 
genes and identified CARD11 as a key upstream target [18].  Professor 
Staudt’s group has gone on to demonstrate activating mutations in the coiled 
coil domain of CARD11 of ABC subtype cell lines, which when inhibited result 
in lethality to these cells [19]. 
Despite a wide range of upstream events all the mutations and translocations 
discussed act to enhance cell growth; inhibit apoptosis; or block 
differentiation.  For example in the germinal centre the NFқB transcription 
factor family are repressed leading to low expression of their target genes    
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potentially resulting in the negative selection observed [14].  Physiological 
activation of this pathway leads to upregulation of Bcl XL, Bcl2A1 and Bcl-2 
[20-22] resulting in positive selection of appropriate cells.  Many NHL 
subtypes have been shown to activate the NFқB pathway at some point 
during lymphomagenesis and as described above ABC DLBCLs are critically 
dependent on this pathway [17].  As our knowledge of the critical oncogeneic 
events increases, it is becoming possible to devise strategies for specifically 
targeting the pathways concerned. 
1.3  Apoptotic pathway and lymphomagenesis 
Evasion of apoptosis is one of the key features required for maintaining the 
malignant phenotype and one of the hallmarks of cancer [23].  Broadly 
speaking apoptosis is mediated by two distinct pathways with a common 
terminal signalling cascade involving proteolytic cleavage of a family of 
cysteine proteases (caspases) resulting in death [Figure 1-2].  This family is 
devided into two types: initiator (apical) caspases (2,8,9) and effector 
(executioner) caspases (3, 6, 7) 
The intrinsic pathway is initiated by hypoxia, radiation, cytotoxics and a whole 
range of genotoxic stimuli.  These stimuli act to alter the balance of Bcl-2 
family proteins.  Pro apoptotic members induce mitochondrial membrane 
depolarization resulting in release of cytochrome c (Cc) [24].  Cc binds to 
apoptotic protease-activating factor-1 (APAF-1) initiating formation of the 
apoptosome.  The apoptosome recruits procaspase 9, resulting in cleavage 
into the active caspase 9 (35, 10 kDa subunits) [25].  Once activated, 
caspase 9 recruits the effector caspase,  ‘caspase 3’, which is cleaved at 
Asp-28/Ser-29 and Asp-175/Ser-176, generating 17 and 12 kDa subunits 
[26].  Activated caspase 3 can translocate to the nucleus and initiates 
proteolytic cleavage of many key molecules, including poly(ADP-ribose) 
polymerase (PARP) [27]. 
The extrinsic pathway in contrast can act independently of the mitochondria.  
Activation occurs through cell membrane death receptors (e.g. CD95/Fas, 
DR4, DR5) which bind specific pro apoptotic ligands (eg. FasL, Apo2/TRAIL) 
[28].   The intracellular domains of these receptors are known as the 'death 
domains' and bind to the adaptor protein Fas-associated death domain    
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(FADD).  This leads to the assembly of the death-inducing signalling complex 
(DISC) [29].  Recruitment and assembly of initiator caspases 8 and 10, 
allows processing of these molecules with release of active enzyme 
molecules and activation of caspase 3.  It has been shown that in some cells 
(type I cells) active caspase 8 can activate the effector caspases directly [30], 
however in other cells (type II cells) the proapoptotic signal requires a 
mitochondrial amplification loop via cleavage of Bid, Bax/Bak to achieve full 
activation of casapse 3 [31].   
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Figure 1-2 Apoptotic pathways: 
Schematic representation of caspase dependent apoptotic pathways.  Pro 
apoptotic Bcl-2 family members induce Cytochrome C release from the 
mitochondria.  This together with (APAF-1) apoptotic protease-activating 
factor-1 and pro caspase 9 initiates Apoptosome formation.  Caspase 9 
cleavage and activation occurs resulting in activation of the effector caspase 
(caspase 3).  The extrinsic pathway is activated by ligation of death 
receptors.  This induces formation of a death inducing signalling complex 
(DISC) with the adaptor protein Fas-associated death domain (FADD) and 
pro caspase 8 and 10.  Proteolysis releases the active caspase components 
once more initiating effector caspase activation.  Adapted in part [32].  
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Both these pathways are subject to regulation by transcriptional and post 
transcriptional mechanisms.   
One of the key regulatory steps of the intrinsic pathway occurs at the 
mitochondrial membrane where a balance between pro and anti- apoptotic 
Bcl-2 family proteins decide the fate of a cell.  The Bcl-2 family of proteins 
share at least one of four conserved Bcl-2 homology domains (BH1-4).  Anti 
apoptotic family members (Bcl-2, Mcl-1, Bcl2A1, Bcl-XL, Bcl-W) contain BH1-
4. Pro apoptotic members contain only the BH3 domain and are subdivided 
into: effector proteins (Bak, Bax); direct activator proteins (Bid, Bim) and 
derepressor/sensitizer proteins (BAD, BIK, BMF, bNIP3, HRK, Noxa and 
PUMA).  BH1 and BH2 appear to be necessary for anti apoptotic members to 
dimerise with Bax and inhibit apoptosis [33], where as BH3 is required for 
Bax and Bak to dimerise with Bcl-2 and Bcl-XL and initiate apoptosis [34].  
Their basic structure consists of a hydrophobic helical region surrounded by 
amphipathic helices; most contain a membrane binding region and are 
predominantly bound to the mitochondrial outer membrane.  A number of 
investigators have shown that the membrane binding region is crucial to the 
function of these peptides [35, 36], which is logical considering that they act 
by inhibiting or initiating mitochondrial membrane depolarisation and 
cytochrome C release.  Two models for activation have been proposed.  The 
direct activation model proposes that only the activators (Bid, Bim) can 
activate the effectors (Bax, Bak), a second level of regulation involves the 
sensitisers (BAD, BIK, BMF, bNIP3, HRK, Noxa and PUMA) which can 
displace the effectors from anti apoptotic (Bcl-2, Mcl-1, Bcl2A1, Bcl-XL, Bcl-
W) proteins [37, 38].  The indirect model suggests that all BH3 only members 
can bind anti apoptotic molecules, resulting in release of effectors [38-40].  
A further level of control is exerted down stream of the mitochonria.  The 
inhibitors of apoptosis (IAPs) are a family of antiapoptotic proteins which act 
by binding the effector caspases and inhibiting their activation.  In response 
to proapoptotic signals, release of second mitochondria-derived activator of 
caspases (SMAC/DIABLO) results in inhibition of IAPs, promoting apoptosis.  
As well as the dynamic balance between pro and antiapoptotic family 
members, these proteins are also subject to post translational modifications.  
Chang et al performed mutational analysis of the loop domains of Bcl-2 and    
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Bcl-XL, they observed that loss of serine/threonine phosphorylation sites 
enhanced the antiapoptotic function of these proteins without affecting their 
dimerisation [41].  It appears that pro apoptotic Bad is also subject to 
phosphorylation on serine residues, interestingly this sequesters it in the 
cytoplasm inhibiting its pro apoptotic function [42]. 
   
As already discussed, evasion of apoptosis is an important mechanism in 
lymphomagenesis.  The t(14:18) translocation occurs in 85% of follicular 
lymphomas and approximately 20% of DLBCL, and is the most common 
oncogenic event observed in lymphoid malignancies [43, 44].  This 
translocation results in over expression of Bcl-2-Ig chimeric RNA.  In 
transgenic mice a polyclonal follicular lymphoproliferation occurs, which 
progresses to DLBCL, mimicking the effect observed in humans [45].  It 
appears that this event occurs during V(D)J recombination, early in B cell 
development and infers an inappropriate survival advantage following 
exposure to antigen in the germinal centre.  Mutations of pro apoptotic family 
members have also been documented, a Japanese group performed array 
CGH in 29 Mantle lymphoma cases and observed homozygous deletions 
within the Bim gene in 17% of cases [46].  More recent data in Eμ-myc mice 
has shown that loss of noxa and puma together promotes lymphomagnesis 
[47]. 
These wealth of data demonstrate how our understanding of the structure 
and function of these key survival molecules is rapidly advancing and how it 
has heralded the advent of molecularly targeted therapies    
1.4  NFқB pathway and lymphomagenesis   
One of the key pathways for regulation of apoptosis in developing B cells is 
the NFқB pathway.  This transcription factor (TF) family is made up of 5 
mammalian proteins p65 (RelA), RelB, c-Rel, p50/p105 (NFқB1), p52/p100 
(NFқB2) [48].  These proteins appear to be expressed in a wide range of cell 
types but were first described in B cells by nature of their ability to induce 
immunoglobulin kappa light chain transcription [49].  The importance of these 
transcription factors is reinforced by the fact that they are evolutionarily    
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conserved [50].  They act to orchestrate transcriptional response to a wide 
range of inflammatory signals. 
All members of this TF family are characterised by a 300 amino acid Rel-
homology domain which mediates nuclear localisation, dimerisation and DNA 
binding.  NFқB proteins are activated by a wide range of signals via the 
‘canonical’ and ‘alternative’ pathways, and different dimerisation partnering 
partially accounts for the diversity of gene expression observed [Figure 1-3].   
Inactive NFқB complexes are maintained in the cytoplasm through interaction 
with the inhibitor of қB (IқB) proteins.  This family consists of IқBα, IқBβ, IқBε, 
Bcl-3, p100 and p105 and all contain ankyrin-like repeats, their role is 
prevention of NFқB nuclear localisation and hence interaction with DNA.  
Activation of the canonical pathway occurs through the IқB kinase (IKK) 
complex, which leads to phosphorylation and degradation of IκB proteins via 
ubiquitination by the SCF-βTrCP complex and subsequent proteasomal 
degradation.  The alternative pathway has a more restricted set of stimuli 
with activation of IKKα leading to phosphorylation and degradation of p100 to 
p52, which in turn dimerises with RelB.  As well as these post translational 
modifications there is also a transcriptional element to this regulation with 
Bcl-3 capable of acting as a transcriptional co-activator for p50 and p52 [51].   
Once released, complexes are free to translocate to the nucleus where they 
can bind to NFқB binding sites within the promoter and enhancer regions of 
specific genes.  The N terminal domain is primarily responsible for sequence 
specificity, and hydrophobic residues within the c terminal interact to mediate 
dimerisation.  RelA, RelB and c-Rel contain C terminal transactivation 
domains (TAD) and are required in dimers to activate gene transcription. p50 
and p52 are able to bind DNA but without TADs cannot activate gene 
expression, and in fact may inhibit it [52].  Further inhibitory feedback 
mechanisms include the synthesis of IқBα by activated NFқB resulting in 
transport of NFқB back to the cytoplasm terminating the activation [53].  More 
recent data have demonstrated that NFқB activation and specifically DNA 
binding is subject to a whole range of other regulatory mechanisms including 
post translational modifications and association with co factors [54, 55].  Kim 
et al demonstrated that p50 was capable of positively and negatively    
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regulating the metastasis suppressor gene KaI1 and the nature of the 
response was controlled by recruitment of co repressors to the p50 
transcriptional activating complex [56].  Chen et al have observed that p300 
acetylates p65/RelA at multiple lysine residues, each with its own specific 
effect on NFқB activity [55]. 
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Figure 1-3 NFқB activation pathways: 
Adapted from G Packham [57].    
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The target genes of the NFқB family are wide ranging and at least 400 have 
been described [58]. 
As discussed earlier the NFқB pathway has been heavily implicated in 
initiating and maintaining the malignant phenotype in lymphomas, and this is 
almost certainly due to its importance in controlling apoptosis during B cell 
development.  In mouse knockdown experiments, p65-/- mice demonstrate 
lethality from liver degeneration secondary to apoptosis [59], knockdown of 
TNFα  (TNFα-/-, TNFR-/-) rescues mice from this event.  Double knockdown 
mice exhibit impaired innate immunity, class switching in B cells and 
lymphocyte proliferation [60, 61].  In contrast to this p50 knockdown results in 
impaired humoral immunity, p52 null mice fail to develop normal germinal 
centres and secondary lymphoid organs. 
The role of constitutive NFқB activation in ABC DLBCL has already been 
discussed (section 1.4), activation of NFқB is not exclusive to this lymphoma 
subtype.  Compared to TNF stimulated fibroblasts GC DLBCL expresses 
higher levels of NFқB [62] and deletions of the 3’ end of the p52/p100 gene 
leading to oncogenic p100 lacking C-terminal ankyrin-repeats have been 
observed [63, 64].  Another well documented event is Rel amplifications 
which occur in a subset of GC DLBCL, FL, primary mediastinal B-cell 
lymphoma (PMBL) and mucosa-associated lymphoid tissue (MALT) 
lymphoma [63].  The exact consequences of these mutations remain to be 
elucidated, work by Davis et al has shown that GC DLBCL are not dependent 
on NFқB activity [17], however this work has only been performed in a small 
set of cell lines.  It may be that activation of NFқB is an early event that 
occurs in the germinal centre but is not crucial to survival of the malignant 
clone.        
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1.5  Established targeted therapy for B cell NHL 
1.5.1  Introduction 
Until the mid 1990’s the treatment outcome of B cell NHL had changed very 
little over the preceding two decades.  For DLBCL standard treatment 
remained CHOP chemotherapy (cyclophosphamide, vincristine, doxorubicin 
and prednisolone), with no benefit observed with more intensive regimens 
[65].  The median survival of follicular lymphoma had improved to almost 10 
years [66], compared to only 5 years prior to the widespread use of 
chemotherapy [67].  However attempts to intensify chemotherapy have not 
resulted in improvements in this.  
The CD20 receptor is expressed on more than 95% of normal and neoplastic 
B-cells, but not on plasma cells or early pro B-cells, it has not been detected 
in other tissues [68].  This makes it an excellent molecular target and 
prompted the development of anti CD20 therapy. 
1.5.2  CD20 Receptor and monoclonal antibodies 
 
The human CD20 gene is located on chromosome 11, close to the 
breakpoint site of t(11:14) translocation seen in some lymphomas.  Two 
groups cloned CD20 simultaneously [69, 70].  It is a non-glycosylated 33 to 
37-kDa phosphoprotein, with four transmembrane domains, a single 
extracellular loop between the 3rd and 4th transmembrane domain and the 
N- and C-termini inside the cell [Figure 1-4].  CD20 is highly phosphorylated 
in malignant B-cells and nonphosphorylated in nonproliferating B-cells,  
suggesting that phosphorylation is associated with proliferation [71].  Once 
expressed CD20 resides as multimers, usually dimers/tetramers and has 
been reported to localise with CD40, MHC II and B cell receptor for antigen 
(BCR) [72].  The exact role of the CD20 receptor remains unclear and 
knockout mice have been shown to have no phenotype [73].  A number of 
theories concerning its function have been proposed.   
It has been suggested that CD20 acts as a membrane ion channel controlling 
the flux of calcium [71].  This is supported by an increasing body of evidence.  
Bubein et al [74] demonstrated that CD20 transfection into a number of cell    
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lines resulted in an increase in the basal level of cytosolic Ca
2+, in Daudi B 
cells calcium flux was dependent on the type of CD20 antibody used.  As 
CD20 has no known ligand, this effect on calcium flux is transduced by other 
mechanisms.  Li et al [75] have hypothesised that CD20 acts as a store 
operated ion channel by allowing entry of extracellular calcium to replace 
diminishing stores in the endoplasmic reticulum resulting from B cell 
activation.  The exact mechanism of this is not fully understood, however 
CD20 receptor expression correlates with cytosolic ca
2+ levels.  Its structure 
resembles other store operated ion channels [70, 76, 77].  It can exist in 
oligomeric state on cell surface, and in hairy cell leukaemia CD20 expression 
correlates with elevated cytosolic Ca
2+[78, 79].  A new role for CD20 has 
been proposed by Kuijpers et al [80].  This group demonstrated that CD20 
deficiency resulted in impaired T cell independent antibody responses.    
It has been shown that monoclonal antibody binding results in the 
translocation of the CD20 receptor to lipid insoluble rafts [81, 82].  These 
rafts are highly ordered domains rich in glycosphingolipids, cholesterol and 
signalling proteins like Src kinases.  It is not clear what facilitates this 
reorganisation; it does not seem to be linked to kinase activity, cytoskeletal 
function or mAb binding and may be an epitope dependent phenomenon.  
With no known ligand our understanding of signalling events resulting from 
CD20 activation is derived from studying the effect of anti-CD20 mAbs.    
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Figure 1-4 structure of CD20 receptor: 
Cartoon depicting the structure of the human CD20 receptor, there are 4 
membrane spanning domains with the N and C terminals situated in the 
cytoplasm.    
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1.5.3  Anti CD20 monoclonal antibodies (mAbs) 
CD20 monoclonal antibodies were the first monoclonal antibodies to be used 
for the treatment of cancer. Rituximab (Roche) was licensed for the treatment 
of B-cell malignancies in 1997, and is a crucial element of multimodality 
therapy primarily in combination with conventional cytotoxic agents.  A new 
wave of CD20 mAbs are in clinical development with the promise of 
improving outcomes even further [83].  In vitro anti-CD20 mAbs have been 
shown to act via three distinct mechanisms: Complement-dependent 
cytotoxicity (CDC): Antibody dependent cell mediated cytotoxicity (ADCC): 
growth arrest and apoptosis in certain cell lines [Figure 1-5] [84, 85].  Despite 
its widespread usage and success in the treatment of B-cell malignancies [4, 
86], the exact mechanism of action of the human/mouse chimeric CD20 mAb 
Rituximab in vivo is not known. 
CD20 mAbs can be divided into two types, based on their ability to 
translocate CD20 into insoluble ‘lipid rafts’ [82, 87].  Type I mAbs (Rituximab, 
LT20, AT80, IF5, 2H7, 7D8, 2F2) are so classified because of their ability to 
translocate the CD20 receptor into “lipid rafts”, they are potent at inducing 
CDC and are less effective inducers of apoptosis.  Type II mAb (B1 and 
11B8, GA101) are ineffective in CDC but potent at inducing homotypic 
adhesion and apoptosis.  Both types are equally effective at inducing ADCC.  
What is not clear is what characteristic of CD20 mAb binding is important for 
these differential effects, for example both Rituximab and B1 appear to bind 
to the same region of the CD20 receptor. 
Lipid rafts are widely acknowledged to be the main signalling platforms for B-
lymphocytes, yet Chan et al have demonstrated that induction of apoptosis 
by a panel of type I and II mAbs is independent of movement of CD20 into 
TX-100 insoluble membrane rafts [87].  Despite this work some investigators 
maintain that smaller rafts, not detected by TX-100, may develop following 
CD20 ligation and that these remain an integral part of the signalling cascade 
[88, 89].  Another effect of formation of these microdomains is the provision 
of an optimal environment for activation of the classical complement cascade 
and this may account for the effectiveness of type I over type II mAb in 
inducing CDC.    
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Figure 1-5 Potential mechanisms of action of CD20 mAb: 
The three potential mechanisms of action of CD20 mAb are shown. (a.) 
CD20 mAb binding results in clustering of Fc domains, this allows binding of 
C1q and activation of the classical complement pathway. (b.)  CD20 mAb 
bound to B cells can directly recruit effector cells via the FcγR receptor 
family.  This results in phagocytosis of CD20 mAb bound cells. (c.) CD20 
mAb in vitro, in the presence of crosslinking, induce cytosolic Ca
2+ flux and 
can induce apoptosis. Adapted from figure by Professor MJ Glennie.    
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As discussed earlier CD20 mAb cytotoxic activity is mediated by three main 
mechanisms.  
Complement dependent cytotoxicity (CDC) 
CD20 mAb binding results in clustering of Fc domains, this allows binding of 
C1q and activation of the classical complement pathway, resulting in 
phagocytosis and activation of effector cells and potentially lysis via c3b and 
the memebrane attack complex (MAC).  There is conflicting literature on the 
importance of complement in CD20 mAb activity.  Various groups have 
demonstrated the importance of complement pathways in tumour cell 
depletion in xenograft models [90, 91].  The evidence supporting the 
importance of complement activity in vivo is compelling, but not clear cut [92].  
Following treatment with Rituximab, complement depletion rapidly occurs, 
and is implicated in infusion related toxicity.  Whilst cells surviving treatment 
have been shown to have increased expression of CD59, a complement 
defence molecule.[93] 
Antibody dependent cellular cytotoxicity (ADCC) 
As discussed above both type I and II mAb are equally effective at inducing 
ADCC.   FcγR are expressed on macrophages, NK cells and neutrophils, 
they can be both inhibitory and stimulatory and their activation results in 
release of cytokines, chemokines, proteases and reactive oxygen species 
[94].  FcγR can be activated by complement, but CD20 mAb bound to B cells 
can directly recruit effector cells via this receptor family, resulting in 
phagocytosis [95].  In mouse models FcγR activity appears to be important 
for CD20 activity, such that removal of FcγR activity results in loss of 
therapeutic activity of Rituximab [96].  This mechanism explains the rapid 
depletion of circulating CD20 positive cells, where FcγR effector levels are 
high, and slower depletion in tissues where levels are lower following mAb 
treatment.  The importance of this mechanism is apparent in humans as well, 
where polymorphisms in FcγR result in differential response rates to 
Rituximab therapy [97]. 
Intracellular signalling and induction of apoptosis 
This mechanism has been difficult to demonstrate in vivo.  In vitro the 
treatment of Burkitt’s lymphoma cell lines with CD20 monoclonal antibodies 
resulted in induction of apoptosis [85].  This effect is usually dependent on    
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the addition of an Fc region cross-linking agent or Fc-receptor-bearing 
accessory cells, and is employed in most studies of signalling events 
following CD20 mAb treatment [85, 98].  It is argued that cross linking in vitro 
with anti IgG antibodies or using homodimers of Rituximab mimics the action 
of effector cells recapitulating in vivo mechanisms, but this hypothesis 
remains unproven.   
The mechanisms of cell death resulting from mAb binding appear to differ 
depending on the class of mAb used (review [83]). Rituximab treatment in the 
presence of crosslinking results in Ca
2+ flux but this is not seen with type II 
mAb [99].  This appears in part to be due to ‘hijacking’ of the BCR signalling 
cascade and culminates in classical apoptosis with caspase activation and 
PARP cleavage [84, 85].  Recent data from Ivanov, Beers et al have shown 
that type II mAb act in an entirely different fashion [100].  They induce cell 
death through non apoptotic, non autophagic mechanisms, ultimately through 
a lysosome-dependent pathway.   
The intermediate signalling events following type I mAb ligation are becoming 
increasingly clear.  Jazirehi et al have demonstrated that Rituximab down 
regulates Bcl-XL through modulation of the NFқB pathway.  Upregulation of 
Raf-1 kinase inhibitor protein (RKIP) results in inhibition of NFқB activity and 
downregulation Bcl-XL [68].  They also demonstrated that over expression of 
Bcl-XL blocked the sensitizing effect of Rituximab on paclitaxel induced 
apoptosis, whilst pharmacological Bcl-XL inhibitors augmented this effect 
[101, 102].  In support of this Stolz et al observed that over expression of Bcl-
XL blocked the therapeutic effect of Rituximab in vitro and in a xenograft 
model [103].  They were also able to resensitise cells by using 
pharmacological inhibition of Bcl-2 and Bcl-XL.    
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1.5.4  Clinical trials of CD20 monoclonal antibodies  
Rituximab is now well established in the treatment of all CD20 positive 
lymphomas, and has had a dramatic effect on outcomes.  Anti idiotypic 
antibodies were first used in the early 1990’s with some encouraging results.  
However these studies were hampered by the immunogenicity of these 
murine antibodies [104].  As technology evolved chimeric antibodies were 
developed with the emergence of Rituximab in animal studies and early 
phase clinical trials [105, 106].  Phase II studies of Rituximab 375mg/m
2 
weekly x4 as a single agent demonstrated a response rate 46%-50% with 
median time to progression of 10.2 months in follicular NHL and helped to 
achieve FDA approval [107, 108].  Following these studies phase II trials of 
Rituximab in combination with chemotherapy were performed [5, 109, 110]..  
The subsequent randomised studies commenced to investigate the overall 
survival benefit of this approach, have resulted in the incorporation of 
Rituximab with combination chemotherapy as the first line treatment of 
follicular and other indolent B cell NHL [111-113].  The most recent 
adaptation to standard practice is the addition of maintenance Rituximab for 
up to two years.  This has again resulted in improvements in progression free 
survival with an improved 5 year survival in some studies [114-117]. 
With the well recognised standard therapy of CHOP chemotherapy for diffuse 
large B cell NHL for the last 20 years, the logical approach was the addition 
of Rituximab to this.  The pivotal study by Coiffier et al in 2002 [4] 
demonstrated an 18% benefit in 5-year event free survival for R-CHOP 
compared to CHOP.  This impressive benefit has been recapitulated in a 
number of other studies, with longer term follow up confirming an overall 
survival benefit [118-121]. 
Although clinical trials of CD20 monoclonal antibodies have been dominated 
by the archetypal type I antibody Rituximab, other CD20 mAb have been 
utilised.  The fully human antibody ofatumumab offers potential benefit over 
Rituximab in view of its in vitro efficacy especially at inducing complement 
activity.  A phase I/II dose escalation trial resulted in excellent tolerability, B 
cell depletion and promising activity in pre treated follicular lymphoma [122].  
Despite encouraging pre clinical data the type II antibody Tositumomab has    
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only been utilised in radioimmunotherapy with conjugation to Iodine
131.  This 
approach resulted in encouraging results [123], and is now being assessed in 
randomised clinical trials.   
What is clear is that CD20 mAb have shown their most potent clinical activity 
when given in combination with other agents, which have classically been 
standard chemotherapeutic drug combinations.  This effect is presumed to 
occur due to synergistic induction of apoptotic pathways, based on pre 
clinical studies [102].  There remains untapped potential in maximising the 
effects of these agents through potentiating apoptosis and effector cell 
mechanisms with novel combinations. 
1.6  Novel targeted therapies for B cell NHL 
1.6.1  Introduction 
Understanding what molecular events drive the malignant phenotype is not 
only key to understanding the aetiology and mechanisms of 
lymphomagenesis, but has resulted in a targeted approach to treating these 
conditions.   
Monoclonal antibodies 
The CD20 monoclonal antibody Rituximab is now well established in the 
treatment of B cell NHL.  It is widely regarded as one of the first successful 
targeted treatments for cancer.  Other monoclonal antibodies have also 
shown activity in lymphoma.  The clinical activity of anti CD19 antibodies 
have been investigated [124] with mixed responses, current studies are 
attempting to exploit this attractive target utilising mAb with improved ADCC 
function [125].  Other B cell targeting antibodies include Galiximab (anti 
CD80) [126], and Epratuzumab (anti CD22) [127, 128] Based on its activity in 
other tumour sites [129] and evidence of high levels of VEGF in ‘poor 
responders’ [130] clinical trials of the VEGF monoclonal antibody 
bevacizumab are also underway.  Its activity as a single agent has proved 
disappointing [131]. Its benefit in combination with CHOP-R is currently being 
assessed [132].  It remains to be seen whether any of these approaches will 
match the outcomes from targeting CD20.  
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Agents targeting intracellular signalling 
A novel approach is the use of inhibitors of Bcl-2 family members with a 
number of promising agents already in early phase clinical trial for lymphoma.   
The principal agents in development are ABT-737/ABT-263, the first agents 
with nM potency against Bcl-2 and Bcl-XL [133].  Pre clinical studies have 
also demonstrated μM EC50’s against NHL cell lines harbouring t(14:18) and 
primary FL cells.  Efficacy was also seen in xenograft studies with evidence 
of caspase 3 processing, consistent with the mechanism of action of this 
agent.  ABT-737 has been superseded by ABT-263 which has oral 
bioavailability [134] and is in phase I/II clinical trials [www.cancer.gov].  
These agents bind the hydrophobic BH3 domain binding site.  This inhibits 
dimerisation with pro apoptotic family members leading to induction of 
apoptosis.  One of the concerns with ABT-263 is its inability to inhibit Mcl-1 
activity.  A strategy to overcome this issue is combination with Obatoclax 
(GX015-070) which inhibits Mcl-1 dimerisation [135, 136]..However it remains 
to be seen what the clinical efficacy and toxicity of these agents will be alone 
and in combination. 
 
Targeting the proteasome is another novel strategy that has already shown 
promising clinical activity in some NHL subtypes.  The 26S proteosome is a 
major part of the ubiquitin-proteasome pathway.  It is responsible for the 
degradation of a wide range of cellular proteins including cyclins, cyclin-
dependent kinase inhibitors such as p21 and p27 and the tumour suppressor 
p53.  Perhaps the most important target for its efficacy in NHL is IқB [137].  
As discussed earlier IқB binds to NFқB subunits and is degraded by poly 
ubiquitination via the 26S proteosome.  Proteosome inhibitors have shown 
good pre clinical activity in MCL, with inhibition of constitutive NFқB 
activation, down-regulation of bcl-2 family members Bcl-XL and Bcl2A1 and 
induction of apoptosis [138].  Bortezomib (velcade) has shown promising 
efficacy as a single agent in clinical trials in heavily pretreated FL and MCL 
[139].  Interestingly in the study by Strauss et al response to bortezomib 
correlated with reduction in plasma TNFα levels, consistent with the 
hypothesis that inhibiting NFқB may be important.  Recent studies have    
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assessed the benefit of bortezomib in combination with a range of other 
agents including chemotherapeutics [140] and Rituximab [141].   
One such combination approach is dual targeting of the NFқB pathway with 
histone deactylase inhibitors and bortezomib.  Treating myeloma cell lines 
with bortezomib followed by vorinostat produced synergistic induction of 
mitochondrial injury, caspase activation, and apoptosis associated with NFқB 
inactivation [142].  Similar findings were also observed in BCR/ABL positive 
and negative leukaemia cell lines [143].  This approach also produced 
synergistic cell killing in solid tumour cell lines (hepatoma and head and neck 
squamous cell carcinoma), again with induction of caspase mediated 
apoptosis [144-147] 
 
1.6.2  Chromatin and histone modifications 
Histone deacetylase inhibitors (HDI) are a novel class of anticancer agents 
which have moved rapidly into clinical trials.  Their therapeutic activity arises 
from targeting chromatin regulation and the post translational modification of 
a rapidly expanding number of non histone proteins. 
In Eukaryotic organisms DNA is coated with an equal mass of protein and 
stored in the nucleus[148], this protein-DNA complex is called chromatin, The 
protein components are called histones, which are evolutionarily conserved 
and equivalents  have been identified in single-cell prokaryotic organisms 
[149].  In dividing cells this complex is seen as chromosomes, in non-dividing 
cells it is distributed throughout the nucleus as euchromatin (open) and 
heterochromatin (condensed).  
Core histones are made up of an octamer of two each of H2A, H2B, H3 and 
H4.  Core histone assembly relies on two pairs of H3 and H4 dimerising to 
form a stable tetramer.  This in turn binds 2 dimers of H2A and H2B to form a 
stable octamer that binds 2 superhelical turns of DNA (165 base pairs), this 
structure was discovered by X-ray diffraction, to a resolution of 2.8Ǻ [150].  
Nucleosomes are joined to each other by a short segment of linker DNA, this 
is stabilised by histone H1, which assists in higher order structural 
organisation.    
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In the 1960s it was first described how histones control gene expression and 
the importance of post translational modification in the control of gene 
expression and hence RNA synthesis [151].  Core histones contain multiple 
potential sites for modification, predominantly on the tail domains [152].  It is 
somewhat contentiously postulated that these modifications work to create 
an epigenetic ‘histone code’, where the isolated changes in histone tails 
combine to create their effects on gene transcription[153].  Modifications can 
be methylation (on lysine and arginine residues), acetylation (upon lysine 
residues), phosphorylation (upon serine and threonine residues) ubiquination 
or ADP-ribosylation [Figure 1-6].   
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Figure 1-6: Histone structure and sites of modification: 
Cartoon depicting octamer of core histones binding 2.5 turns of DNA.  Sites 
of histone tail modification are shown. ■ Phosphorylation, ■ methylation, ■ 
acetylation and ■ ubiquitination.  Adapted from Marks et al [154]. 
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Histone modifications result in two structural effects on chromatin.  Firstly 
modification of histone tails result in changes in electrostatic charge resulting 
in structural and DNA binding changes,  For example studies have shown 
that phosphorylation of H1 reduces the DNA:H1 binding affinity, and that this 
is a function of changes in charge [155].  Secondly, changes in the binding 
surface can allow recruitment of protein complexes to sites that were 
previously hidden.  One of the best examples of this was shown by Lachner 
et al, who demonstrated that H3K9 methylation, catalysed by the histone 
methyltransferase (Suv39h) facilitated a specific binding site for HP1 leading 
to its specific chromatin regulatory effects [156].  Through these mechanisms 
post translational modifications are implicated in DNA transcription, 
replication and repair as well as instigating chromatin conformational 
changes.    
Of these ‘marks’ lysine acetylation has been one of the most studied [157] 
partly due to the early identification of the regulatory enzymes responsible. 
Histone acetyltransferases (HATs)[158] and histone deacetylases 
(HDACs)[159].  Dynamic acetylation and deacetylation of the lysine residues 
is catalysed by these complementary enzymes.  It is the discovery of 
pharmacological inhibitors of these enzymes that has facilitated our 
understanding of the enzymatic effects. 
The dynamic acetylation and deacetylation of lysine residues is not confined 
to histones[160].  An ever increasing number of proteins have been identified 
which undergo lysine acetylation as part of their post translational regulation 
[Figure 1-7]. One of the best described groups is DNA binding proteins [161-
163].  For example the transcriptional repressor Bcl6, which is expressed in 
the germinal centre has been shown to be acetylated on lysine residues by 
p300 and use of the Histone Deacetylase inhibitor (HDI), Trichostatin A 
(TSA), demonstrated the it also binds HDAC enzymes [163].  Moreover 
acetylation inhibited its transcriptional repressor function.  Other examples 
include the molecular chaperone hsp 90 [164], the structural protein 
tubulin[165], and nuclear import factors (importin-α family)[166].    
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Figure 1-7 Non histone targets of HDAC enzymes: 
Cartoon depicting known non Histone targets of HDAC enzymes.      
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1.6.3  Acetyltransferases and deacetylases 
These 2 classes of enzymes regulate the lysine acetylation state of histones 
and other proteins [Figure 1-8].  Acetylation, catalysed by HATs, in 
association with transcriptional activators, neutralises the positive charge 
associated with the ε-amino group of conserved lysine residues within the 
NH2 terminal domains of core histones.  This decreases their DNA affinity, 
allowing the nucleosomes to unfold and increasing access to transcription 
factors, resulting in up regulation of gene expression [167-170].  HATs can 
be divided into three major families based on a number of structural motifs 
(GNAT, MYST, p300/CBP)[154]. 
At least 18 proteins with Zn dependent Deacetylase catalytic activity have 
been reported.  They are divided into two families; the histone deacetylases 
and Sir2-like deacetylases (sirtuins).  Sirtuins contains seven members, they 
all contain a highly conserved catalytic domain different to the conventional 
HDACs, consist of homologues of yeast and mouse Sir2 and require 
nicotinamine adenine dinucleotide (NAD+) as a 1:1 co-factor.  The 
therapeutic potential of their inhibition is currently being investigated (review 
[171]).   
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Figure 1-8 Action of HDAC and HAT enzymes:  
HDACs counter the effects of HATs by hydrolysing the ε-amino acetyl group 
within core histones and restoring their positive charge at physiological pH.  
This results in tighter DNA binding and transcriptional repression. 
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1.6.4  HDAC family members 
The first human HDAC (HDAC1) was isolated using its high affinity for the 
naturally occurring histone deacetylase inhibitor trapoxin A [159].  This tied 
together earlier work that had identified a cDNA homologue to yeast Rpc3, 
with unknown protein function [172]; demonstrated trapoxin binding to an 
unknown protein [173, 174]; and the histone deacetylase function of an 
unknown protein (Allfrey 1971). 
These proteins are evolutionarily conserved from insects to humans 
suggesting they perform a critical function [175].  Phylogenetic analysis of 
bacterial HDAC suggests their development precedes that of histone proteins 
indicating that the primary activity of some family members may be against 
non histone proteins [176]. 
To date 11 human HDACs have been identified, this classical HDAC family is 
divided into three classes; HDAC1, -2, -3 and -8 (Class I, 377-488 amino 
acids) [177];  HDAC4, -5, -6, -7, -9 and -10 (class II, 700-1215 amino acids) 
and HDAC11 (class IV, 347 amino acids) [Figure 1-9].  They have a highly 
conserved catalytic domain containing a zinc cation and restore the positive 
charge to lysine residues upon hydrolysis of ε-amino acetyl moieties.  
HDAC1 and -2 share high levels of homology, and require co-factors for their 
activity.  They are found together in three complexes Sin3, NuRD and Co-
REST, but can also directly bind DNA binding proteins [178-180].  HDAC1 
knockout in mice is embryologically lethal, even with compensatory 
upregulation of other class I HDACs [181].   HDAC3 shares less homology 
but also contains the nuclear localisation sequence (NLS) seen in all class I 
HDACs and a nuclear export sequence (NES).  It is mainly found in multiple 
protein complexes with N-CoR (nuclear receptor co-repressor) and SMRT 
(silencing mediator for retinoic acid and thyroid hormone receptors) cofactors.  
It appears to regulate gene expression mediated via nuclear hormone 
receptors [180].  It also inhibits acetylation of non histone targets, for 
example NFқB [182]  In contrast to other class I HDACs, HDAC8 has not 
been found in these complexes, and appears to be expressed at low levels 
except in smooth muscle. It has also been shown that HDAC3 oligomerises 
with other HDACs.   
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Figure 1-9 Histone Deacetylase family: 
 
Schematic diagram of HDAC family.  Class I (HDAC 1, 2, 3, 8) contain a 
common homology domain ■ [177];  class II  (HDAC4, -5, -6, -7, -9 and -10) 
also share a different common domain ■.  Class IV (HDAC11) has similar 
properties to class I and II but has a different structure.    
- 43 - 
Class II are larger proteins that shuttle between cytoplasm and nucleus, they 
all share a distinct homology domain. HDAC4, -5 and -7 are closely related 
[183].  They all contain binding domains for myocyte enhancer factor 2 
(MEF2) and C-terminal binding protein (CtBP) and can interact with the 
SMRT and N-CoR complexes.  It appears they control differentiation in 
muscle and cartilaginous tissue, with knock out mice dying of chondrocyte 
hypertrophy [184].  HDAC6 is preferentially cytoplasmic and regulates 
microtubule dependent cell motility [185], it also regulates HSP90 
deacetylation [164].  HDAC9 exists as a number of different splice variants, 
allowing for different function in different cell types.  HDAC10 is usually found 
to interact with other HDACs, and although it has some deacetylase activity it 
may function as a recruiter.  
HDAC11 appears to share features of both class I and II but is structurally 
different [186].  It has been shown to have deactylase activity, but is not 
found in the characteristic multicomponent complexes. 
1.6.5  HDACs in tumourgenesis 
It has become increasingly clear that repression of genes via HDAC over 
activity in these multicomponent HDAC complexes is a hallmark of many 
cancers [187] [Figure 1-10].  Trimethylation of lysine 20 (K20-H4) and loss of 
acetylation of lysine 16 (K16-H4), of histone 4 is commonly seen in human 
cancers and cancer cell lines [188].  Hypoacetylation can occur through a 
number of mechanisms.  Firstly it may result from reduced HAT activity or 
aberrant HDAC activity.  Aberrant HDAC activity can affect lysine acetylation 
on core histones as well as non histone proteins.  There is evidence of 
overexpression of individual HDAC family members in a number of cancers.  
Zhu et al demonstrated how in some colorectal cancers overexpression of 
HDAC2 results from increased signalling of the APC/β-catenin/c-Myc 
pathway, and that this inhibits apoptosis [189].  HDAC2 overexpression has 
been documented in gastric cancer [190] and cervical cancer [191].  Huang 
et al also demonstrated the functional significance of HDAC2, with 
knockdown resulting in increased apoptosis through upregulation of 
p21
cip1/waf1 [191].    
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Figure 1-10 The role of HDACs in tumourgenesis:  
Diagram summarising the role of HDAC family members in tumourigenesis 
taken from review by Witt et al.[192] 
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Overexpression of other class I HDACs is also seen.  The only class II HDAC 
that has been shown to be overexpressed is HDAC6, although it appeared to 
correlate with a favourable response to endocrine therapy in breast cancer 
[193].  HDAC over expression is also involved in tumour progression and 
metastasis.  Hypoxia results in over expression of HDAC1, this results in 
repression of the p53 and VHL tumour suppressors and over expression of 
HIF-1α and VEGF [194]. 
A second mechanism by which HDACs are implicated in tumourgenesis is 
through their interaction with protooncogene fusion proteins.  One of the 
clearest examples of this is in acute promyelocytic leukaemia (APL).  APL is 
characterised by translocations of the retinoic acid receptor A (RARA) gene 
most commonly with the PML gene.  The resulting fusion protein transcription 
factor has enhanced co-repressor binding properties, increasing HDAC and 
DNA methyltransferase recruitment.  This aberrant retinoid signalling results 
in potent transcriptional silencing of target genes maintaining the malignant 
phenotype [195].  Another example of this is in AML where the AML-1/ETO 
fusion protein resulting from the t(8:21) translocation, represses transcription 
through recruitment of HDACs [196].          
A third mechanism by which HDACs are implicated in tumourgenesis is 
through their interactions with non histone proteins.  As discussed earlier 
transcription factors (e.g. p53, NFқB, Bcl-6, Bcl-2, HIF, and VEGF), nuclear 
binding proteins, molecular chaperones, and cytoskeletal proteins are all 
known to require acetylation for their activation and regulation.  Many of 
these molecules are under or over expressed in malignant phenotypes.  p53 
was one of the first of these non histone proteins shown to be regulated by 
acetylation.  It has been shown that mutation of K120 to arginine, which 
occurs in some cancers, results in loss of acetylation at that site rendering 
p53 unable to activate proapooptotic genes, suggesting other mechanisms of 
deacetylation may also have a similar effect [197].  Acetylation is also 
important for P53 stability in that lysine residues are also prone to 
ubiquination; deacetylation of these residues allows ubiquitin binding and 
degradation reducing p53 stability.    
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This evidence linking aberrant HDAC activity with cancer has provided a 
clear rationale for exploring the effects of HDIs as anti cancer agents. 
1.6.6  HDAC inhibitors (HDIs) 
HDIs were first identified in the literature in the 1970’s [198, 199], n-Butyrate 
was shown to reversibly inhibit partially purified HDAC and cause 
accumulation of acetylated histones in the nucleus [200].  It was the 
discovery of these inhibitory compounds that enhanced our understanding of 
HDAC function and led to the development of more specific synthetic 
inhibitors.  HDIs are structurally diverse, but all chelate the Zn atom in the 
active site of Class I and/or II HDACs, thereby blocking enzyme activity.   
These inhibitors conform to a common pharmacophore, comprising a “linker” 
mimicking the side chain of lysine, and a “cap” structure of variable size that 
makes additional covalent interactions around the rim of the enzyme active 
site [Figure 1-11A].  Their potency and selectivity varies greatly mainly due 
to the strength of these covalent interactions, the more potent molecules 
have an aliphatic chain, which very closely mimics the lysine side chain and 
interacts tightly with the Zn atom, and a hydrophobic “cap” which interacts 
with the catalytic pocket.  Less potent compounds have an acyl group which 
interacts less tightly with the Zn atom and cannot interact with the catalytic 
pocket.  As well as these structural differences affecting their enzymatic 
potency, there is also evidence that a reduction step is necessary for the 
activity of FK228 [201] [Figure 1-11B].      
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Figure 1-11 Structure of HDI molecule: 
Basic structure of HDI molecule, with cartoon depiction of Zn binding at 
HDAC enzyme active site.  Molecules shown are (A.) SAHA (vorinostat).  
(B.) FK228 (depsipeptide) requires intracellular reduction to facilitate effective 
binding within enzymatic groove, adapted from Furumai et al [201]. 
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HDI are divided into a number of classes based on their structure (Table 1-2) 
Trichostatin A (TSA), a naturally occurring hydroxamate, was originally identified as 
a fungistatic antibiotic in 1976 [202].  It was subsequently shown to induce histone 
acetylation resulting in Friend leukaemia cell differentiation as well as causing G1 
and G2 arrest [203].  This class includes suberoylanilide hydroxamic acid (SAHA), 
Cinnamic acid bishydroxamic acid (CBHA), LAQ-824, sulphonamide hydroxamic 
acids and oxamflatin.  
SAHA is a less complex molecule than TSA, and has a 30-fold weaker inhibitory 
activity.  It contains the crucial hydroxamic acid group which inserts into the 
hydrophobic pocket and binds to the zinc atom.  This aliphatic chain fits less snugly 
into the pocket and this together with the phenyl-amino ketone group cap accounts 
for the weaker inhibition than TSA [204].  Studies have shown SAHA to have 
antitumour activity in vitro,  in vivo and in  phase I/II clinical trials [154, 205].  SAHA 
gained FDA approval for the treatment of cutaneous T cell lymphoma (CTCL) in 
2007. 
Cyclic peptides are the next most developed class in terms of clinical trials. 
These are the most structurally complex class, with potency at nanomolar 
concentrations.  depsipeptide (FK228) has also shown good activity in CTCL [206], 
and solid tumours.  Aliphatic Acids are the weakest of HDIs, only active at millimolar 
concentrations.  This class includes the anticonvulsant valproic acid and phenyl-
butyrate.  The compounds in this group have an acyl group which interacts with the 
zinc atom but cannot interact with the catalytic pocket, resulting in reduced potency. 
The Benzamide class includes the agents MS275 and MGCD0103.  They are both 
less potent than the corresponding hydroxamic acids and cyclic tetrapeptides, but 
are class I HDAC selective.  This agents are also currently in a multitude of phase I 
and II studies.    
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Table 1-2 HDAC inhibitors in clinical development.    
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Mechanisms of action 
As can be predicted from the function of HDAC enzymes, HDIs cause 
accumulation of acetylated histone and non histone proteins by blocking the 
deacetylation catalysed by the HDAC family of enzymes.  The reasons 
behind their differential toxicity between normal and malignant cells are not 
fully understood. 
Expression profiling has shown that in the presence of HDAC inhibitors only 
a small number of genes show altered expression (2-10 %) [207-210], with 
both up regulation and down regulation of genes, which is surprising 
considering their transformation of chromatin into an open state.  Interestingly 
it seems that there are a core set of genes which are persistently regulated 
across different cell lines and with different HDI (for example p21
waf1), there 
are also reproducible changes which are cell line and HDI specific [210, 211].  
The overall effect on cells is to induce terminal differentiation, cell cycle arrest 
and apoptosis, through regulation of gene expression [212].  For example in 
MCF-7 cells incubated with SAHA, differentiation was confirmed by the 
presence of milk fat proteins [213].  Cell cycle arrest (G2M) was observed by 
microscopy.  Interestingly these changes were reversed within 24 hours of 
removal of the drug.   
The ability to induce apoptosis appears to be cell line and HDI specific.  
Gene expression studies in CEM and Jurkat cells have demonstrated 
regulation of genes from the instrinsic apoptotic pathway, as well as genes 
associated with regulation of this pathway [211].  The role of the intrinsic 
pathway is supported by other investigators [214, 215].  In contrast to this 
there is evidence that the extrinsic pathway can also be modulated albeit in 
combination [216].  The role of caspases in B cell NHL has also been 
questioned [217]   
Induction of apoptosis can also occur as a result of acetylation of non histone 
proteins.  In Bcr-Abl positive CML K562 cells, inhibition of HDAC6 by 
LAQ824 resulted in depletion of HSP90 client proteins [164].    
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HDIs have been utilised as single agents in a large number of early phase 
clinical trials.  The first clinical reports of HDI activity were published in 2001 
with a case report of a complete response to FK228 (depsipeptide) in a 
patient with CTCL [218].  Until recently SAHA and FK228 were the two most 
advanced agents in clinical development.  Phase I studies have shown SAHA 
to be well tolerated in intravenous and oral preparations.  Dose limiting 
toxicities were diarrhoea, nausea and vomiting, fatigue, dehydration, 
anorexia and myelosupression [205, 219-221].  Based on these studies the 
maximum tolerated dose (MTD) was 400mg daily or 200mg twice daily for 
continuous dosing or 300mg twice daily for three days per week.  Phase II 
studies in CTCL [222, 223] have shown response rates of 24.2% and 29% in 
heavily pretreated patients and have formed the basis for the FDA approval.  
FK228 has also shown its most promising activity in CTCL.  As a result of the 
studies discussed SAHA was licensed in 2006 for the treatment of CTCL.  
More recently early phase studies of ‘second generation’ HDI have been 
published.  The isoform specific HDI MGCD0103, which targets class I 
HDACs, was well tolerated in solid tumours but showed limited anti tumour 
activity [224].  This agent has shown more promising activity in 
haematological malignancies, but its benefit over SAHA remains to be seen 
[225].  One of the overriding issues from these studies was the poor 
correlation between the pharmacokinetic (PK) and pharmacodynamic (PD) 
endpoints.  Universally histone acetylation has been used as a PD endpoint.  
It has been measured by a number of techniques including western blotting, 
ELISA and confocal microscopy.  More recently an in vitro HDAC enzyme 
assay has also been used [224].  In the study by Kelly et al there was 2 fold 
increase in histone acetylation at the MTD, but this had fallen at the 8 hour 
timepoint [205].  In the recent study of MGCD0103 1.3 to 1.5 fold histone 
acetylation was detected using an ELISA [225].  There is a clear need for a 
more robust biomarker of HDI target effect.  Current clinical and preclinical 
studies are concentrating on their activity in combination with other agents.      
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1.6.7  HDAC inhibitors in combination 
HDIs have been tested in combination with a variety of conventional cytotoxic 
chemotherapeutic agents, monoclonal antibodies, anti hormonal therapies 
and other epigenetic modifiers [226] 
Conventional cytotoxics 
The most robust combinations with chemotheraputics have been seen with 
topoisomerase I inhibitors (camptothecin, irinotecan, topotecan) 
topoisomerase II inhibitors (epirubicin, doxorubicin, etoposide, mitoxantrone).  
This approach has been used In vitro [227, 228] and in breast cancer 
xenograft models [228, 229].  A phase I clinical trial of VPA combined with 
epirubicin showed a 22% partial response rate in multiply pre-treated solid 
malignancies with acceptable toxicity [230].  A phase II trial combining VPA 
with chemotherapy (5FU, epirubicin and cyclophosphamide) is currently 
recruiting in metastatic breast cancer [231].  These effects are underpinned 
by compelling mechanistic data.    For example, with reference to 
topoisomerase II inhibitors, HDAC1 and 2 have been shown to bind and 
interact with topoisomerase II, and form an integral part of the NuRD complex 
[232, 233]. It appears that Pre-exposure of breast cancer cells to vorinostat 
for 48 hours is needed to induce synergistic apoptosis, increase nuclear 
epirubicin levels and increase DNA damage.  Shorter pre-exposure periods 
abrogated synergy and exposure after chemotherapy resulted in antagonistic 
effects, implying that HDI relaxation of chromatin allows greater access for 
topoisomerase II inhibition.  Expression of the chemotherapeutic target may 
also be crucial as potentiation was lost in topoisomerase II null cells if the 
HDI was combined with epirubicin but not topotecan [234].  Conversely 
sequencing was also important for combination with topoisomerase I 
inhibition but with apparent benefit for HDI exposure after the 
chemotherapeutic to exploit cell cycle effects of each agent.  Potentiation has 
been shown for an HDI added 24 to 48 hours after camptothecin in breast 
and lung cancer cells [235]. Cells arrested in G2-M by camptothecin 
appeared most sensitive to subsequent HDI addition possibly through HDI 
induced decreases in cyclin B levels, and of the anti-apoptotic proteins XIAP 
and survivin. These findings suggested reduced expression of these anti-   
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apoptotic factors could increase efficacy of topoisomerase I inhibitors if given 
in a sequence that does not prevent tumour cell progression through S phase 
[235].  Enhancement of cisplatin induced apoptosis by HDIs in oral 
squamous cell carcinoma [236, 237] and Taxanes in endometrial cancer and 
breast cancer [238, 239].  
Agents targeting the epidermal growth factor receptors  
Another encouraging approach is combination with agents targeting the HER 
family of receptors.  Trastuzumab, a humanized monoclonal antibody to the 
HER2 extra cellular domain, is effective for those with receptor over 
expression, however optimization of HER2 targeted therapy and avoidance 
of resistance mechanisms is required [240]. In vitro studies indicate that HDI 
have single agent activity in HER2 over expressing breast cancer cell lines 
including attenuation of HER2 expression, its tyrosine kinase activity, its cell 
membrane localisation and dimerization with HER3. [238, 241, 242].  
Combination with trastuzumab produced synergistic induction of apoptosis 
[238, 242]. Synergy may result from counteracting HER2 over expression as 
HDAC inhibition reduced HER2 mRNA transcript expression and induced 
HER2 protein degradation [241-243].  The latter mechanism occurred via 
acetylation of heat shock protein (HSP) 90 causing its inactivation and loss of 
multiple HSP90 client proteins.  HSP90 acetylation decreased ATP binding 
inducing a shift from HER2 binding with HSP90 to HSP70, resulting in HER2 
targeting for ubiquitination and proteasomal degradation [242]. On the basis 
of these in vitro data, clinical trials of trastuzumab and HDI combinations are 
in progress for locally advanced and metastatic breast cancer .  
 
It remains unproven to what degree synergism between HDIs and 
trastuzumab in HER2 positive breast cancer models might also apply to other 
HER2 directed therapeutics which are in various stages of clinical testing 
[240]. However, inhibition of proliferation, apoptosis and signalling inhibition 
were potentiated when vorinostat was co-administered with the pan-HER 
tyrosine kinase inhibitor CI-1033 in breast as well as prostate and head and 
neck squamous carcinoma cells [241]. 
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Regarding other members of the HER family, in non small cell lung cancer 
(NSCLC), synergy has been shown between HDIs and the HER1 (EGFR) 
tyrosine kinase inhibitors erlotinib and gefitinib [244, 245]. HDACs are 
recruited by transcriptional repressors such as Slug/Snail and ZEB1 which 
are implicated in resistance mechanisms to these agents and gefitinib 
sensitivity appeared to be restored in NSCLC cell line models of gefitinib 
resistance when combined with an HDI [245].  In a separate study, HSP90 
acetylation and reduced association with HER1, Akt, and STAT3 was seen in 
cell lines harbouring HER1 kinase mutations following exposure to HDIs 
leading to apoptosis. Conversely, little effect on apoptosis was seen in cells 
not dependent on HER1 through kinase mutations. Therefore, HER1 
mutation status might be a predictive factor for HDI combination with HER1 
inhibitors in this setting [244]. This highlights the value in dissecting the 
mechanisms underlying beneficial combinations to allow for rational targeting 
of appropriate cancer phenotypes early in clinical development. 
Proteasome inhibitors 
Proteasome inhibitors act by binding within the catalytic 26S core of the 
proteasome, resulting in the build up of proteins targeted for degradation.  
Cancer cells appear more likely to accumulate misfolded proteins than 
normal cells producing a therapeutic window with promising activity in 
haematological malignancies [246]  Evidence exists regarding synergistic 
interactions with HDIs. Treating myeloma cell lines with bortezomib followed 
by vorinostat produced synergistic induction of mitochondrial injury, caspase 
activation, and apoptosis associated with NFκB inactivation [142].  Similar 
findings were also observed in BCR/ABL positive and negative leukaemia 
cell lines [143].  Interestingly this approach also produced synergistic cell 
killing in solid tumour cell lines (hepatoma and head and neck squamous cell 
carcinoma), again with induction of caspase mediated apoptosis [144, 145].   
Combined HDAC-proteasomal inhibition may be effective because both 
interact with NFκB pathways.  Proteasome inhibitors cause accumulation of 
IκBα increasing its NFκB binding, thereby preventing nuclear localisation and 
activation of NFκB target genes.  NFκB subunits are acetylated at multiple 
lysine residues by p300/CBP acetyltransferases. Acetylation of different 
residues regulates different NF-κB functions (including transcriptional    
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activation, DNA binding affinity, IκBα assembly and sub-cellular localization) 
and HDIs manipulate gene expression patterns resulting from NF-κB 
activation both via direct NF-κB subunit acetylation and indirectly through 
chromatin remodelling [146, 147]. 
Retinoic acid 
Another combination approach for targeting aberrant gene silencing directly 
is with retinoic acid in acute promyelocytic leukaemia (APL).  APL is 
characterised by translocations of the retinoic acid receptor A (RARA) gene 
most commonly with the PML gene.  The resulting fusion protein transcription 
factor has enhanced co-repressor binding properties increasing HDAC and 
DNA methyltransferase recruitment.  This aberrant retinoid signalling results 
in potent transcriptional silencing of target genes.  All trans-retinoic acid 
(ATRA), alone or combined with chemotherapy, is effective in reversing this 
silencing but resistance may occur.  Addition of an HDI to this combination is 
logical in view of the enhanced co-repressor binding and HDAC recruitment 
by RARA-fusion proteins.  HDI therapy alone does not induce differentiation 
in APL but can induce this in retinoic acid resistant cell lines when the two 
agents are combined [247]  In APL, this approach requires clinical testing to 
prove its effectiveness over retinoic acid treatment alone.  In acute myeloid 
leukaemia (AML) or myelodysplastic syndrome (MDS) unsuitable for, or 
relapsed following, conventional therapy, combined VPA and ATRA has 
produced modest efficacy in phase I/II clinical trials [248, 249]. 
 
HDIs may be of value in combination with hormonal therapy for breast 
cancer. They potentiate the anti-proliferative effects of the selective 
oestrogen receptor (ER) modulators tamoxifen and raloxifene, the pure anti-
oestrogen fulvestrant and the aromatase inhibitor letrozole in breast cancer 
cell lines. Interestingly the partial agonist effect of endometrial 
adenocarcinoma cell proliferation induced by tamoxifen was blocked by HDI 
co-administration [250]. In further work, treatment with an HDI rendered 
formerly unresponsive ERα negative breast cancer cells responsive to 
tamoxifen. The HDI enhanced overall ER transcriptional activity in these 
cells. Interestingly this appeared to be by inducing expression and nuclear 
translocation of ERβ but not ERα.  Reduction of ERβ expression by short    
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interfering RNA abrogated this HDI-induced sensitization effect [251]. Other 
evidence exists that DNA methylation and histone deacetylation interact to 
maintain a repressive chromatin complex at the ER promoter. Inhibition of 
either may be sufficient to activate the silenced ER gene [252]. Clinical 
investigation following from these observations is in progress. 
HDI combination with targeted agents for BCR/ABL positive leukaemia 
The role of HDIs in combination with agents targeting the BCR/ABL 
oncoprotein has been investigated in chronic myeloid leukaemia (CML) 
where the BCR/ABL tyrosine kinase inhibitor imatinib is now standard 
therapy but resistance can develop.  In vitro, vorinostat has been shown to 
synergistically enhance the activity of imatinib and the second generation 
agent dasatinib possibly via inhibition of HSP90 chaperone function.  In 
addition to down regulation of BCR/ABL expression, multiple perturbations in 
signalling and cell cycle-regulatory proteins are induced by this combination 
including the Ras/Raf/MEK/ERK, Akt,  STAT and JNK pathways and cyclin 
D1 [253, 254]. Subsequently, combination of HDI with sorafenib, an inhibitor 
of multiple kinases including Raf-1, platelet-derived growth factor, vascular 
endothelial growth factor receptors 1 and 2, and FLT3, was found to induce 
synergistic cell death in BCR/ABL positive cells, imatinib resistant cells and 
primary CD34+ bone marrow cells from CML patients [255]. 
 
Interestingly, both imatinib and sorafenib blocked HDI mediated induction of 
p21WAF1/CIP1, perhaps the most consistently observed HDI downstream 
molecular effect. Forced expression of p21WAF1/CIP1 depleted the 
combined HDI/sorafenib effect, implying that this may be required for 
synergism. Potential mechanisms include disruption of p21WAF1/CIP1 
mediated G1 arrest, interference with its direct anti-apoptotic actions such as 
inhibition of caspase-3 or c-Jun NH2-terminal kinase activation or disruption 
of the upstream Raf/MEK/ERK axis. [254, 255]. 
Other epigenetic modifiers 
One reason for the relatively modest number of genes affected by HDIs is the 
dominant effect of methylation status over acetylation. Dual administration of 
HDIs with DNA hypomethylating agents is therefore of interest.  Aberrent 
DNA methylation is characteristic of a number of myeloid leukaemias [256]    
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and dual epigenetic modulation might allow suppression of the malignant 
clone.  In vitro, combination of VPA and 5-aza-2’-deoxycytidine (decitabine) 
produced synergistic growth inhibition and induction of apoptosis in 
leukaemia cell lines [257].  In a subsequent phase I/II clinical trial of this 
combination, 54 patients with AML or high risk MDS, either relapsed or 
unsuitable for first line chemotherapy, received a fixed dose of decitabine and 
escalating doses of VPA. Twelve (22%) had objective responses with 10 
complete remissions.  Major cytogenetic response was documented in 6 of 8 
responders.  Of five target genes investigated, hypomethylation of the key 
cell cycle regulating gene p15INK4B was found to be the best indicator of 
response. Pre-treatment p15 methylation was significantly lower in 
responders versus non-responders, however neither the absolute or 
percentage change in p15INK4B methylation was statistically significant and 
responses were not correlated with induction of H3 or H4 acetylation [258].  
In another study, utilising phenylbutyrate and 5-azacytidine in a similar 
patient population, 11 of 29 patients responded.  Furthermore, 6 of 6 with 
pre-treatment methylation of p15INK4B or CDH-1 (E-cadherin) promoters 
reversed methylation during the first cycle of therapy whereas none of 6 non-
responders showed any demethylation [259].  Further identification and 
validation of predictive biomarkers would be of immense value in the ongoing 
clinical assessment of HDIs in this and other settings but may need to be 
tumour and combination specific.     
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2  Materials and methods 
2.1  Materials 
2.1.1  Cancer cell lines 
Ramos, Akata 6, SU-DHL-4 and RL cell lines were a gift from Professor 
Packham, DoHH2 cell line was a gift from Professor Stevenson.  Ramos cells 
stably transfected to overexpress Bcl-2 were a kind gift from Dr M Cragg.  All 
cell lines were maintained in logarithmic growth in a humidified cell incubator 
(HERA Cell, Heraeus) at 37
oC and 5% CO2 with cell density between 2.0x10
5 
and 1.0x10
6.  Complete growth medium of RPMI ( Roswell Park Memorial 
Institute 1640 medium, Invitrogen, UK) supplemented with 10% (v/v) heat 
inactivated fetal calf serum (FCS, Invitrogen, UK), 2.0 mM L-glutamine 
(Invitrogen, UK) and 1.0 mM  sodium pyruvate was used.  Cell viability was 
assessed using Trypan blue exclusion prior to their usage. 
This panel of B cell NHL cell lines was selected as they have been routinely 
used to investigate the in vitro activity of Rituximab.  They were all initially 
used to investigate for synergistic cell killing, but subsequent studies utilised 
predominantly the SU-DHL-4 and Ramos cell lines.    
2.1.2  Peripheral Blood Mononuclear Cells (PBMCs) 
10ml whole blood was collected from volunteers into EDTA collection tubes 
(BD, UK) in accordance with local ethics procedures.  5mls of lymphoprep
TM 
(AXIS-SHIELD Poc AS, Norway) was placed in a Falcon tube (BD, UK) and 5 
mls of whole blood was layered on top.  Samples were centrifuged at 2500 
RPM (1349Xg) for 15 minutes and the interphase was removed to a fresh 
Falcon tube.  This was washed twice in complete medium and cells were 
resuspended in complete medium at 1.0x10
6 cells/ml prior to utilisation.
  
2.1.3  Laboratory animals 
Severe combined immunodeficient (SCID) mice (CB17 strain), bred locally, 
were kept under standard conditions in accordance with local ethics policy.   
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Cell line  Source  Notes 
Ramos  Professor G. Packham  Burkitt’s lymphoma 
Bcl-2 Ramos  Dr M Cragg  Burkitt’s lymphoma 
RL  Professor G. Packham  Diffuse large B cell Non Hodgkin’s lymphoma 
SU-DHL-4 Professor  G.  Packham  Diffuse  large B cell Non Hodgkin’s lymphoma 
Dohh2 Professor  F  Stevenson Transformed follicular lymphoma 
Akata 6  Professor G. Packham  Burkitt’s lymphoma 
  
Table 2-1 Cell lines used for this work: 
Cell lines were sourced as indicated.  All cell lines were originally sourced from the European Collection of Cell Cultures 
(ECACC) or the American Type Culture collection (ATCC).   
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2.1.4  Solutions 
 
RIPA Lysis Buffer (5X Concentrate) 
N a C l          0 . 7 5   M  
IGEPAL  (Sigma,  U.K)      5  %  (v/v) 
Sodium  Deoxycholate        2.5  %  (w/v) 
Sodium  Dodecyl  Sulphate      0.5  %  (w/v) 
Tris  Hcl  pH  8.0       0.25  M 
Protein Running Buffer 
T r i s   H C l         2 5   m M  
G l y c i n e         2 0 0   m M  
Sodium  Dodecyl  Sulphate      0.1  %  (w/v)   
Protein Transfer Buffer 
T r i s   H C l         2 5   m M  
G l y c i n e         2 0 0   m M  
Sodium Dodecyl Sulphate            0.1 % (w/v) 
Ethanol        25  %  (v/v) 
Tris-Buffered Saline (TS) 
Tris-HCl  pH  8      10  mM 
N a C l          1 5 0   m M  
    
- 61 - 
Tris-Buffered Saline – Tween (TS-T) 
Tris-HCL  pH  8       10  mM 
N a C l          1 5 0   m M  
Tween  20        0.1  %  (v/v) 
  
Phosphate Buffered Saline (PBS) 
N a C l          1 2 5   m M  
Sodium  Phosphate       16  mM 
Sodium  Hydrogen  Phosphate     10  mM 
pH 7.3 
Phosphate Buffered Saline – Tween (PBS-T) 
N a C l          1 2 5   m M  
Sodium  Phosphate       16  mM 
Sodium  Hydrogen  Phosphate     10  mM 
pH 7.3 
Tween 20        0.1 % (v/v) 
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2.1.5  Investigational compounds and reagents 
HDAC inhibitors 
1. SAHA (Alexis Biochemicals, UK)  
2. FK228 was a kind gift from Dr Minoru Yoshida, RIKEN, Japan 
These were diluted in DMSO and aliquots were stored at -20
0c 
CD20 monoclonal antibodies 
1. Rituximab was a kind gift from Southampton University Hospital Trust 
pharmacy 
2. B1 was a kind gift from Professor MJ Glennie [90] 
These were diluted in PBS and stored at 4
0c. 
Cross linking agent 
1. Rabbit anti Human IgG1 cross linking agent was a kind gift from Professor 
MJ Glennie  
This was diluted in PBS and stored at 4
0c     
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2.2  Methods 
2.2.1  Propidium iodide exclusion assay 
This assay is routinely used for assessing levels of cell death.  Cells are 
stained with propidium iodide (PI), apoptotic or dead cells allow PI to enter 
where it binds DNA resulting in a 20-30 fold increase in fluorescence, live 
cells have impermeable membranes so display no change in fluorescence. 
This assay was performed in 96 well plates (Greiner, Uk).  Cells suspended 
in 100µl complete medium were plated in each well (4.5X10
4/well).  These 
were incubated for 48 hours with investigational agents in a humidified cell 
incubator.  Following this cells were resuspended and transferred to Falcon 
tubes (BD, UK) prior to centrifugation at 1500 rpm (486Xg) for 5 minutes.  
Medium was removed and cells were resuspended in 400µl of 10µg/ml 
propidium iodide (PI) solution (Sigma, UK) and incubated in the dark at room 
temperature for 15 minutes.  Levels of cell death were measured by flow 
cytometry, with the proportion of dead cells calculated relative to the live cell 
peaks.  Control samples were treated with complete medium or the 
corresponding dilution of DMSO or PBS.    
2.2.2  Apoptosis Assays 
A flow cytometry based assay was used for measuring levels of apoptosis. 
Phospholipid phosphatidylserine (PS) translocation from the inner to the 
outer leaflet of the plasma membrane is one of the earliest events identified 
in cells indergoing apoptosis.  Annexin V, a 35-36 kDa, Ca 2+-dependent, 
phospholipid binding protein with a high affinity for PS is used to identify cells 
in the early stages of apoptosis. Cells are co stained with FITC conjugated 
Annexin V and PI this allows measurement of early and late apoptosis. 
These assays were performed in 96 well plates (Greiner, Uk).  Cells 
suspended in 100µl complete medium were plated in each well 
(4.5X10
4/well).  They were incubated for different times with investigational 
agents in an humidified cell incubator.  Following this cells were resuspended 
and transferred to Falcon tubes (BD, UK) prior to centrifugation at 1500 rpm    
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(486Xg) for 5 minutes.  Following this cells were resuspended and 
transferred to Falcon tubes (BD, UK) prior to centrifugation at 1500 rpm 
(486Xg) for a further 5 minutes.  Medium was removed and cells were 
resuspended in 300 µl annexin V binding buffer (BD, UK) with 2.5 µl 
(50µg/ml) PI and 2.5 µl FITC labelled annexin V (Annexin V:FITC Apoptosis 
Detection Kit I, BD, UK).  Cells were subjected to flow cytometry with levels 
of early and late apoptosis measured as a percentage of all cells, and 
normalized to levels in untreated cells. 
2.2.3  Western Blotting 
Western blotting is a method to detect the levels of a specific protein in a 
given sample.  Samples are subjected to gel electrophoresis to separate 
native or denatured proteins by the length of the polypeptide.  The 
proteins are then transferred to a nitrocellulose membrane, where they 
are detected by a specific antibody and a labeled conjugated secondary 
antibody.  
Sample preparation 
Whole cell lysates 
2x10
6 cells were treated in 24 well plates for different time periods, and then 
harvested and transferred to Falcon tubes. Samples were then centrifuged at 
1500 RPM (486Xg) for 3mins at 4
oC.  Samples were washed once with ice 
cold PBS, recentrifuged and the supernatant removed leaving the cell pellet.  
Cell pellets were snap frozen in liquid nitrogen and stored at -80
0C.  Cell lysis 
was performed with addition of 50µl 3X reducing SDS loading buffer per 
1x10
6 cells (1/10 volume 30X Reducing Agent to 1 volume of 3X SDS, Cell 
signalling, USA) used prior to sonication (Sonicator 3000, Misonix, Inc., 
USA), samples were stored at -80
0C until required. 
RIPA cell lysis 
2x10
6 cells were treated in 24 well plates for variable time periods, and then 
harvested and transferred to Falcon tubes. Samples were then centrifuged 
(Heraeus Biofuge Fresco, Rotor F-8134) at 1500 rpm (486xg) for 3mins at    
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4
oC.  Supernatant was removed and cell pellet was washed once with ice 
cold PBS, recentrifuged and the supernatant removed leaving the cell pellet. 
Pellets were re-suspended in 100 µl of 1X RIPA buffer and incubated on ice 
for 30 minutes. Samples were then subject to centrifugation at 4 
oC for 20 
minutes at 12000 rpm (13700xg) (Heraeus Biofuge Fresco, Rotor F-8134). 
The supernatant was transferred to new 1.5 ml eppendorf (Griener, U.K) and 
the cell debris discarded. Samples were subject to protein quantification 
using Bio-Rad protein assay reagent (Bio-Rad, U.K) and a BSA standard 
curve. Protein concentrations were equalised by addition of 1X RIPA. 
Immunoblotting 
Samples were heated at 95
oC for 3 minutes and 15µl was loaded onto a pre 
cast 4-15 % gradient tris HCl SDS- polyacrylamide gel ( Bio-Rad, UK).  
Electrophoresis was carried out at 200Volts for 30-45 minutes, using 
MiniProtean III apparatus (Bio-Rad, UK) in protein running buffer.  Protein 
was transferred from polyacrylamide gel onto nitrocellulose membrane 
(Protran, Schleicher and Schuell, Germany) using MiniProtean II apparatus 
at 100 Volts for 1 hour. 
Nitrocellulose was blocked in non fat marvel milk for one hour, incubation 
with primary antibodies were overnight at 4
0C, incubation with the 
appropriate secondary antibodies was for one to two hours at room 
temperature.  Nitrocellulose was treated with HRP substrate (Super Signal 
West Pico Substrate Chemoluminescence working solution, Pierce, UK) for 5 
minutes at room temperature.  Chemoluminescence was performed using 
Quantity One software package (V4.3.0).    
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Antibody to  Name/Clone  Source  Type  Antigen 
Bcl-2  C-2  Santa Cruz  Mouse monoclonal  amino acids 1-205 of human Bcl-2 
H4K8Ac #2594  Upstate  Rabbit  polyclonal  KLH-H4 amino acids 7-17(Ac-K8) 
Caspase 3  #9662  Cell signalling  Rabbit polyclonal 
full length (35kDa) and large cleaved 
fragment (17kDa) 
Caspase 9  #9502  Cell signalling  Rabbit polyclonal 
full length (47kDa) and large cleaved 
fragments 
Caspase 8  1-3-9  BD  Mouse monoclonal 
full length (55/50kDa) and cleaved 
fragment (40/36kDa) and 23kDa 
PARP C2-10  R&D  Mouse  monoclonal 
full length (116kDa) and large cleaved 
fragment (85kDa) 
PCNA  PC10  Cancer Research UK  Mouse monoclonal  Rat PCNA 
 
Table 2-2 Antibodies used in this study: 
Antibodies were either kind gifts from Professor G Packham or sourced as indicated.   
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2.2.4  Xenograft studies 
Severe combined immunodeficient mice (SCID) were inoculated 
subcutaneously in the left flank with 5x10
7 Ramos cells diluted in 200µl of 
complete medium.  After 7 days mice were divided into 4 groups and 
received intraperitoneal injection of a DMSO control solution, SAHA, 
Rituximab or the combination of SAHA and Rituximab.  Tumour volume was 
measured in millimetres (mm) in two dimensions three times weekly and 
mice were weighed three times weekly.  Mice were culled according to home 
office guidelines when a single tumour measurement exceeded 15mm.  
Following culling tumours were removed and cell suspensions were created 
as described earlier.   
2.2.5  Nucleic acid isolation 
RNA isolation for microarray analysis  
Ramos cells in logarithmic growth phase were treated with SAHA and 
crosslinked Rituximab alone or in combination and cells were harvested 
together with untreated cells at 6 and 16 hours.  Samples were washed twice 
with ice cold PBS and maintained in RNase free conditions at all times.  Cell 
pellets were treated with Trizol reagent (Invitrogen, UK) and RNA was 
extracted according to standard protocols.  RNA purification was performed 
using a Qiagen RNeasy kit (Qiagen, UK) according to the product protocol.  
RNA quality and quantitiy was assessed using Agilent bioanalyser (Agilent 
Technologies UK Limited, UK) and 3µg RNA was used for microarray 
analysis.  Duplicate samples for each condition were sent to the CRUK 
GeneChip Microarray Facility (PICR, Manchester), samples were labeled 
using Affymetrix One Cycle Protocol V1.0 and hybridised to the Affymetrix 
human array, the U133 Plus 2.0 array. 
Quantitative reverse transcription-polymerase chain reaction (Q-RT-
PCR) 
This technique is used to amplify and simultaneously quantify a targeted 
DNA molecule. It enables both detection and quantification of a specific 
sequence in a DNA sample.    
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Ramos cells in logarithmic growth phase were treated with SAHA and/or 
Rituximab.  Samples were washed twice with ice cold PBS and maintained in 
RNase free conditions at all times.  Cell pellets were treated with Trizol 
reagent (Invitrogen, UK) and RNA was extracted according to standard 
protocols.  RNA was quantified using Spectrophotometer nano drop ND-1000 
(Thermo Fisher scientific, USA) and 1µg RNA was used for cDNA synthesis.  
1µg RNA was made upto 14µl with nuclease free water. This was mixed with 
1µl oligo (dT) primer (500µg/ml, Promega, UK) and incubated for 5 minutes 
at 70
oC in a thermal cycler (Techne, UK).  Following this 5µl 5x buffer, 1.25µl 
10mM dNTP (1/10 dilution of dATP (100mM), dNTP(100mM),  
dGTP(100mM),  dCTP (100mM) made up in RNase free water, 0.625µl 
RNasin (40u/µl), 1µl M-MLV RT enzyme (200u/µl) (all Promega, UK) and 
2.125µl water was added to each sample.  Samples were mixed and 
incubated in a thermal cycler for 60 minutes at 42
 oC.  Samples were diluted 
to 85µl with RNase free water.  Q-RT-PCR was performed in 96 well optical 
plates (Applied Biosystems, UK) duplicate wells were loaded with 5µl 
sample, 10µl PCR master mix (Applied Biosystems, UK), 4µl water and 1µl of 
appropriate taqman gene expression assay (Applied Biosystems, UK).  All 
reactions were performed in duplicate using the ABI PRISM 7500 Sequence 
Detection system (Applied Biosystems) according to the following thermal 
cycle protocol: 94°c 10 mins, 94
0c 15 secs followed by 60°c 1 min for 40 
cycles and 60°c for 1 min. Control reactions with no cDNA were run on each 
plate for each Taqman gene Expression Assay used, no amplification was 
detected in any control reaction.      
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Gene Assay  ID  Accession  number  Commments 
β-actin Hs99999903_m1 NM_001101.2  β-actin 
PRG1 Hs01004159_m1  NM_002727.2 Proteoglycan  1, secretory granule 
Fos Hs00170630_m1  NM_005252.2  v-fos murine osteosarcoma viral oncogene 
homolog 
CD69 Hs00156399_m1  NM_001781.1 CD69  molecule 
Bcl2A1 Hs00187845_m1  NM_004049.2  BCL-2-related protein A1 
LTA Hs00236874_m1  NM_000595.2  lymphotoxin alpha (TNF superfamily, member 1) 
Bcl-2L1 Hs00236329_m1  NM_138578.1 BCL-2-like 1, Bcl-XL 
 
Table 2-3 Gene Expression assays used for real time PCR:   
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2.2.6  HDAC assay 
This Colorimetric HDAC Activity Assay uses an HDAC colorimetric substrate 
(Boc-lys(ac)-AMC), which comprises an acetylated lysine side chain.  
Deacetylation of the substrate results in production of a chromophore which 
can be analysed using a spectrophotometer.  SU-DHL-4 cells at 0.5x10
6 
cells/ml in complete medium (2 x10
4 cells/well) were plated in 96 well plates 
(Greiner, Uk) and cultured for 2 hours in a humidified cell incubator (HERA 
Cell, Heraeus) at 37
oC and 5% CO2 with SAHA or SAHA and rituximab.  
Control wells were treated with corresponding concentrations of DMSO or 
rituximab alone.  Boc-lys(ac)-AMC (chemicon, USA) was diluted to a stock 
concentration of 2 mM in complete media with 4 % DMSO. 10 µl of stock 
substrate is added to each well giving a final concentration of 200 µM in the 
well.  The cells were then incubated for a further 3 hours at 37°C.  Following 
this 100 µl of lysis buffer/developer mix (50 mM Tris-HCl pH8.0, 137 mM 
NaCl, 2.7 mM KCl , 1 mM MgCl2, 1% v/v Nonidet-P40, 2 mg/ml trypsin, 10 
µM TSA) was added and the cells were incubated overnight in a humidified 
cell incubator (HERA Cell, Heraeus) at 37
oC and 5% CO2.  The plate was 
read at excitation 355 nM and emission 460 nM on a fluorescent plate reader 
(Varioskan flash, Thermo scientific).  
2.2.7  Flow cytometry techniques 
CD69 analysis 
PBMCs extracted from whole blood were resuspended in complete medium 
at a concentration of 1x10
6 cells/ml. 1x10
6 cells were plated in 24 well plates 
(Greiner, UK) and treated with variable doses of SAHA and rituximab alone 
or in combination for variable durations.  Following this cells were harvested 
and washed twice with PBS containing 1% BSA (v/v) (complete buffer).  Cells 
were subsequently resuspended in 100µl complete buffer in Falcon tubes 
(BD, USA) and incubated in the dark on ice for 30 mins with 5µl CD69 and 
5µl CD19.  Control samples were incubated with equivalent concentrations of 
CD19 and IGg2a isotype control antibody [Table 2-4].  Samples were    
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subsequently washed twice and resuspended in 500µl complete buffer 
before being subjected to flow cytometric analysis (FACSCanto, BD, USA) 
Ca flux assay 
1x10
7 cells (Ramos, Su-DHL-4) in logarithmic growth phase were treated 
with SAHA or a corresponding concentration of DMSO for 2 hours. They 
were then subjected to centrifugation at 1500 rpm for 5 minutes, and washed 
twice in 5mls of RPMI growth medium (Roswell Park Memorial Institue 1640 
medium, Invitrogen, UK) supplemented with 2.0 mM L-glutamine (Invitrogen, 
UK) and 1.0 mM  sodium pyruvate (serum free medium).  Cell pellets were 
mixed with 10µM Indo-1-AM with 0.2% pluronic-F127, resuspended in 500µl 
serum free medium and incubated for 30 minutes in a humidified cell 
incubator (HERA Cell, Heraeus) at 37
oC and 5% CO2.  Following this cells 
were washed twice in 5mls of serum free medium, resuspended in complete 
RPMI growth medium and allowed to rest in the dark in a humidified cell 
incubator (HERA Cell, Heraeus) at 37
oC and 5% CO2.  Cells were 
subsequently divided into two samples and one sample was treated with 
rituximab 5µg/ml for 15 minutes.  Samples were diluted to a flow rate of 100-
200 cells/second and subjected to flow cytometric analysis (FACS vantage 
flow cytometer, BD Biosciences). 
ERK phosphorylation 
1x10
7 SU-DHL-4 cells in logarithmic growth phase were treated with SAHA, 
Rituximab, B1 or the combination for 15 minutes.  Control samples were 
incubated with a corresponding concentration of DMSO for 15 minutes.  
Following this an equal volume of buffered pH normal saline with 4% w/v 
paraformaldehyde (cytofix fixation buffer, BD, USA) was added.  Cells were 
incubated at 37
oC for 10 minutes, and collected by centrifugation.  1ml of 
80% w/v methanol was added, and cells were incubated on ice for a further 
30 minutes.  Samples were washed twice and resuspended in 100μl 
complete buffer with 5 μl phosphoERK (cell signalling, UK) antibody [Table 
2-4].  After 30 minute incubation at room temperature cells were washed 
again, resuspended in 200μl complete buffer and subjected to flow 
cytometric analysis.    
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Antibody to  Source  Type  Conjugate  Clone 
pERK1/2 Cell  signalling  IgG1  AlexaFluor-488  - 
CD19 BD IgG1  APC  HIB19 
CD69 BD IgG1  PE  FN50 
CD20  Dr M Cragg  Rituximab FITC  - 
CD20  Dr M Cragg  B1  FITC  - 
Isotype control  BD  IgG2a  FITC  G155-178 
Isotype control  BD  IgG1  FITC  MOPC-21 
Isotype control  BD  IgG1  R-PE  MOPC-21 
 
Table 2-4 Antidodies used for flow cytometric analysis:   
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2.3  Statistical analysis 
2.3.1   Dose response curves and IC50 calculations 
These were performed using prism version 4.03 (GraphPad Software inc, 
USA).  Analysis of synergy assays was performed using Calcusyn version 
2.0 (Biosoft, UK) statistical software package. This program uses formulae 
developed from Chou’s enzyme models of mass action and is routinely used 
to look at drug interactions [260].  A “combination index” value is derived 
which provides a quantification of the degree of drug interaction. Whereby a 
value less than 1 indicates a synergistic interaction and a value grater than 1 
indicates an antagonistic interaction. 
2.3.2  Microarray analysis 
Bioinformatic input for analysis of microarray was received from Richard 
Mitter at the Cancer Research UK Bioinformatics service (London).  Briefly 
Raw data was extracted from the MIAME VICE database (PICR, 
Manchester).  The probe level data (Cel files) were normalized using Robust 
Multi-Array Average (RMA) (Bioconductor, Affymetrix,UK) 
http://bioconductor.org/packages/2.1/bioc/vignettes/affy/inst/doc/affy.pdf) 
Expression fold change was calculated from mean levels from duplicate 
samples and was compared to controls.  A moderated t-test was used to 
assess differential expression and filtered on a false discovery rate adjusted 
p value of ≤ 0.05, and an absolute fold change of ≥2.   
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3  Project Aims and Outline of Investigation  
Combining targeted therapies for the treatment of malignant disease is a well 
established strategy and the beneifit of this approach has clearly been 
demonstrated with both HDI and CD20 mAb.  When considering novel 
combinations two major considerations are important.  Firstly a clear 
mechanistic rationale for combining agents must exist in order to potentiate 
their effects.  Secondly it is paramount that when given in combination, 
therapeutic doses of both agents must be achievable without predictable 
toxicity based on the side effect profile of either agents given alone.   
The published data discussed demonstrates that both HDI and CD20 mAb 
have shown some of their most promising activity when given in combination.  
Their ability to induce apoptosis and to modulate a number of important 
common survival pathways provides a clear rationale for investigating their 
effects together.  With these factors in mind this project was conducted via 
three distinct approaches. 
1. Firstly the ability of different HDI and CD20 mAb to induce cell death and 
apoptosis was investigated in a panel of CD20 positive B cell NHL cell lines, 
with the primary aim of establishing whether a synergistic effect was 
apparent and whether this was cell line or investigational agent specific. 
2. Secondly the underlying mechanism for this effect was sought.  Two 
approaches were used to do this.  Initially the modulation of early 
biochemical responses to either class of agents was investigated prior to 
trying to elicit the effects of combination treatment on the intrinsic and 
extrinsic apoptotic pathways. 
3. Thirdly gene expression analysis was performed to try to identify a 
cooperative transcriptional effect on previously described common survival 
pathways and to investigate novel interactions for further investigation.  This 
technique was also utilised to try and identify a biomarker of HDI 
transcriptional effect.   
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4  Synergistic cell killing in B cell NHL cell lines 
4.1  Introduction 
 
The initial aim of this project was to investigate the induction of cell death by 
CD20 monoclonal antibodies and HDIs in a panel of B cell NHL cell lines.  
Despite the dramatic effect of rituximab in improving overall survival for 
patients with non Hodgkin’s lymphoma [261],  many patients relapse and 
new strategies are needed to try and overcome this problem.  As has been 
discussed earlier one of the mechanisms employed by CD20 mAb is direct 
induction of cell death pathways following antibody binding.  The induction of 
cell death was measured in B cell NHL cell lines following treatment with 
Rituximab and SAHA alone and in combination.  Once a synergistic 
interaction had been observed the effect was investigated in different cell 
lines and with different combinations of CD20 mAb and HDI. A panel of 5 B 
cell non Hodgkin’s lymphoma cell lines was chosen to investigate this 
interaction.   
4.2  Effect of HDAC inhibitors 
Prior to investigating a combination effect it was important to characterise 
the activity of two different classes of HDI.  The hydroxamate SAHA and the 
cyclic tetrapeptide FK228 were chosen as they were two HDI in clinical 
development.  The Ramos cell line was initially chosen to investigate the 
cytotoxic effect of the HDAC inhibitor SAHA.  SAHA treatment resulted in 
dose dependent induction of cell death measured by propidium iodide 
staining and flow cytometric analysis [Figure 4-1].  Multiple data points were 
plotted using prism v4.03 software.  The IC50 was calculated as the 
concentration required to produce 50% of the maximal effect.  The mean 
IC50 was then calculated from multiple experiments.  SAHA treatment 
resulted in induction of cell death in a dose dependent manner with an IC50 
of 5.5 (±1.4) µM.   
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Figure 4-1  The effect of SAHA on Ramos cell survival: 
 
(A) Ramos cells were treated with variable concentrations of SAHA (1.25-
20µM) or left untreated as a control.  After 2 days, the proportion of cells that 
failed to exclude PI was determined by flow cytometry.  Representative 
histograms are shown with the percentage of PI positive cells in untreated 
(left) and 10µM SAHA treated (right) samples indicated. 
(B) Ramos cells were treated with the indicated concentrations of SAHA.  
After 2 days the proportion of cells that failed to exclude PI was determined 
by flow cytometry.  Data shown are the mean increase in the percentage of 
PI positive cells derived from duplicate determinations (±range) relative to 
untreated cells.  Experiment shown is representative of three experiments.    
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This assay was repeated to investigate whether this effect was preserved 
across different B-cell NHL cell lines and with FK228.  Figure 4-2 shows a 
representative dose response curve for Ramos cells treated with FK228. As 
was observed with SAHA this resulted in dose dependent cell killing, 
although FK228 was much more potent.   
Table 4-1 shows IC50s for the five cell lines treated with variable 
concentrations of SAHA and FK228.  There was little variation in IC50 
between the cell lines with SAHA effective at micromolar concentrations, 
while FK228 was more potent with cell death induced at nanomolar 
concentrations.  This data was consistent with reports from other 
investigators using solid tumour and lymphoid cell lines [262-264].      
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Figure 4-2 the effect of FK228 on Ramos cell survival: 
 
Ramos cells were treated with variable concentrations of FK228 (0.4-100nM) 
or left untreated as a control.  After 2 days, the proportion of cells that failed 
to exclude PI was determined by flow cytometry.  Data shown are the mean 
increase in the percentage of PI positive cells derived from duplicate 
determinations (±range) relative to untreated cells.  Experiment shown is 
representative of two experiments.    
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SAHA FK228 
IC50 Concentration 
(µM) 
Maximum cell death 
(%) 
IC50 Concentration 
(µM) 
Maximum cell death 
(%) 
Cell line 
mean SD  Mean SD  mean  SD  mean  SD 
Ramos 5.5  1.4  39.3  19.5  0.005 0.002 51.3  14.4 
SU-DHL-4 2.8  1.0  63.6  26.6 0.005  0.0006  57.2  11.3 
RL 3.2  0.6  33.0  8.1  0.006  0.0006  15.3  1.5 
Akata 2.1  0.6 37.2 6.0  0.003  0.0002  47.2  2.3 
Dohh2 0.9  0.0  41.1  1.0  0.006  0.0005  55.6  9.4 
 
 
 
Table 4-1 Sensitivity of B cell NHL cell lines to HDI: 
  
Summary of IC50’s and maximum levels of PI positive cells for the panel of B cell NHL cell lines treated with SAHA or FK228.  
Data shown are the mean IC50 and % PI positive cells (±SD) from at least duplicate independent experiments for the cell lines 
and HDI indicated.    
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4.3  Effect of CD20 monoclonal antibodies 
 
The effect of the CD20 monoclonal antibodies was again initially investigated 
in the Ramos cell line.  Cells were treated with a range of concentrations of 
the type I antibody rituximab alone and in combination with an anti human 
IgG crosslinking agent, or the type II antibody B1.  After 48 hours the levels 
of cell death were measured using a propidium iodide exclusion assay 
following incubation with Rituximab and B1 [Figure 4-3].  Both agents 
resulted in very low levels of cell killing in this assay with with no clear dose 
response relationship.  Rituximab and B1 in the absence of crosslinking do 
not result in intracellular Ca
2+ flux [99], so Ramos cells were also treated with 
Rituximab in combination with a crosslinking agent.  The addition of 
crosslinking resulted in a small increase in the levels of cell death observed 
but no clear dose response relationship. 
 
Data from Southampton, Teeling et al [265], has already demonstrated that 
CD20 receptor binding is saturated at concentrations greater than 0.5µg/ml 
mAb in cell lines with similar levels of surface CD20 to our panel of B cell 
lines. The assay was modified to investigate the effect of a saturating dose 
of mAb (10µg/ml) simultaneously across the panel of B cell lines. Cells were 
treated for 48 hours with levels of cell death estimated with the PI exclusion 
assay.  The percentage of PI positive cells observed in the 5 cell lines tested 
is shown [Figure 4-4].  Even at saturating concentrations low levels of cell 
death were observed with rituximab, B1 did result in higher levels of cell 
death in all the cell lines tested but the activity remained modest.  This data 
emphasises the finding that CD20 mAb induce low levels intracellular 
signaling and cell death.  Of note these assays were performed using heat 
inactivated fetal calf serum, which neutralizes any complement activity.  
Thus in the absence of functional ADCC and CDC; CD20 mAb demonsrate 
modest cytotoxic activity.  This result suggested that mechanisms to 
enhance this effect would provide a promising strategy for improving the 
cytotoxic activity of these agents.   
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Figure 4-3 Effect of CD20 monoclonal antibodies in Ramos cell line: 
 
Ramos cells were treated with variable concentrations of rituximab (0.125-
10µg/ml) with or without crosslinking agent.  After 2 days, the proportion of 
cells that failed to exclude PI was determined by flow cytometry. (A.) shows 
representive flow cytometry histograms for untreated (i), rituximab treated (ii) 
or crosslinked rituximab treated cells (iii).  (B.) Shows the mean increase in 
the percentage of PI positive cells derived from duplicate determinations 
(±range) for rituximab with (▲) or without (■) crosslinking agent.  Crosslinker 
only (∆) and untreated cells (●) are also shown. Experiment shown is 
representative of two experiments.  (C.) shows Ramos cells treated with 
variable concentrations of B1 (1-20µg/ml).  After 2 days, the proportion of 
cells that failed to exclude PI was determined by flow cytometry. Data shown 
are the mean increase in the percentage of PI positive cells derived from 
duplicate determinations (±range) untreated cells are again shown as a 
control (●).  Experiment shown is representative of two experiments.     
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Figure 4-4 Effect of rituximab and B1 in a panel of B cell NHL cell lines: 
 
B cell NHL cells were treated with rituximab 10µg/ml (□) or B1 10µg/ml (■).  
After 2 days, the proportion of cells that failed to exclude PI was determined 
by flow cytometry.  Data shown are the mean increase in the percentage of 
PI positive cells derived from triplicate determinations from two independent 
experiments (±range) relative to untreated cells.     
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4.4  Effect of combination treatment 
 
The data already presented established working concentrations for CD20 
mAb and HDI alone.  To investigate the effect of combination treatment 
Ramos cells were treated with crosslinked rituximab and SAHA alone or in 
combination using the same assays.  A saturating dose of rituximab was 
used with crosslinking as this achieved maximal effect with the weakly 
cytotoxic antibody, an active but sub optimal dose of SAHA was chosen to 
avoid maximal cell death with this agent.  After 48 hours levels of cell death 
were measured by PI exclusion assay [Figure 4-5].  Combination treatment 
resulted in an increase in the percentage of PI positive cells compared to 
treatment with crosslinked rituximab or SAHA alone.  An independent 
student’s t-test comparing combination treatment demonstrated a significant 
increase in cell death compared to either treatment alone.   
A similar effect was observed in Ramos cells treated with FK228 and 
rituximab [Figure 4-6].  This again resulted in a significantly higher level of 
cell death following combination treatment compared to either agent alone. 
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Figure 4-5 effect of SAHA in combination with rituximab in Ramos cell 
line: 
 
(A) Ramos cells were (I.) untreated, (II.) treated with SAHA 2.5µM, (III.) 
treated with crosslinked rituximab 10µg/ml or (IV.) treated with both agents.  
After 2 days, the proportion of cells that failed to exclude PI was determined 
by flow cytometry.  Representative histograms are shown. 
(B) Ramos cells were treated with the indicated concentrations of SAHA, 
rituximab or the combination.  After 2 days the proportion of cells that failed 
to exclude PI was determined by flow cytometry.  Data shown are the mean 
increase in the percentage of PI positive cells derived from duplicate 
determinations (±range) relative to untreated cells.  Experiment shown is 
representative of two experiments.  Independent student’s t-test was 
performed comparing combination treatment to either agent alone.    
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Figure 4-6 effect of FK228 and Rituximab in Ramos cell line: 
 
Ramos cells were untreated or treated with 5.3nM FK228, rituximab 10µg/ml 
or the combination.  After 2 days the proportion of cells that failed to exclude 
PI was determined by flow cytometry.  Data shown are the mean increase in 
the percentage of PI positive cells derived from duplicate determinations 
(±range).  Experiment shown is representative of two experiments. 
Independent student’s t-test was performed comparing combination 
treatment to either agent alone. 
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To investigate this effect further the assay was repeated in different B-cell 
NHL cell lines using the same concentrations of SAHA and rituximab [Figure 
4-7].  As was observed in Ramos cells there was a significant increase in the 
levels of cell death observed with combination treatment compared to either 
agent alone in 3 of the 4 additional cell lines investigated. 
These data demonstrate that CD20 mAb and HDI in combination can 
produce significantly higher levels of cell death than when either agent is 
used alone but does not prove whether this effect is synergistic or simply 
additive.   
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Figure 4-7 Effect of combination treatment in other cell lines: 
 
(A.) Dohh2, (B.) Akata 6, (C.) RL, (D.) SU-DHL-4 cell lines were left 
untreated or treated with SAHA 2.5µM, rituximab 10µg/ml or a combination 
of the two agents. After 2 days the proportion of cells that failed to exclude 
PI was determined by flow cytometry.  Data shown are the mean percentage 
of PI positive cells derived from duplicate or triplicate determinations 
(±range) and are representative of at least two independent experiments.  
Independent Student’s t-test was performed comparing combination 
treatment to either agent alone.    
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4.5  Synergy calculations 
 
The propidium iodide cell death assay used demonstrated cooperative cell 
killing but was limited by a number of factors.  PI is a late marker of cell 
death requiring loss of membrane integrity and DNA binding to alter the 
fluorescence of the dye.  Once cells have reached this stage, they are 
rapidly lysed.  PI positive cells have short term viability in culture making 
detection of 100% positivity unfeasible.  Another problem was the profile of 
PI staining (Figure 4-3A) which resulted in difficulty in gating true PI positive 
cells.  Despite these limitations significant cooperative effect was seen, 
however it was important to determine whether this was an additive or 
synergistic effect.  In this context synergy was defined as combination 
treatment resulting in greater levels of cell death than would be expected 
from the sum the effect of either agent alone.  The experimental conditions 
were optimised prior to investigating whether this interaction was synergistic 
in nature.  The initial aim was to investigate whether at an earlier time point 
induction of apoptotic pathways could be identified using annexin V staining 
and flow cytometry.  Annexin V, is a 35-36 kDa, Ca
2+ -dependent, 
phospholipid binding protein and is used to identify cells in the early stages 
of apoptosis. Cells are co stained with FITC conjugated Annexin V and PI 
allowing measurement of early and late apoptosis [Figure 4-8].  The 
percentage of apoptotic cells was analysed at the different timepoints with 
the most significant difference in levels of apoptosis between the treatments 
observed at 24 hours.  On this basis 24 hours was chosen as the timepoint 
to investigate synergistic induction of apoptosis.  The other important 
optimisation steps were to investigate the effect of scheduling and type of 
mAb.  Scheduling, has previously been demonstrated to be important for the 
interaction between HDI and a number of other agents [235].  The effect of 
scheduling was investigated in Ramos and SU-DHL-4 cells with no 
significant effect observed (data not shown).    
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Figure 4-8 Induction of apoptosis in Ramos cell line: 
(A) Ramos cells were (I.) untreated, (II.) treated with SAHA 5.5µM, (III.) 
treated with cross linked Rituximab 10µg/ml or (IV.) treated with both agents.  
Cells were harvested at 6, 16, 24 and 48 hours and co stained with annexin 
V and propidium iodide before being subjected to flow cytometric analysis.  
Representative dot plots for the 24 hour timepoint are shown with the % cells 
within each quadrant shown. 
(B) Ramos cells were treated with the indicated concentrations of SAHA (■), 
Rituximab (■) or the combination (□).  At variable time points the % of 
annexin V positive cells was determined by flow cytometry.  Data shown are 
the mean increase in the percentage of annexin V positive cells derived from 
duplicate determinations (±range) relative to untreated cells.  Experiment 
shown is representative of two experiments. Independent Student’s t-test 
was performed comparing SAHA to combination treatment.    
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It was also important to investigate whether cooperative induction of 
apoptosis was specific to CD20 mAb or was simply part of a generalised 
response to mAb membrane binding.  The effect of a panel of mAb, kindly 
provided by Dr M Cragg, alone or in combination with SAHA is shown 
[Figure 4-9].  The top panel shows the effect of CD20 mAb alone (clear 
bars) or with SAHA (black bars).  As has previously been shown, 
combination treatment resulted in a significant increase in levels of apoptosis 
compared to SAHA treatment alone.  The bottom graph shows the effect of 
irrelevant mAb (CD3) and isotype matched non CD20 specific mAb.  These 
mAb did not result in any significant increase in the level of apoptosis seen 
compared to SAHA alone.  Interestingly the anti BCR mAb (M15/8) resulted 
in higher levels of apoptosis than CD20 mAb alone and appeared to 
potentiate the effects of SAHA, although this effect was not statistically 
significant.        
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Figure 4-9 The specificity of CD20 mAb at inducing apoptosis: 
 
Ramos cells were treated with SAHA (5.5µM) (■) or a corresponding 
concentration of DMSO (□) in combination with the mAb indicated (10µg/ml)  
After 24 hours  cells were harvested and co stained with annexin V and 
propidium.  The percentage of annexin V positive cells was determined by 
flow cytometry.  Data shown are the mean increase in the percentage of 
annexin V positive cells derived from duplicate determinations from two 
independent experiments (±range) relative to untreated cells.  Independent 
Student’s t-test was performed comparing each combination to SAHA alone 
(* ns, ** p≤0.05).     
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Rigorous testing of the synergistic interaction between SAHA and rituximab 
was performed initially in the Ramos and SU-DHL-4 cell lines using the 
calcusyn statistical software package (Biosoft, UK).  Ramos cells were 
treated with a range of concentrations of SAHA distributed around the IC50 
from the initial PI exclusion assays.  A Rituximab dose range of 0.75–12 
µg/ml was chosen.  Combination treated samples were treated with either 
drug at a fixed ratio.  The levels of apoptosis were measured following 24 
hours incubation.  A dose response curve is shown for the three 
experimental conditions in Ramos and SU-DHL-4 cell lines. Combination 
treatment results in higher levels of apoptosis at all dose levels compared to 
either agent alone [Figure 4-10].  The mean percentage of annexin V 
positive cells for each condition at each dose level was analysed using 
calcusyn and is shown below.  Synergistic induction of apoptosis (CI <1) was 
seen across a wide dose range.      
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Figure 4-10 Synergistic induction of apoptosis in Ramos cell line: 
 
Ramos cells were treated with a range of concentrations of SAHA, Rituximab 
or the combination.   Cells were harvested at 24 hours and co stained with 
annexin V and propidium iodide before being subjected to flow cytometric 
analysis.   
(A)  Representative dot plots for Ramos cells (I.) untreated, (II.) treated with 
SAHA 5.5µM, (III.) treated with crosslinked rituximab 3µg/ml or (IV.) treated 
with both agents are shown with the % cells within each quadrant illustrated. 
Dose response curve (B) is shown.  Data shown are the mean increase in 
the percentage of annexin V positive cells derived from duplicate 
determinations (±range) relative to untreated cells for SAHA (♦), Rituximab 
(■) or the combination (▲) treatments.  CI value for each data point are 
shown.  Results shown are representative of two independent experiments.  
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This assay was repeated initially in Ramos cells with uncrosslinked rituximab 
and B1 in combination with SAHA and subsequently with FK228 in 
combination with rituximab.  The CI values at the IC50 point for these 
combinations are shown in Figure 4-11.  All combinations resulted in 
synergistic induction of apoptosis.  The mean CI value at the IC50 from 
duplicate experiments for other representative cell lines and treatment 
combinations is summarised in Table 4-2.  Synergistic induction of apoptosis 
was observed across 4 of the 5 cell lines treated with SAHA in combination 
with rituximab.  The Ramos and SU-DHL-4 cell lines were used to 
investigate the interaction between FK228 and rituximab and SAHA and B1.  
Synergistic induction of apoptosis was observed with all the different HDI 
CD20 mAb combinations tested.    
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Figure 4-11 Synergistic interactions in Ramos cells. 
 
Ramos cells were treated with SAHA±Cross linked Rituximab (A), SAHA± 
Rituximab (B), FK228± Rituximab (C) or SAHA±B1 (D):  Cells were 
harvested at 24 hours and co stained with annexin V and propidium iodide 
before being subjected to flow cytometric analysis.  Bar charts show the 
mean increase in the percentage of annexin V positive cells derived from 
duplicate determinations (±range) at the IC50 for the treatments indicated.  
CI values derived used calcusyn software are shown. 
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cell line  HDI  mAb  CI 
SAHA 5.5µM  rituximab 3µg/ml  0.42 
FK228 5.3nM  rituximab 3µg/ml  0.45  Ramos 
SAHA 5.5µM  B1 3µg/ml  0.58 
SAHA 2.8µM  rituximab 3µg/ml  0.06 
FK228 5nM  rituximab 3µg/ml  0.19  SU-DHL-4 
SAHA 2.8µM  B1 3µg/ml  0.24 
Dohh2 SAHA  0.9µM  rituximab  3µg/ml  0.26 
Akata 6  SAHA 2.1µM  rituximab 3µg/ml  0.33 
RL SAHA  3.2µM  rituximab  3µg/ml  3.1x10
6 
 
Table 4-2 Summary of combination index (CI) across panel of B cell 
NHL cell lines:  
Mean CI values from duplicate experiments at the concentrations of HDI and 
CD20 mAb indicated are shown.    
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4.6  Combination therapy in a xenograft model 
 
Having observed synergistic induction of apoptosis in vitro, a xenograft 
model was tested using subcutaneous Ramos tumours in severe combined 
immunodeficient mice (SCID).  Published data using a prostate cancer 
xenograft model had demonstrated that doses of SAHA 25mg/kg-100mg/kg 
intraperitoneal (IP) daily were well tolerated [262].  Initial experiments utilised 
SAHA at a dose of 25mg/kg on day 7 for 7 days, rituximab 250µg/ml on day 
7 or the combination of SAHA and rituximab at the above doses and 
schedule. Control animals received DMSO diluted in PBS on day 7 for seven 
days.  Figure 4-12 A. shows rate of tumour growth for the different 
treatments, this approach resulted in large variation in tumour size between 
mice and although combination treatment resulted in the slowest rate of 
tumour growth this was not statistically better than rituximab treatment alone. 
The toxicity of the treatments was estimated by assessing the change in 
weight of mice during treatment, there appeared to be no measurable 
changes in weight observed between the treated groups (Figure 4-12 B).  
To establish that SAHA was producing a target effect, western blotting for 
histone acetylation was performed on tumours extracted from mice at 
different timepoints. 1.8 fold induction of histone acetylation was detectable 
six hours after intraperitoneal injection of SAHA (Figure 4-13).   
To optimise the model, treatment of established tumours was adopted.  
Based on a predicted tumour failure rate of 20%, thirty mice were inoculated 
with tumour and twenty mice were selected to receive treatment once 
tumours were measurable.  The SAHA treatment schedule was also 
adapted.  Initially mice were treated for 14 days with SAHA 25mg/kg, this still 
resulted in little activity in the SAHA alone treatment arm (data not shown). 
When the dose was increased to 50mg/kg, SAHA became poorly soluble 
over the duration of the experiment.  Figure 4-14 shows tumour growth 
against time for the established tumour model.  Combination treatment again 
resulted in reduced tumour growth during treatment with SAHA, however this 
effect was lost once treatment was withdrawn.    
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Figure 4-12 Ramos xenograft: 
SCID mice were inoculated with 5x10
6 Ramos cells in the flank.  Following 7 
days mice were treated with DMSO for 7 days(x), SAHA 25mg/kg for 7 days 
(♦), Rituximab 250µg/ml on Day 7 (■) or the combination (▲).  Tumour size 
in 2 dimensions and weight were estimated three times weekly. Data shown 
represents: (A.). Mean tumour size (+/-SEM) from surviving mice for each 
treatment (n=5), (B.). Mean change in weight (%) of mice from baseline for 
each treatment (n=5).  
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Figure 4-13 Western blot of tumours from Ramos xenografts: 
 
SCID mice with established subcutaneous Ramos tumours were treated with 
SAHA 50mg/kg or a corresponding concentration of DMSO via intrperitoneal 
injection.  After 6 hours the mice were culled and tumours were removed.  
and homogenised to create a single cell suspension.  1x 10
6 cells were lysed 
in 70μl sample buffer (3x loading buffer, 30x DTT, H20) and sonicated. 
Samples were subjected to immunoblotting as described. 
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Figure 4-14 Rate of tumour growth in SCID mice with established 
tumours: 
SCID mice were inoculated with 5x10
6 Ramos cells in the flank.  Once 
tumours were palpable, mice were randomly assigned to treatment groups: 
DMSO/control (x), SAHA 25mg/kg for 14 days (♦), Rituximab 250µg/ml on 
Day 7 (■) or the combination (▲).  Tumour size in 2 dimensions and weight 
were estimated three times weekly. Data shown represents: mean tumour 
size (+/-SEM) from surviving mice for each treatment (n=5).    
- 100 - 
The effect of the different treatments on survival is shown [Figure 4-15].  
The Kaplan Meier plot shows the cumulative survival from 4 separate 
experiments.  Combination treatment resulted in a statistically significant 
improvement in survival compared to control or SAHA treated animals 
(p<0.001).  Across the entire duration of the experiments combination 
treatment showed an improved median overall survival compared to 
rituximab alone, but this was of borderline significance (p=0.067).  When the 
survival curves were compared at an earlier timepoint closer to completion of 
SAHA dosing there was a statistically significant benefit for combination 
treatment over Rituximab alone (p=0.017).  These data demonstrate the 
effect of combination treatment in a xenograft model, reinforcing the 
synergistic effect observed in vitro.    
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Figure 4-15 cumulative survival in xenograft model 
 
Kaplan Meier analysis of cumulative survival of mice from 4 experiments are 
shown (n=80).  Survival was measured from the first day of treatment for 
mice with established and non established tumours.  All control mice 
received DMSO and PBS IP at concentrations corresponding to the active 
agents. Rituximab treated mice received 250μg on day 1.  SAHA treatment 
arm includes mice who received SAHA 25mg/kg for 7 days, 50mg/kg for 14 
days and 25mg/kg for 14 days.  All control mice received.  Both Rituximab 
and combination treated arms showed a significant survival benefit over the 
control arm (p<0.05).  Combination treatment showed a trend towards 
improved median survival compared to rituximab alone (25 Vs15.5 days, 
p=0.067)     
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4.7  Discussion 
 
The data presented in this chapter regarding the single agent activity of 
CD20 mAb and HDI are consistent with the published data for the activity of 
these agents in inducing cell death in non Hodgkin’s lymphoma cell lines.  It 
has been shown that treatment of B cell NHL cell lines with type I mAb 
(rituximab) results in little or no induction of cell death [84, 266] unless 
crosslinking is used.  In subsequent studies Shan et al utilised Annexin V 
and PI staining and demonstrated induction of apoptosis without cross 
linking [85].   In the time course assay [Figure 4-8] cross linked rituximab 
resulted in 36% Annexin V positive cells after 48 hours treatment.  Work in 
Southampton has concentrated on type II mAb (B1) which are more effective 
at inducing cell death than type I mAb [87], as shown here [Figure 4-4].  It 
appears that type II mAb utilise different mechanisms for inducing cell death 
to type I mAb.  In the case of type II mAb this cell death is independent of 
caspase activity and only partially blocked by overexpressing Bcl-2 [71, 87, 
90].  Type I mAb appear to utilise classical apoptotic pathways with PARP 
cleavage and DNA fragmentation [85, 88, 267].  Despite persisting debate 
about the exact mechanism of action of these agents, they have proven 
most effective in clinical use when given in combination with other agents.  
This cooperative activity is underpinned by mechanistic data supporting the 
importance of intracellular signaling events in these interactions.  Demidem 
et al [268] observed that cell lines resistant to chemotherapeutic agents 
(doxorubicin and cisplatin) could be resensitised by pre treatment with CD20 
mAb.  Further studies by this group have suggested that downregulation of 
BclxL and Bcl-2 are responsible for this effect [68].  They have been able to 
show that rituximab modulates a number of key upstream pathways 
responsible for regulating these Bcl-2 family proteins.  Initially they assessed 
the effect of rituximab on the ERK 1/2 pathway.  They showed that 
monomeric rituximab inhibited ERK 1/2 phosphorylation resulting in 
downregulation of BclxL [102].  Inhibition of the NFkB pathway was also 
observed using EMSA, with time dependent downregulation of Bcl-XL 
expression demonstrated with western blotting [269].  Regulation of STAT    
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pathways have also been implicated in the generation of a chemosensitive 
phenotype by rituximab via down regulation of IL-10 and STAT3 
phosphorylation [270].   
The ability of HDI to induce cell death in a dose dependent manner has been 
well described with other investigators demonstrating this effect at similar 
concentrations to those illustrated here [262-264].   The data in this chapter 
demonstrates that 2 clinically relevant HDI induce apoptosis in a dose and 
time dependent fashion in a panel of B cell NHL cell lines.  It also illustrates 
that this effect is not dependent on the inhibition of class II HDAC enzymes 
as the effect is observed with FK228 which is a specific inhibitor of class I 
HDACs [201].   
Despite their ability to induce cell death in a wide range of haematological 
and solid tumour cell lines, the exact mechanism of action of HDIs remains 
elusive.  Their ability to induce apoptosis was reported in 1999 by Vrana et 
al [214].  They observed that treatment of U937 leukaemia cell line with 
SAHA resulted in PARP cleavage and induction of caspase 3 activity.  They 
also demonstrated that this effect could be overcome by overexpression of 
Bcl-2 and Bcl-XL and required an intact c-Jun/AP1 axis.  Subsequent studies 
have mapped the apoptotic pathways induced more clearly; Henderson et al 
[271] used an MCF7 cell line expressing a dominant negative form of 
Caspase 9.  They observed that although processing of other caspases 
occurred following TSA treatment, over expression of the aberrant caspase 
9 blocked this effect.  They postulated that caspase 9 was activated by 
release of cytochrome C in a Bcl-2 dependent fashion.  The role of 
cytochrome C release is supported by other investigators [272], although this 
group showed that caspase activity was dispensible, albeit in a different cell 
line.  Taken together this data suggests that the effects seen may be cell line 
and HDI specific.   
Despite the ability of HDI to induce apoptosis, their most promising activity 
has been observed in combination with other agents.  They have shown 
promising activity in combination with the monoclonal antibody trastuzumab 
resulting in synergistic induction of apoptosis [238, 242]. Synergy may result 
from counteracting HER2 over expression as HDAC inhibition reduced 
HER2 mRNA transcript expression and induced HER2 protein degradation    
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[242, 243].  The latter mechanism occurred via acetylation of heat shock 
protein (HSP) 90 causing its inactivation and loss of multiple HSP90 client 
proteins.  HSP90 acetylation decreased ATP binding inducing a shift from 
HER2 binding with HSP90 to HSP70, resulting in HER2 targeting for 
ubiquitination and proteasomal degradation [242].  This example 
demonstrates the ability of HDI to interact with monoclonal antibodies to 
potentiate their activity.  Perhaps more relevant to combination with 
rituximab is the cooperative effect observed with the proteosome inhibitor 
bortezomib [273].  In this study combination treatment resulted in synergistic 
induction of classical apoptosis with caspase activation.  Of particular 
relevance was the observation that combination treatment resulted in 
inhibition of NFқB signaling, a mechanism that may be important for 
combination with CD20 mAb [273]. 
The ability of SAHA and rituximab to produce synergistic induction of 
apoptosis has also been described [274].  In this study SU-DHL-4 and Daudi 
cell lines were used to show synergistic growth inhibition as well as induction 
of apoptosis.  The data presented in this chapter demonstrates this effect 
across a wider range of cell lines and with different combinations of mAb and 
HDI.  These differences are important as they help to probe some of the 
potential mechanisms underlying this interaction.   
All except one of the cell lines tested resulted in synergistic induction of 
apoptosis despite a broad spectrum of expression of Bcl-2 and STAT family 
proteins (data not shown).  Of note the RL cell line has high levels of Bcl-2, 
BclXL and STAT3 all of which have been implicated in resistance to HDI 
mediated induction of apoptosis.  Type I and II mAb appear to utilise 
different cell death pathways yet both agents synergise with HDI.  The 
assays utilised in this chapter are not specific for the different apoptotic 
pathways, but it seems clear that synergistic activity results in translocation 
of PS to the cell membrane and ultimately loss of membrane integrity.  
Further investigation of the apoptotic mechanisms involved will be discussed 
in chapter 5.  It is clear from the literature that type II mAb do not invoke 
intracellular Ca
2+ flux [99], yet synergistic induction of apoptosis was still 
observed with SAHA suggesting that this is irrelevant for synergistic killing.      
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5  Mechanisms underlying cytotoxicity 
5.1  Introduction 
 
With the mechanism of action of both agents in vivo unclear, investigations 
initially explored simple interactions that might account for the synergistic 
induction of apoptosis observed.  The effect of combination treatment on 
levels of histone acetylation, surface CD20 expression and intracellular Ca
2+ 
flux were assessed.  Subsequently the effect of treatment on Bcl-2 family 
protein expression was examined.  Having demonstrated that combination 
treatment resulted in induction of apoptosis, western blotting was used to 
investgate processing of caspases and poly ADP ribose polymerase 
(PARP).  Subsequently overexpression of Bcl-2 and caspase inhibitors were 
utilised to explore this interaction. 
5.2  Induction of histone acetylation 
 
Induction of histone acetylation is one of the best described direct 
biochemical responses following treatment with HDAC inhibitors.  Two 
assays were performed to identify whether combination treatment with 
HDAC inhibitors and CD20 mAb resulted in changes in the dynamics of 
histone acetylation compared to HDAC inhibitors alone. Initially timecourse 
assays were performed to examine the dynamics of histone acetylation in 
Ramos cells treated with SAHA.  Cells were treated at the IC50 from 
previously performed cell death assays with or without crosslinked rituximab.  
This concentration was chosen as it had induced robust synergistic 
apoptosis.  Acetylation was increased within 2 hours and was not affected by 
the addition of Rituximab which had no effect on histone acetylation [Figure 
5-1].  To investigate this effect further western blotting was performed in the 
RL cell line, which had not shown synergistic induction of apoptosis with the 
combination.  [Figure 5-2].  This again demonstrates that Rituximab 
treatment resulted in no change in the dynamics of histone acetylation 
resulting from treatment with SAHA     
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Figure 5-1 Histone acetylation in Ramos cells: 
Ramos cells at 0.5x10
6/ml were plated in 24 well plates.  Cells were treated 
with SAHA (5.5μM) alone or in combination with crosslinked Rituximab 
(3μg/ml).  Control samples were left untreated, treated with crosslinked 
Rituximab (3μg/ml), X linker alone or an equivalent concentration of DMSO.  
At the time points indicated cells were harvested and whole cell lysates were 
prepared for western blotting as described above. Results shown are 
representative of two independent experiments. 
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Figure 5-2 Histone acetylation in RL cells: 
RL cells at 0.5x10
6/ml were plated in 24 well plates.  Cells were treated with 
SAHA (3.2μM) alone or in combination with crosslinked Rituximab (3μg/ml).  
Control samples were left untreated, treated with crosslinked Rituximab 
(3μg/ml), or an aquivalent concentration of DMSO with X linker.  At the time 
points indicated cells were harvested and whole cell lysates were prepared 
for western blotting as described above. Results shown are representative of 
two independent experiments.    
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To quantify the effect of the various treatment combinations on the levels of 
histone acetylation, western blotting was repeated at the 24 hour timepoint 
with SAHA alone or in combination with Rituximab or B1.  Quantification of 
band intensity was performed from duplicate immunoblots.  Figure 5-3, 
shows a representative blot from Ramos cells with levels of histone 
acetylation shown in the bar chart.  There was no significant difference in the 
levels of histone acetylation observed in SAHA or combination treated cells.  
This effect was also observed in the SU-DHL-4 cell line [Figure 5-4]. 
Western blotting with quantification of levels of histone acetylation is widely 
used as a measure of HDI activity.  As already discussed histone acetylation 
occurs as a result of the balance between HDAC and HAT activity.  An 
HDAC enzyme inhibition study was performed with a dose range of SAHA 
alone or in combination with Rituximab to specifically analyse enzyme 
inhibition.  This colorimetric HDAC enzyme activity assay uses colorimetric 
HDAC substrate with an acetylated lysine side chain.  Deacetylation of the 
substrate results in production of a chromophore.  This can be measured 
using a spectrophotometer, to determine HDAC enzyme activity.  This assay 
was performed in the SU-DHL-4 cell line as a representative cell line to 
corroborate the findings from western blotting.  Cells were treated for 2 hours 
with increasing concentrations of SAHA alone or in combination with 
Rituximab.  This timepoint was chosen as western blotting had confirmed 
histone acetylation and cells would remain viable.  The addition of Rituximab 
had no effect on the dose response curve for the HDAC enzyme inhibition of 
SAHA [Figure 5-5]. Taken together these data demonstrate that SAHA 
produces HDAC enzyme inhibition in a dose dependent fashion with time 
dependent accumulation of acetylated core histones, as measured by 
histone 4 lysine 8 acetylation.  The addition of CD20 mAb does not appear 
to affect the modulation of this specific HDAC target. 
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Figure 5-3 Histone acetylation in Ramos cells: 
Ramos cells at 0.5x10
6/ml were plated in 24 well plates.  Cells were treated 
with SAHA (5.5μM) alone or in combination with crosslinked Rituximab 
(3μg/ml) or B1 (3μg/ml).  Control samples were left untreated, treated with 
crosslinked Rituximab (3μg/ml), or B1 (3μg/ml).  After 24Hrs cells were 
harvested and whole cell lysates were prepared for western blotting.  
Results shown are representative of two independent experiments.  Bar 
chart shows mean level of H4K8Ac (±range) from duplicate blots normalised 
to PCNA loading control, relative to SAHA treated cells (set to 1.0). 
Independent Student’s t-test was performed comparing SAHA to 
combination treatment.     
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Figure 5-4 Histone acetylation in SU-DHL-4 cell line: 
SU-DHL-4 cells at 0.5x10
6/ml were plated in 24 well plates.  Cells were 
treated with SAHA (2.4μM) alone or in combination with Rituximab (3μg/ml) 
or B1 (3μg/ml).  Control samples were treated with DMSO, Rituximab 
(3μg/ml), or B1 (3μg/ml).  After 24Hrs cells were harvested and whole cell 
lysates were prepared for western blotting.  Results shown are 
representative of two independent experiments.  Bar chart shows mean level 
of H4K8Ac (±range) from duplicate blots normalised to PCNA loading 
control, relative to SAHA treated cells (set to 1.0).  Independent Student’s t-
test was performed comparing SAHA to combination treatment.   
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Figure 5-5 HDAC enzyme assay in SU-DHL-4 cell line: 
SU-DHL-4 cells at 0.5x10
6 cells/ml were plated in 96 well plates and cultured 
for 2 hours with SAHA (0.075-10µM) (■) or SAHA and Rituximab (3µg/ml) 
(▲).  Control wells were treated with corresponding concentrations of DMSO 
or rituximab alone.  HDAC enzyme assay was performed.  Graph shows a 
dose response curve for mean percentage enzyme activity (+/-range), 
normalised to control wells (DMSO) for triplicate samples from a 
representative experiment.    
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5.3  Modulation of CD20 expression 
 
Having excluded modifications of HDAC inhibitor associated histone 
acetylation, it was important to exclude that SAHA was upregulating surface 
CD20 expression or modifying CD20 association with Triton X insoluble lipid 
rafts.  Initially the baseline level of CD20 expression was assessed in the 
panel of B cell NHL cell lines already utilised.  There was a large range of 
CD20 expression, and RL cells which had not shown synergistic killing 
displayed high levels of surface CD20 compared to cell lines which had 
displayed strong synergy [Figure 5-6].   
The Ramos cell line, with a moderately high surface CD20 level, was again 
chosen to examine the effect of treatment on CD20 expression.  This was 
assessed in two ways using a flow cytometry assay.  Firstly the global levels 
of surface CD20 expression were assessed with and without pretreatment 
with SAHA.  This appeared to have no effect on FITC labelled Rituximab or 
B1 binding at the time points utilised [Figure 5-7].  Secondly the extent of 
CD20 lipid raft redistribution was examined.  It has already been described 
that type I, but not type II CD20 mAb induce CD20 lipid raft redistribution 
[87].  In these experiments lipid rafts were defined by their confinement to 
the Triton X-100 insoluble membrane portion.  In the Triton X-100 insoluble 
fraction Rituximab had resulted in accumulation of CD20, with binding 
≥100% of the whole membrane fraction. The type II mAb had not resulted in 
translocation of CD20 to Tx-100 insoluble lipid rafts with binding reduced to ≤ 
40% of the whole membrane fraction consistant with published data.  This 
effect on CD20 was not influenced with pretreatment with SAHA for the 
timepoint indicated [Figure 5-7].  In conclusion this data suggested that 
synergy was observed in cell lines with a range of CD20 expression and that 
treatment with SAHA did not result in modulation of CD20 or influence 
redistribution patterns at early timepoints following CD20 mAb ligation.   
Having demonstrated that the synergy observed was not due to alterations 
in the putative targets of HDI or CD20 mAb, further investigation 
concentrated on the effect of either agent on induction of apoptotic 
pathways.   
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Figure 5-6 CD20 expression in panel of B cell NHL cell lines: 
0.5x10
6 cells from each cell line was placed in a FACS tube and washed in 
FACS buffer, cells were resuspended in 50μl FACS buffer with FITC labelled 
rituximab or FITC labelled IgG1 isotype control antibody.  Cells were 
incubated on ice for 30 minutes, then washed twice in FACS buffer.  Cells 
were resuspended and analysed by flow cytometric analysis.  Graph shows 
mean MFI (±range) relative to Isotype control for each cell line from two 
independent experiments.    
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Figure 5-7 Effect of SAHA on CD20 expression in Ramos cells: 
Ramos cells at 0.5x10
6 were treated overnight with 5.5μM SAHA or a 
corresponding concentration of DMSO.  Cells were harvested and washed in 
FACS buffer, and incubated on ice with 10μg/ml FITC labelled rituximab or 
B1 for 30 minutes.  At this point samples were split, 1 part was incubated 
with Triton X100 for 30 minutes (III, IV), 1 part remained on ice (I, II).  All 
samples were washed twice and resuspended with FACS buffer. 
Representative histograms are shown with isotype control DMSO (■), SAHA 
(■) and rituximab plus DMSO (■), SAHA (■) in I and III.  B1 DMSO (blue) 
and SAHA (purple) in II and IV.  Bar charts show (A) mean CD20 binding (± 
range) with Rituximab (□) and B1 (■) for DMSO or SAHA pretreated cells 
from duplicate experiments. (B). mean percentage Tx-100 insoluble CD20 
binidng (± range) with Rituximab (□) and B1 (■) for DMSO or SAHA 
pretreated cells from duplicate experiments.      
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5.4  Measurement of Ca
2+ flux and ERK phosphorylation 
 
In contrast to histone acetylation one of the earliest events occurring after 
mAb binding is Ca
2+ fluxing.  Therefore flow cytometric analysis of Ca
2+ 
fluxing following Rituximab binding was performed in Ramos cells in the 
presence or absence of SAHA pretreatment to elucidate whether Ca
2+ flux 
was potentiated by combination treatment [Figure 5-8].  In the absence of 
Rituximab no Ca
2+ flux occurs even with the addition of crosslinking agent.  
Rituximab only results in Ca
2+ fluxing after the addition of the crosslinking 
agent.  This effect is not changed by pretreatment with SAHA.  The 
histogram shows mean values for the FL5/FL4 ratio against time for 
untreated and SAHA pretreated samples.  This result demonstrates that the 
synergistic killing observed is not due to changes in Ca
2+ fluxing following 
Rituximab treatment.   
Another well described downstream sequlae of Rituximab binding to the 
CD20 receptor is ERK 1/2 phosphorylation.  A flow cytometry assay was 
performed to investigate whether SAHA affected ERK 1/2 phosphorylation.  
The SU-DHL-4 cell line was chosen as ERK 1/2 phosphorylation occurs in 
this cell line following CD20 ligation in the absence of crosslinking.  
Consistent with published literature type I but not type II CD20 mAb induce 
ERK 1/2  phosphorylation, this is unaffected by the addition of SAHA [Figure 
5-9]. 
These two experiments do not support the hypothesis that SAHA modulates 
early intra cellular signalling events following type I mAb ligation.      
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Figure 5-8 Ca
2+ flux following Rituximab treatment in Ramos cells 
1x10
7 Ramos cells were treated with 5.5µM SAHA or a corresponding 
concentration of DMSO for 2 hours and stained for Ca
2+ measurement as 
described.  Cells were subsequently divided into two samples and one sample 
was treated with rituximab 5µg/ml and one treated with a corresponding 
concentration of PBS for 15 minutes. Ca
2+ flux was measured for 60 seconds 
before addition of crosslinking agent.  Dot plots are shown for cells treated with I. 
PBS, II. Rituximab and III. SAHA and Rituximab.  IV. Shows mean FL5/FL4 ratio 
for Rituximab treated (■) and SAHA + Rituximab (■) treated cells.  Data shown 
are representative of two independent experiments.    
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Figure 5-9 ERK phosphorylation in SU-DHL-4 cell line 
1x10
6 SU-DHL-4 cells were treated incubated with Rituximab or B1 with or 
without SAHA.  Control samples were treated with SAHA alone or a 
corresponding concentration of DMSO.   After 15 minutes cells were 
harvested, permeabilised and stained with pERK antibody for 30 minutes.  
Samples were washed twice and resuspended in FACS buffer.  I. shows 
untreated (■) and SAHA treated controls (■) and Rituximab (■) and 
combination treated samples (■).  II. Shows untreated (■) and SAHA treated 
controls (■) and B1 (■) and combination treated samples (■).  Data shown 
are representative of two independent experiments.    
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5.5  Mechanisms of cell death 
 
With clear evidence of synergistic cell killing demonstrated with flow 
cytometry using Annexin V and PI staining and no evidence that this was 
due to changes in CD20 expression, Ca
2+ flux, ERK phosphorylation, or 
histone acetylation, investigation turned to the mechanism of cell death. 
Published data suggest that cell death due to HDAC inhibitors is via capsase 
dependent apoptotic pathways with regulation of genes from the instrinsic 
apoptotic pathway [211].  The role of the intrinsic pathway is supported by 
other investigators [214, 215].  These observations are not universally 
observed with evidence of modulation of the extrinsic pathway [216].  Thus it 
appears that their ability to induce apoptosis appears to be cell line and HDI 
specific.  In Ramos cells treated with SAHA time dependent induction of 
apoptosis occurs [Figure 5-10].  PARP cleavage was observed after 16 
hours incubation with cleavage of effector caspase 3 at the same timepoints.  
Processing of the intrinsic initiator caspase 9, appeared to preceed these 
events, implying it was an upstream event.  The effect on caspase 8 was 
also investigated and there did not appear to be any processing visable. 
In contrast to this the mechanisms adopted by CD20 mAb are much more 
controversial.  In Burkitt lymphoma cell lines CD20 mAb can induce 
apoptosis [85].  This effect is usually dependent on the addition of an Fc 
region cross-linking agent or Fc-receptor-bearing accessory cells [85, 98].  
The mechanisms of cell death resulting from mAb binding appear to differ 
depending on the class of mAb used (review [83]). Rituximab treatment in 
the presence of crosslinking results in classical apoptosis with caspase 
activation and PARP cleavage [84, 85].  In Ramos cells incubation with a 
saturating concentration of CD20 mAb produced apoptosis [Figure 5-11]. 
Western blotting from these experiments showed that this level of cell death 
was not accompanied by PARP cleavage or caspase 9 processing following 
incubation with the type II mAb B1.  The addition of hypercrosslinking 
resulted in a small increase in the level of apoptosis and induction of PARP 
cleavage and caspase 9 processing. 
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Figure 5-10 Apoptosis following SAHA treatment: 
Ramos cells at 0.5x10
6 cells/ml were plated in 6 well plates and treated with 
SAHA (5.5μM).  Control samples were left untreated or treated with an 
equivalent concentration of DMSO.  At the timepoints indicated cells were 
harvested.  Duplicate samples from each well were prepared for flow 
cytometric analysis using Annexin V/PI staining.  The remainder was 
resuspended in a RIPA lysis buffer.  Following quantification, 20μg of protein 
per sample was used for immunoblotting.  (A.) shows PARP, Caspase 9 and 
8, with PCNA as a loading control. (B.) Shows caspase 3 processing with 
PCNA loading control.  (C.) Shows mean % increase in annexin V positive 
cells (± range) compared to untreated cells from the same experiment.  Data 
shown are representative of two independent experiments.      
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Figure 5-11 Mechanism of induction of cell death with CD20 mAb in 
Ramos cells: 
Ramos cells at 0.5x10
6 cells/ml were plated in 6 well plates and treated with 
Rituximab (3μg/ml) alone or with a crosslinking agent (X), or B1 (3μg/ml).  
Control samples were left untreated or treated with a corresponding 
concentration of crosslinking agent.  At the timepoints indicated cells were 
harvested.  Duplicate samples from each well were prepared for flow 
cytometric analysis using Annexin V/PI staining.  The remainder was 
resuspended in a RIPA lysis buffer.  Following quantification, 20μg of protein 
per sample was used for immunoblotting. (A.) shows B1 treated cells, (B.) 
Rituximab and (C.) Crosslinked Rituximab.  (D.) Shows mean % increase in 
annexin V positive cells following 24 hours treatment (± range) compared to 
untreated cells from 2 independent experiments.  Data shown are 
representative of 2 independent experiments.    
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The effect of combination treatment was investigated in three B cell NHL cell 
lines.  Compared to SAHA alone combination treatment appeared to induce 
higher levels of PARP cleavage in Ramos and SU-DHL-4 cells [Figure 
5-12]. Treatment of RL cells with either SAHA or Rituximab alone or in 
combination did not result in induction of PARP cleavage, this was 
consistent with the low levels of cell death observed in previously shown cell 
death assays.   
These timecourse studies did not allow simultaneous camparison of type I 
and type II CD20 mAb in combination with SAHA, so the experiment was 
redesigned.  Ramos and SU-DHL-4 cells were incubated for 24 hours in the 
presence of SAHA, Rituximab and B1 alone and in combination [Figure 
5-13].  Quantification of the levels of PARP cleavage induced by the 
treatment conditions was performed from duplicate blots using “quantity one” 
software.  The levels of PARP cleavage are shown in the bar charts.  There 
was a modest but significant increase in the levels of cleaved PARP in both 
cell lines following combination treatment compared to SAHA alone.  This 
data supports the Annexin V/PI cell death analysis and suggests that the 
synergistic interaction observed is feasibly through activation of apoptotic 
pathways culminating in PARP cleavage.   
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Figure 5-12 Combination treatment in B cell NHL cell lines: 
B cell NHL cells at 0.5x10
6/ml were plated in 24 well plates.  Cells were 
treated with SAHA, at the concentration shown, alone or in combination with  
Rituximab (3μg/ml).. Control samples were left untreated, treated with 
crosslinked Rituximab (3μg/ml), or an equivalent concentration of DMSO 
and/or crosslinking agent.  At the time points indicated cells were harvested 
and whole cell lysates were prepared for western blotting as described 
above. Results shown for (A) Ramos, (B) SU-DHL-4 and (C) RL cell lines 
are representative of two independent experiments.    
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Figure 5-13 Induction of PARP cleavage following combination 
treatment: 
Ramos or SU-DHL-4 cells at 0.5x10
6/ml were plated in 24 well plates.  Cells 
were treated with SAHA (5.5μM Ramos, 2.8μM SU-DHL-4) alone or in 
combination with Rituximab (3μg/ml) or (B1 3μg/ml).  Control samples were 
treated with an equivalent concentration of DMSO.  After 24Hrs cells were 
harvested and whole cell lysates were prepared for western blotting as 
described above. Results shown are representative of two independent 
experiments from (A) SU-DHL-4 and (C) Ramos cells  Bar charts show 
mean level of cleaved PARP (±range) from duplicate blots for (B) SU-DHL-4 
and (D) Ramos cells.  Independent Student’s t-test was performed for mean 
level of cleaved PARP in SAHA compared to combination treated samples. 
(** p≤0.05)    
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To investigate whether caspase processing was necessary for the induction 
of apoptosis observed following combination treatment, Ramos cells were 
again incubated with SAHA, Rituximab and B1 alone and in combination in 
the presence and absence of the pan caspase inhibitor QVD-oph (MP 
Biomedicals, Aurora, Ohio, USA).  SAHA and combination induced 
apoptosis was inhibited by caspase inhibition [Figure 5-14].  The Addition of 
QVD-oph had no significant effect on levels on annexin V positive cells in 
Rituximab treated cells, consistent with the observation that caspase activity 
is not necessary for this effect.  Importantly the addition of the pan caspase 
inhibitor abolished any cooperative effect seen with combination treatment.  
A similar effect was seen with B1 (data not shown).  To establish whether 
the abolition of cooperative induction of apoptosis observed was through 
inhibition of caspase processing samples were also prepared for western 
blotting.  Induction of PARP cleavage and caspase 3 and 9 processing was 
seen, the addition of QVD-oph abolished this effect [Figure 5-15].  Taken 
together these observations support the hypothesis that the synergistic cell 
death observed is dependent on caspase processing and ultimately PARP 
cleavage.    
- 124 - 
FL1-H
F
L
2
-
H
10
0
10
1
10
2
10
3
10
4 10
0
10
1
10
2
10
3
10
4
0% 4%
85% 10%
FL1-H
F
L
2
-
H
10
0
10
1
10
2
10
3
10
4 10
0
10
1
10
2
10
3
10
4
35% 59%
6% 0%
FL1-H
F
L
2
-
H
10
0
10
1
10
2
10
3
10
4 10
0
10
1
10
2
10
3
10
4
0% 7%
74% 19%
untreated
SAHA (5.5μM)
SAHA (5.5μM) + 
QVD-oph (12.5μM)
A. B.
SAHA
Rituximab
SAHA+Rituximab
0
10
20
30
40
50
60
70
%
 
i
n
c
r
e
a
s
e
 
i
n
 
a
n
n
e
x
i
n
 
V
p
o
s
i
t
i
v
e
 
c
e
l
l
s
p<0.001
p<0.001
ns
 
 
Figure 5-14 Effect of caspase inhibitor on induction of apoptosis in 
Ramos cell line: 
Ramos cells at 0.5x10
6 cells/ml were suspended in complete medium with 
QVD-oph (12.5μM) (□) or an equivalent concentration of DMSO (■).  Cells 
were then plated in triplicte in 96 well plates and incubated with SAHA 
(5.5μM) or Rituximab (3μg/ml) alone or in combination, control samples were 
treated with an equivalent concentration of DMSO.  After 24 hours cells were 
harvested and prepared for flow cytometric analysis using Annexin V/PI 
staining.  (A.) shows representative flow cytometry dot plots. (B.) Shows 
mean % increase in annexin V positive cells (± range) from a representative  
experiment compared to untreated cells.  Independent Student’s t-test was 
performed comparing presence or absence of QVD-oph.  Data shown are 
representative of two independent experiments. 
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Figure 5-15 Effect of QVD-oph on caspase processing in Ramos cell 
line: 
Ramos cells at 0.5x10
6 cells/ml were suspended in complete medium with 
QVD-oph (12.5μM) or an equivalent concentration of DMSO.  Cells were 
plated in 6 well plates and incubated with SAHA (5.5μM), Rituximab (3μg/ml) 
and B1 (3μg/ml) indicated for 24 hours.  Control samples were treated with 
an equivalent concentration of DMSO.  Cells were harvested by 
centrifugation and resuspended in a RIPA lysis buffer.  Following 
quantification, 20μg of protein per sample was used for immunoblotting.  
Results for PARP, caspase 9 and caspase 3 (*denotes activated cleaved 
caspase) are shown and are representative of 2 independent experiments. 
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The synergy data presented in chapter 4 demonstrated that there was 
variability in the extent of synergistic induction of apoptosis seen across the 
panel of B cell NHL cell lines.  In particular the RL cell line showed no 
synergistic activity, with only low levels of apoptosis following HDI treatment.  
In attempting to explain this, the baseline expression of Bcl-2 family proteins 
was examined.  The RL cell line was found to express high levels of Bcl-2 
[Figure 5-16]. 
To further investigate whether this was important the assay was repeated in 
Ramos cells which were stably transfected to overexpress Bcl-2.  This cell 
line was kindly provided by Dr Mark Cragg.  Published data by Chan et al 
[87] had already demonstrated that overexpression of Bcl-2 in these cells 
was able to inhibit the intrinsic apoptotic pathway.  Overexpression of Bcl-2 
appeared to result in lower levels of apoptosis following treatment with 
SAHA compared to the same concentration in standard Ramos.  As would 
be expected there was little effect seen on Rituximab or B1 alone.  Following 
combination treatment overexpression of Bcl-2 results in loss of the 
synergistic induction of apoptosis seen with SAHA and Rituximab, but not B1 
[Figure 5-17].  The addition of QVD-oph resulted in loss of this cooperative 
activity.  Western blotting was also performed and immunoblots for PARP, 
caspase 3 and 9 are shown [Figure 5-18].  Caspase processing and PARP 
cleavage was still observed in SAHA treated samples but did not appear to 
be increased with combination treatment. Once again the addition of the pan 
caspase inhibitor completely inhibited PARP cleavage.      
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Figure 5-16 Expression of Bcl-2 in B cell NHL cell lines: 
0.5x10
6 cells were harvested by centrifugation and whole cell lysates were 
prepared as described.  15μl of each sample was loaded and gel 
electrophoresis was performed as described.  Immunoblots for Bcl-2 are 
shown with PCNA as a loading control.  Data shown are representative of 
two independent experiments.   
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Figure 5-17 Induction of apoptosis in Bcl-2 overexpresing Ramos: 
Bcl-2 overexpressing Ramos cells at 0.5x10
6 cells/ml were suspended in 
complete medium with 12.5μM QVD-oph or a corresponding concentration of 
DMSO.  Cells were then plated in triplicate in 96 well plates and incubated 
with SAHA 5.5μM, Rituximab 3μg/ml or B1 3μg.ml alone or in combination, 
control samples were treated with a corresponding concentration of DMSO.  
After 24 hours cells were harvested and prepared for flow cytometric analysis 
using Annexin V/PI staining.  (A.) Shows clonal Bcl-2 overexpression 
(■)compared to isotype control antibody (■). (B.) shows representative flow 
cytometry dot plots (C.) Shows mean % increase in annexin V positive cells 
for QVD-oph treated (□) and untreated (■) cells (± range) compared to 
untreated cells.  Independent student’s t-test was performed comparing 
SAHA to combination treated samples.  Data shown are representative of 
two independent experiments.  
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Figure 5-18 Capase processing in Bcl-2 Ramos: 
Bcl-2 overexpressing Ramos cells at 0.5x10
6 cells/ml were suspended in 
complete medium with 12.5μM QVD-oph or a corresponding concentration of 
DMSO.  Cells were plated in 6 well plates and incubated with the 
concentrations of SAHA, Rituximab and B1 indicated for 24 hours.  Control 
samples were treated with a corresponding concentration of DMSO.  Cells 
were harvested by centrifugation and resuspended in a RIPA lysis buffer and 
prepared as described above.  Following quantification, 20μg of protein per 
sample was used for immunoblotting.  Immunoblot for PARP, caspase 9 and 
caspase 3 is shown and is representative of two independent experiments. 
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5.6  Discussion 
 
The data presented in this chapter illustrates two key points.  Firstly the 
synergistic induction of apoptosis following combination treatment occurs 
without changes in the early biochemical responses to either agent alone.  
Secondly there is strong evidence that the intrinsic apoptotic pathway is 
necessary for the activity of HDI but not CD20 mAb.  The synergistic activity 
demonstrated in chapter 4 appears to be dependent on this pathway. 
Rituximab is well known to cause lipid raft formation [81, 82].  This results in 
altered composition of the cell membrane.  This has been shown by a 
number of investigators to alter the activity of p-glycoprotein and hence 
reverse multi drug resistance phenotypes [275].  Thus it was important to test 
the hypothesis that Rituximab altered the intracellular levels of HDI.  Histone 
acetylation is the classically used biomarker of target effect in cells following 
incubation with HDAC inhibitors, and western blotting for histone 4 
acetylation is commonly used to demonstrate this [217].   Robust histone 
acetylation was detected within 2 hours and persisted upto 24 hours in 
Ramos and RL cells and did not appear to be affected by the addition of 
Rituximab.  Using a late timepoint, levels of histone acetylation were 
quantified.  This demonstrated that there was no significant difference 
between SAHA alone and in combination with either Rituximab or B1.  A 
single timepoint of 24 hours incubation was chosen as synergy had already 
been demonstrated at this timepoint, as had high levels of histone 
acetylation.  These experiments were able to demonstrate that time 
dependent histone acetylation was not influenced by combination treatment.  
Western blotting did not however differentiate between reduced HDAC 
activity or increased HAT activity.  To investigate the effect on direct 
enzymatic activity  an in vitro  enzyme assay was used.  The dose response 
curves for SAHA and combination treated cells were super imposable 
confirming that there was no interaction.  Reassuringly the IC50 for SAHA in 
this cell line was approximately 10 fold higher than the IC50 for induction of 
apoptosis.     
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Having identified that CD20 mAb do not effect HDI pharmacokinetics, the 
effect of HDI on CD20 expression and CD20 lipid raft redistribution was 
investigated.  There was a wide range of CD20 expression across the cell 
lines used and this did not seem to have an effect on the levels of cell death 
observed or synergistic activity.  There is some preliminary data to suggest 
that down regulation of surface CD20 expression may be a mechanism of 
resistance to Rituximab.  This was initially suggested following the 
observation that CD20 negative clones can be detected in patients with 
CD20 positive NHL who have received multiple treatments with Rituximab 
[276, 277].  These observations have been recapitulated in in vitro models of 
rituximab resistance [278, 279].   Czuczman et al [279] have demonstrated 
that this down regulation is possibly due to post transcriptional regulatory 
mechanisms.  There are also some preliminary data demonstrating that HDI 
can upregulate CD20 mRNA expression [280].  The effect of treatment with 
SAHA on CD20 expression, and more specifically Rituximab and B1 binding 
was investigated in Ramos cells.  Overnight incubation with SAHA was 
chosen as it facilitated assessment of transcriptional and post transcriptional 
regulatory mechanisms yet yielded high levels of cell viability.  Surface CD20 
expression was measured with FITC conjugated Rituximab and B1 mAb.  At 
the timepoints chosen it was not possible to detect significant changes in the 
level of surface or triton X insoluble compartment CD20 expression.  As 
would be expected rituximab showed a 2:1 binding ratio compared to B1 
[265], and this was unaffected by pre incubation with SAHA.  Although the 
data from these assays are convincing with measurement of CD20 
expression occurring at timepoints already shown to result in induction of 
synergistic apoptosis, they do not exclude an effect at earlier timepoints.  To 
investigate the early sequelae of CD20 mAb binding in combination with 
SAHA, flow cytometry was used to measure intracellular Ca
2+ flux and ERK 
phosphorylation.  It was chosen to incubate Ramos cells with SAHA or an 
equivalnet concentration of DMSO for 2 hours as this timepoint had been 
previously identified as sufficient to allow intracellular accumulation of SAHA 
as measured by histone acetylation.  Hypercrosslinking produced rapid 
induction of intracellular Ca
2+ fluxing.  This event was not affected by pre 
treatment with SAHA.  The effect of SAHA on the type II mAb B1 was not    
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assessed as data already published by Walshe et al had shown that type II 
mAb did not induce Ca
2+ fluxing [99].  To corroborate these findings flow 
cytometric analysis of ERK 1/2 phosphorylation was performed in SU-DHL-4 
cells.  This cell line was chosen as it was known that ritxumab could induce 
ERK 1/2 phosphorylation without the hypercrosslinking allowing direct 
comparison of type I and II mAb.  Consistent with published reports rituximab 
induced ERK phosphorylation within 15 minutes, but no effect was seen with 
B1.  Once again these early CD20 mAb induced molecular events were 
unaffected by the addition of SAHA.  Taken together these data 
demonstrates that the cooperative cell death observed with the combination 
of these agents is not due to effects on the early signaling events known to 
occur following CD20 mAb binding. 
As discussed earlier it was important to clarify the effects of these agents at 
inducing apoptosis.  Time dependent induction of PARP cleavage following 
incubation of cells with SAHA was seen. This corresponded with the 
induction of Annexin V positive cells.  Caspase 9 processing appeared to 
preceed this, suggesting that in this cell line SAHA induces apoptosis through 
caspase 9 processing, possible as a result of mitochondrial cytochrome C 
release.  In support of this hypothesis; there was no caspase 8 processing 
and the pan caspase inhibitor QVD-oph blocked SAHA induced apoptosis as 
did overexpression of Bcl-2. 
The data for CD20 mAb are less clear.  The data presented here show that in 
the absence of cross linking, PS translocation occurs without caspase 
processing or PARP cleavage.  This is consistent with the majority of 
published data [87, 281].  The addition of crosslinking to Rituximab results in 
PARP cleavage and caspase 9 processing, again a common finding in the 
literature [266, 282].  The differences between type I and II mAb is further 
demonstrated in cells overexpressing Bcl-2.  This abrogates any cooperative 
effect seen with rituximab but not with B1, suggesting that the B1/SAHA 
cooperative effect is not Bcl-2 dependent.  Interestingly western blotting of 
the cell lines used demonstrated that the RL cell line, which did not show 
synergy, had a high level of Bcl-2 expression, supporting the hypothesis that 
this mechanism confers resistance to SAHA/Rituximab induced apoptosis.      
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The role of pharmacological caspase inhibition in blocking synergistic 
induction of apoptosis is clear.  The addition of QVD-OPh inhibited all 
caspase processing, PARP cleavage and PS translocation in all the 
experimental conditions tested.  This observation supports the hypothesis 
that apoptosis induced by SAHA/Rituximab is caspase and Bcl-2 dependent.  
A model for this interaction is shown in [Figure 5-19].   
 
However, the fact that the cooperative effect seen with SAHA/B1 in Bcl-2 
overexpressing Ramos is blocked by caspase inhibition is harder to explain 
and might be due to the fact that QVD-oph is not completely specific.  It may 
be that apoptosis is induced in these cells by non Bcl-2 dependent apoptotic 
mechanisms, which are inhibited by QVD-oph.  Caspase 8 cleavage was not 
seen following treatment with SAHA or with combination treatment (data not 
shown), suggesting the ‘extrinsic apoptotic pathway’ is not involved.  It is 
possible that other Bcl-2 independent mechanisms such as calpain activation 
are involved.  It has been shown that cross talk between these pathways 
occurs and may explain why caspase inhibitors also block this mechanism 
[283].   
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Figure 5-19 Model of interaction between HDI and type I and II CD20 
mAb:     
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6  Transcriptional mechanisms for cooperative 
activity. 
 
6.1  Introduction 
With data showing clear synergistic cell killing with HDI in combination with 
CD20 mAb and evidence of induction of apoptotic pathways, investigation 
turned to transcriptional regulation.  HDI exert their effects through the 
regulation of genes and understanding the transcriptional consequences of 
their effect was potentially important for understanding how they interacted 
with CD20 mAb.  As discussed earlier, HDI mediated acetylation of core 
histone proteins results in conformational change in chromatin.  This allows 
access of transcription factors to previously ‘condensed regions’ of DNA as 
well as facilitating binding of cofactors to docking sites.  HDI also modulate 
gene expression through the post transcriptional regulation of a host of 
transcription factors and DNA binding proteins.  Although CD20 mAb produce 
little direct effect on transcription, ligation of CD20 receptor has been shown 
to induce intracellular signalling with modulated expression of a number of 
genes, including Bcl-2 family apoptotic regulators. 
Recent advances in gene expression profiling have facilitated investigation of 
the regulation of gene transcription across the entire genome.  To investigate 
the role of transcriptional modulation in this cooperative effect gene 
expression profiling was performed in Ramos cells following incubation with 
SAHA and Rituximab alone or in combination.  RT-Q-PCR was used to 
confirm changes observed in individual genes and geneset enrichment 
analysis was performed to assess the regulation of NFқB target genes and to 
explore for enrichment of genes with functional associations.  The secondary 
aim of these experiments was to identify biomarkers that could be utilised to 
confirm transcriptional target effect of HDIs.  Clinical trials of HDIs have 
utilised histone acetylation as a marker of biological effect.  This approach 
has proved problematic for a number of reasons.  In one of the defining 
phase I studies although they were able to demonstrate histone acetylation in 
PBMC, there was no correlation with dose [205], a finding that has been    
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mirrored in other studies.  Histone acetylation is a result of the enzyme 
inhibitory activity of HDI, but needs to be sustained in order to achieve 
transcriptional regulation.  
6.2  Microarray design and sample preparation 
This analysis was performed using the Affymetrix human U133 plus2.0 gene 
expression profiling platform, to analyse over 47,000 transcripts.  Two time 
points were chosen to investigate early (6 hours) and later (16 hours) 
transcriptional effects.  It was decided to use concentrations of SAHA and 
crosslinked Rituximab that had resulted in strong synergistic activity in earlier 
assays.  Samples were prepared in triplicate, at each time point.  RNA was 
extracted using TRIzol reagent, followed by an RNA cleanup protocol using 
Qiagen RNA columns.  The experimental design with representative 
electrophoresis and electropherogram images is shown [Figure 6-1].  
Duplicate samples with the best quality RNA traces were selected and 
couriered on dry ice to the PICR Microarray facility, Manchester, UK.   
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Figure 6-1 Microarray sample preparation: 
Ramos cells at 0.5x10
6/ml were plated in triplicate in 6 well plates as indicated.  
After six and sixteen hours incubation cells were harvested by centrifugation and 
RNA was extracted using TRIzol reagent, and purified using qiagen RNA columns.  
RNA quality was checked using bioanalzer and duplicate samples were labelled 
and hybridised to Affymetrics u133 plus2.0 array.    
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Target cRNA was synthesized using the Affymetrix one cycle labelling protocol 
(http://bioinformatics.picr.man.ac.uk/mbcf/One_Cycle_Target_Prep_Protocol_PIC
R_v1-0.pdf).  Following this RNA quality was rechecked using a standard Agilent 
bioanalyzer protocol.  Labelled RNA was hybridized to human 133 plus 2.0 chips.  
Probe level data (Cel files) were normalised using Robust Multi-Array Average 
(RMA) (Bioconductor, Affymetrix, UK).  This analysis was performed by Richard 
Mitter from the Cancer Research UK bioinformatics service (Lincolns Inn Field, 
London, UK).  For initial analysis of the data set expression fold change was 
calculated from the mean of duplicate samples and was compared to controls.  A 
moderated t-test was used to identify differential expression and filtered on a false 
discovery rate adjusted p value of ≤ 0.05, and an absolute fold change of ≥ 2.  The 
total number of transcripts for each experimental condition meeting these criteria 
are summarised with number of up/down regulated and unchanged genes shown 
[Table 6-1]. 
Comparison of control samples at the two timepoints revealed close concordance 
in the gene expression patterns, with only 34 genes with differential expression 
identified.  This confirms the robustness of the whole experimental procedure and 
RMA normalisation.  For all future analysis all the untreated samples were 
combined and used as comparators for the different treatment conditions.  
Consistent with published data, treatment with SAHA resulted in the significant 
regulation of approximately 3% of genes at both time points.  Rituximab resulted in 
very modest transcriptional effects.  Combination treatment resulted in a larger 
number of genes than either agent alone. 
Cluster dendrograms graphically present the relationship between duplicate 
samples and the different treatment conditions.  Horizontal lines depict the level of 
clustering of samples, whilst vertical lines represent the differences between 
samples.  There was tight clustering of the duplicates for each sample.  Rituximab 
treated samples also clustered with control samples.  The SAHA transcriptional 
signature clustered closely with combination treated samples, confirming the 
dominance of the HDI transcriptional signature. There was tight clustering of the 
duplicates for each sample, although with such a weak transcriptional signature    
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duplicate variance was greater with Rituximab treated samples than SAHA 
treated.  The highest level of clustering was between samples incubated with or 
without SAHA. The next most striking feature was that the SAHA transcriptional 
signature clustered closely with combination treated samples, confirming the 
dominance of the HDI transcriptional signature [Figure 6-2].   
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6 hours  16 hours    
SAHA  Rituximab  Combined SAHA  Rituximab  Combined  Control 6 hrs 
Downregulated 1351  101  1655 1400  17  2295  8 
Unchanged 51689 54386  51343 51290  54432  49359  54641 
Upregulated 1635  188  1677 1985  226  3021  26 
 
Table 6-1 Differentially expressed transcripts: 
FDR ≤0.05, fold change ≥2.  total number of differentially expressed genes 
for each time point compared to controls at that timepoint are shown.    
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Figure 6-2 Cluster dendrogram of Ramos cells gene expression analysis: 
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To examine the effect of each experimental condition on the expression of all 
the genes examined, the expression level of gene transcripts was expressed 
as a linear fold change induction (positive values) or down regulation 
(negative values) relative to control samples.  All genes which reached 
statistical significance with a false discovery rate (FDR) of p≤0.05 were 
included in this analysis.  Genes were ranked according to fold change 
induction in SAHA treated samples and this ‘gene expression signature’ for 
the three experimental conditions is shown [Figure 6-3].  As was 
demonstrated with the cluster dendrogram, the combination signature was 
dominated by the effect of SAHA.  There were only 736 genes differentially 
expressed by combination treatment alone and 163 genes regulated solely 
by Rituximab.  Within the combination gene signature there were genes 
which were differentially expressed compared to SAHA or Rituximab alone.  
For example CD69 was upregulated 8.6 fold with SAHA and 15.8 fold with 
combination treatment.     
To systematically identify genes which might be responsible for the 
cooperative effect observed in apoptotic assays, the subset of genes which 
was significantly regulated in combination treated samples compared to 
SAHA following six hours incubation was identified [Figure 6-4], [Table 6-2]. 
This analysis revealed a subset of 64 genes.  This data set was notable for 
containing 8 well described NFқB target genes (CD69, TRAF1, BLR1, 
BCL2A1, CD83, CCR7, and CCL3).  This observation was important as it 
suggested that combination treatment was able to modulate NFқB target 
genes independently of either agent alone.   
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Figure 6-3 expression of all significant genes compared to control: 
Bar charts shows the genes which were statistically significantly regulated 
(FDR p≤0.05, Fold change ≤≥2) for any treatment condition compared to 
controls following 6 hours incubation.  Each bar represents the fold change of 
a single gene transcript, derived from the mean of duplicate samples 
compared to controls for (A.) SAHA, (B.) Rituximab or (C.) the combination.    
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Figure 6-4 Differentially expressed genes following combination treatment: 
All 64 differentially expressed genes in combination treated samples compared to SAHA following six hours incubation are 
shown (p≤0.05, any FC).  Genes are ranked according to fold change induction.  Each bar represents the fold change of a single 
gene transcript, derived from the mean of duplicate samples.  For example BIK is upregulated 3.9 fold compared to SAHA alone.    
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CCL3  chemokine (C-C motif) ligand 3  CD69  CD69 molecule 
RGS1  regulator of G-protein signalling 1    NA 
CCR7  chemokine (C-C motif) receptor 7  DUSP2  dual specificity phosphatase 2 
EGR2  early growth response 2 (Krox-20 homolog, Drosophila)  ATF3  activating transcription factor 3 
BIK  BCL2-interacting killer (apoptosis-inducing)  MAP3K8  mitogen-activated protein kinase kinase kinase 8 
RGS1  regulator of G-protein signalling 1  GLS  glutaminase 
KCNJ2  potassium inwardly-rectifying channel, subfamily J, member 2  FCRL4  Fc receptor-like 4 
FAM102A  family with sequence similarity 102, member A  CLEC2D  C-type lectin domain family 2, member D 
SRGN serglycin  LPIN1  lipin  1 
CD83 CD83  molecule  GLS  glutaminase 
EGR3  early growth response 3  HOMER1  homer homolog 1 (Drosophila) 
NR4A1  nuclear receptor subfamily 4, group A, member 1  LPIN1  lipin 1 
BCL2A1  BCL2-related protein A1  EIF2C2  eukaryotic translation initiation factor 2C, 2 
 NA    NA 
BIC  BIC transcript  RGS14  regulator of G-protein signalling 14 
SQSTM1  sequestosome 1  HOMER1  homer homolog 1 (Drosophila) 
  NA  SLCO4A1  solute carrier organic anion transporter family, member 4A1 
BLR1  Burkitt lymphoma receptor 1, GTP binding protein (chemokine 
(C-X-C motif) receptor 5) 
ABCC5  ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
MCTP1  multiple C2 domains, transmembrane 1  ANKRD10  ankyrin repeat domain 10 
CREM  cAMP responsive element modulator  SGK  serum/glucocorticoid regulated kinase 
CREM  cAMP responsive element modulator  GLA  galactosidase, alpha 
CREM  cAMP responsive element modulator  C21orf91  chromosome 21 open reading frame 91 
ADARB1  adenosine deaminase, RNA-specific, B1 (RED1 homolog rat)    NA 
TRAF1  TNF receptor-associated factor 1  C21orf57  chromosome 21 open reading frame 57 
LOC283454  hypothetical protein LOC283454  RGS5  regulator of G-protein signalling 5 
CREM  cAMP responsive element modulator  DKFZp667G2
110 
hypothetical protein DKFZp667G2110 
 NA  FLJ13195  stromal  antigen  3-like 
LY9  lymphocyte antigen 9  DIDO1  death inducer-obliterator 1 
TRAF1  TNF receptor-associated factor 1  HIST1H2BI  histone cluster 1, H2bi 
KLHL6  kelch-like 6 (Drosophila)  LOC339929  hypothetical protein LOC339929 
VGLL4  vestigial like 4 (Drosophila)  UBE3C  ubiquitin protein ligase E3C 
JUND  jun D proto-oncogene  GRAP  GRB2-related adaptor protein   
Table 6-2: Differentially expressed genes following 6 hours combination treatment 
All differentially expressed genes in combination treated samples compared to SAHA are shown (p≤0.05, any FC).   
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6.3  Validation  
As an initial validation step the ‘gene expression signatures’ seen were 
compared with available data sets.  For Rituximab effect Cittera et al had 
published data using Affymetrix HG-U95av2 chips  [284].  They identified no 
genes significantly downregulated greater than two fold and only 16 and 12 
genes upregulated in DHL-4 and BJAB respectively (P≤0.0025).  Geneset 
enrichment analysis, Performed by Richard Mitter, of the Rituximab treated 
data set from this experiment confirmed significant enrichment of these 
previously identified genes within our larger data set (p≤0.0001).  By 
superimposing these genes onto the Rituximab Vs. control 6 hour data set it 
can be seen how the genes with the greatest fold induction in our data set 
showed concordance with those previously identified [Figure 6-5].      
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Figure 6-5: Scatter plot of Rituximab regulated genes. 
This scatter plot shows all the genes significantly differentially regulated by 
Rituximab following six hours incubation (○) (FDR≤0.05, FC≤≥2) compared to 
controls.  Genes identified by citerra et al [284] (●) are shown superimposed 
on this data set. Non significant genes are also shown (●).  Blue line depicts 
the linear 2 fold induction/down regulation cut off.     
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Validation of the SAHA data was performed using the Connectivity Map 
(http://www.broad.mit.edu/cmap/displayServlet?servletAction=mainMenu).  This web-
based tool allows comparison of gene expression profiles to a database 
generated through responses to small molecules in the MCF7 breast cancer 
cell line.  The top 1000 up or down regulated genes from the SAHA gene 
signature were used to query this database.  The top ranked molecules, 
based on connectivity score are shown, all 10 were HDAC inhibitors [Table 
6-3].   
These validation steps demonstrated the reproducibility of the gene 
expression signatures generated with either agent alone, and serve to 
validate the signature observed with combination treatment.  Of particular 
note is the strong connectivity score for HDI of different classes across 
different cell lines, once again confirming the regulatory effects of HDI on a 
number of core genes [210].    
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0.871 HL60 10 mM valproic acid 44 10
0.901 MCF7 1 µM trichostatin A 513 9
0.905 MCF7 100 nM trichostatin A 513 8
0.909 MCF7 10 µM vorinostat 513 7
0.933 MCF7 1 µM trichostatin A 504 6
0.941 MCF7 100 nM trichostatin A 506 5
0.952 MCF7 100 nM HC toxin 505 4
0.958 MCF7 1 µM trichostatin A 502 3
0.989 MCF7 10 µM vorinostat 506 2
1 MCF7 1 µM trichostatin A 506 1
Connectivity 
score cell dose cmap name batch rank
0.871 HL60 10 mM valproic acid 44 10
0.901 MCF7 1 µM trichostatin A 513 9
0.905 MCF7 100 nM trichostatin A 513 8
0.909 MCF7 10 µM vorinostat 513 7
0.933 MCF7 1 µM trichostatin A 504 6
0.941 MCF7 100 nM trichostatin A 506 5
0.952 MCF7 100 nM HC toxin 505 4
0.958 MCF7 1 µM trichostatin A 502 3
0.989 MCF7 10 µM vorinostat 506 2
1 MCF7 1 µM trichostatin A 506 1
Connectivity 
score cell dose cmap name batch rank
 
 
Table 6-3 Connectivity score for SAHA dataset compared to Cmap 
database: 
The top 1000 up or down regulated genes from the SAHA gene signature 
was entered into the Cmap database.  Listed are the top ten ranked matches 
based on connectivity score.      
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To validate the effect on individual genes RT-Q-PCR was performed from 
excess RNA samples from the same experiment. It was decided to select 
genes which had been significantly upregulated in the combination treated 
data set compared to control samples.  Two gene probes with the highest 
levels of differential expression were selected; proteoglycan 1, serglycin, 
secretory granule (PRG1, NM_002727) and v-fos FBJ murine osteosarcoma 
viral oncogene homolog (FOS, NM_005252).  RT-Q-PCR for these 
transcripts is shown [Figure 6-6].   
As with the microarray analysis there was significant upregulation with 
combination treatment and SAHA alone compared to control samples.  The 
mean fold change for each sample from the microarray analysis was plotted 
against the fold change for RT-Q-PCR analysis, Statistical analysis using 
Pearson’s correlation demonstrated a highly significant relationship 
(p≤0.001).  Of note the magnitude of fold change induction observed with RT-
Q-PCR was consistently higher than was seen in the microarray analysis. 
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Figure 6-6 RT-Q-PCR validation of microarray: 
Ramos cells at 0.5x10
6 cells/ml were plated in duplicate in 6 well plates and 
treated with SAHA 5.5μM, Rituximab 3μg/ml with crosslinking agent or the 
combination. Control samples were left untreated (UT). At the timepoints 
indicated cells were harvested and RNA was extracted using TRIzol reagent, 
and purified using Qiagen RNA columns.  Oligo dT primed cDNA was 
prepared from 1μg RNA and duplicate wells were loaded with 5µl cDNA , 
15µl PCR master mix and appropriate taqman gene expression assay.  Q-
RT-PCR was performed as previously described.  (A.) and (B.) show mRNA 
expression level relative to β actin for the probes described, data shown are 
mean (±range) from two independent experiments.  (C.) Shows correlation 
between microarray fold induction and RT-Q-PCR for these probes, each 
data point represents a condition where fold induction data was available 
from both experimental techniques.  Pearsons correlation coefficient was 
calculated with the r
2 and p value shown.    
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6.4  Functional annotation clustering analysis 
Functional annotation clustering analysis was performed using an online 
bioinformatics tool (The Database for Annotation, Visualization and 
Integrated Discovery (DAVID) http://david.abcc.ncifcrf.gov/home.jsp) [285].  
This web based software uses a modified Fisher Exact test to determine 
whether the proportions of genes, from an uploaded dataset, falling into each 
category differs by group. The Fisher Exact test is adopted to measure the 
gene-enrichment within annotation terms.  The genelist was ranked by fold 
change in combination treated samples and the top 100 genes were selected 
and uploaded for analysis.  The top 3 functional groups are shown with gene 
ontology (GO) [286] functional annotation, percentage of genes and p value 
[Table 6-4].  These 3 functional groups were related to lymphocyte activation 
and immunomodulatory function and their constituent genes are shown 
[Table 6-5].     
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Functional Group 1 
Term 
% PValue 
GO:0050896~response to stimulus  27%  0.009 
GO:0006955~immune response  12%  0.014 
GO:0002376~immune system process  13%  0.019 
Functional Group 2     
GO:0046649~lymphocyte activation  6%  0.007 
GO:0045321~leukocyte activation  6%  0.011 
GO:0001775~cell activation  6%  0.016 
GO:0051239~reg. of multicellular organismal process 6%  0.032 
Functional Group 3     
GO:0006952~defense response  12%  0.001 
GO:0042221~response to chemical stimulus  10%  0.012 
GO:0009605~response to external stimulus  10%  0.016 
GO:0006950~response to stress  12%  0.031 
GO:0006954~inflammatory response  6%  0.035 
GO:0007610~behavior 6%  0.046 
GO:0007626~locomotory behavior  5%  0.048 
   
Table 6-4 Functional annotation clustering analysis: 
 
Gene Name 
PROSTAGLANDIN E RECEPTOR 4 (SUBTYPE EP4) 
PROTEOGLYCAN 1, SECRETORY GRANULE 
BURKITT LYMPHOMA RECEPTOR 1, GTP BINDING PROTEIN (CHEMOKINE (C-X-C MOTIF) RECEPTOR 5) 
HISTONE 1, H2BD 
CD69 ANTIGEN (P60, EARLY T-CELL ACTIVATION ANTIGEN) 
HEAT SHOCK 70KDA PROTEIN 1A 
TUMOR PROTEIN P53 INDUCIBLE NUCLEAR PROTEIN 1 
EARLY GROWTH RESPONSE 2 (KROX-20 HOMOLOG, DROSOPHILA) 
CD24 ANTIGEN (SMALL CELL LUNG CARCINOMA CLUSTER 4 ANTIGEN) 
TUMOR NECROSIS FACTOR (LIGAND) SUPERFAMILY, MEMBER 9 
CYCLIN-DEPENDENT KINASE INHIBITOR 2B (P15, INHIBITS CDK4) 
CHEMOKINE (C-C MOTIF) LIGAND 3 
CD1D ANTIGEN, D POLYPEPTIDE 
LYSOSOMAL TRAFFICKING REGULATOR 
CHEMOKINE (C-C MOTIF) RECEPTOR 7 
CHEMOKINE (C-C MOTIF) LIGAND 3-LIKE 1 
REGULATOR OF G-PROTEIN SIGNALLING 1 
PROTEIN PHOSPHATASE 3 (FORMERLY 2B), CATALYTIC SUBUNIT, ALPHA ISOFORM (CALCINEURIN A 
ALPHA) 
V-FOS FBJ MURINE OSTEOSARCOMA VIRAL ONCOGENE HOMOLOG 
UL16 BINDING PROTEIN 2 
CD83 ANTIGEN (ACTIVATED B LYMPHOCYTES, IMMUNOGLOBULIN SUPERFAMILY) 
SELENOPROTEIN P, PLASMA, 1 
F11 RECEPTOR 
CD274 ANTIGEN 
   
Table 6-5: top ranked functionally associated genes.    
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This gene list was notable for containing well described NFқB target genes 
including CCR3, CCR7, CD83 and CD69. 
The NFқB pathway was a known target of both agents and geneset 
enrichment analysis for NFқB target genes was performed.  This is a 
bioinformatic tool for testing for differential regulation of gene sets of pre 
defined biological relevance as opposed to single genes and was first 
described in 2003 [287].  A list of validated NFқB target genes was obtained  
(http://bioinfo.lifl.fr/NF-KB/NM-human.txt) from a web based search.  Analysis 
was performed, by Richard Mitter, for enrichment of this geneset in treated 
samples compared to control samples using GeneSetTest software package 
[288] [Table 6-6].  
Within the ‘Rituximab geneset’ there was significant enrichment of NFқB 
targets at both 6 and 16 hours.  ‘Combination genesets’ were also enriched 
for NFқB targets when compared to SAHA alone.  To further examine this 
effect the fold change in mRNA expression for each gene probe that reached 
significance (FDR p≤0.05) following six hours incubation was plotted [Figure 
6-7].  This shows that the gene expression profile of NFқB target genes is 
very complex, reinforcing the hypothesis that interpretation of effects on this 
pathway cannot be made by looking at individual genes.  Combination 
treatment appeared to induce the expression of a number of genes 
independently of either agent alone as well as showing enhanced effect on 
genes regulated by either agent independently.  For example the TNF 
superfamily member, lymphotoxin alpha, was upregulated 2.2 fold following 
Rituximab treatment but down regulated by SAHA alone or in combination.  
Where as Chemokine (c-c motif) ligand 3 (CCL3) was upregulated 14.9 fold 
by Rituximab and 16.2 fold by combination but was unaffected by SAHA 
alone.       
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Treatment  
duration  Data set  P value 
SAHA Vs.Control  ns 
Rituximab Vs. Control  0.0001 
Combined Vs. Control  ns 
Combined Vs. SAHA  0.0001 
6 Hours 
Combined Vs. Rituximab  ns 
SAHA Vs. Control  ns 
Rituximab Vs. Control  0.0001 
Combined Vs. Control  0.0926 
Combined Vs. SAHA  0.0002 
16 Hours 
Combined Vs. Rituximab  0.0023 
 
Table 6-6 Geneset enrichment analysis: 
GeneSetTest software package was used to probe differentially expressed 
genes from the data sets indicated for enrichment of genes known to be 
NFқB targets. 
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Figure 6-7 Regulation of NFқB target genes: 
Bar charts show the genes which were statistically significantly regulated 
(FDR p≤0.05) for any treatment condition compared to controls following 6 
hours incubation.  Each bar represents the fold change of a single NFқB 
target gene transcript, derived from the mean of duplicate samples compared 
to controls for (A.) SAHA, (B.) Rituximab or (C.) the combination.    
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6.5  RT-Q-PCR analysis of NFқB target genes 
To confirm the effect of combination treatment on individual NFқB target 
genes RT-Q-PCR was performed using cDNA prepared from duplicate 
experiments.  Taqman gene expression assays were performed using BclXL, 
Bcl2A1, CD69 and LTA. 
Previous studies have used the anti apoptotic Bcl-2 family protein BclXL as a 
marker of NFқB activity so this was initially analysed [274].  In the earlier 
microarray analysis there had been no significant effect on BclXL following 
SAHA and a low level of downregulation following either Rituximab or 
combination treatments (-1.46, -1.29 fold respectively).  In Ramos cells 
timecourse analysis following treatment with Rituximab demonstrated 
downregulation of BclXL within 2 hours.  SAHA appeared to have no 
significant effect on this target in Ramos cells at the timepoints investigated 
[Figure 6-8].  This observation is important because it reinforces the 
hypothesis that individual NFқB target gene regulation cannot be looked at in 
isolation.      
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Figure 6-8 RT-Q-PCR timecourse of BclXL regulation: 
Ramos cells at 0.5x10
6 cells/ml were plated in duplicate in 6 well plates and 
treated with SAHA (5.5μM) (♦), Rituximab (3μg/ml) with crosslinking agent (■) 
or the combination (▲). Control samples were left untreated. At the 
timepoints indicated cells were harvested and RNA was extracted using 
TRIzol reagent, and purified using qiagen RNA columns.  Oligo dT primed 
cDNA was prepared from 1μg RNA and duplicate wells were loaded with 5µl 
cDNA , 15µl PCR master mix and appropriate taqman gene expression 
assay.  Q-RT-PCR was performed as previously described.  Data shown are 
mean (±range) from two independent experiments.    
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Using the six and sixteen hour time points the effect on the other biologically 
relevant targets was investigated [Figure 6-9].   
Bcl2A1 is an antiapoptotic Bcl-2 family protein which is known to protect cells 
from BCR mediated cell death [289].  In the microarray analysis Rituximab 
treatment resulted in 6.16 fold induction an effect that was partially blocked 
by combination treatment at 6 hours (3.34 fold) with a similar effect seen at 
16 hours.  RT-Q-PCR at these timepoints shows a similar effect.  The 
modulation of Rituximab mediated Bcl2A1 upregulation with combination 
treatment demonstrates how SAHA may inhibit an NFқB mediated defence 
mechanism to mitogenic stimuli, and hence sensitise cells.  These data taken 
together, show how combination treatment can result in subtle changes in the 
way that Ramos cells respond to either agent alone and demonstrate how 
the balance of Bcl-2 family proteins may be influenced to promote apoptosis 
following combination treatment. 
The effect on LTA, another well described NFқB target was also investigated 
[290].  LTA acts as a growth factor on B cells and is known to be upregulated 
by IL4 through NFқB binding to its promoter.  The effect on LTA was similar 
to that on Bcl2A1, SAHA blocked the Rituximab mediated upregulation 
observed.  This again demonstrates how combination treatment results in 
modulation of the gene expression changes observed with Rituximab alone 
[Figure 6-9].      
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Figure 6-9 RT-Q-PCR of NFқB target genes in Ramos cells: 
Ramos cells at 0.5x10
6 cells/ml were plated in duplicate in 6 well plates and 
treated with SAHA 5.5μM, Rituximab 3μg/ml with crosslinking agent or the 
combination. Control samples were left untreated. At the timepoints indicated 
cells were harvested and RNA was extracted usingTRIzol reagent, and 
purified using qiagen RNA columns.  Oligo dT primed cDNA was prepared 
from 1μg RNA and duplicate wells were loaded with 5µl cDNA, 15µl PCR 
master mix and appropriate taqman gene expression assay.  Q-RT-PCR was 
performed as previously described.  Data shown are mean (±range) from two 
independent experiments.      
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The effect on CD69 is different to this and demonstrates how combination 
treatment can serve to enhance activation of NFқB targets.  In the microarray 
analysis CD69 was ranked as one of the most differentially expressed genes 
following SAHA treatment (8.6 fold upregulation at 6 hours) and this effect 
was enhanced further with combination treatment (15.8 fold induction at 6 
hours) despite little effect of Rituximab alone (1.7 fold induction at 6 hours).  
This effect was again confirmed with RT-Q-PCR analysis.      
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6.6  CD69 as a Biomarker of HDI transcriptional regulation 
As discussed earlier the secondary aim of the gene expression analysis was 
to identify potential biomarkers indicative of transcriptional regulation 
occurring from HDAC inhibition. 
CD69 is an early activation marker and was identified by Sanchez-Mateos et 
al as a 27/33 kDa homodimeric glycoprotein expressed on the surface of 
lymphoid cells [291].  Genomic analysis of human and murine CD69 gene 
has suggested it is a member of the Ca
2+ dependent lectin superfamily and is 
expressed on the surface of T and B lymphocytes and NK cells upon 
activation [292].  It has no known ligand but appears to be upregulated 
through transcriptional mechanisms in response to a number of stimuli.  
Analysis of the promoter has identified binding sites for a number of 
transcription factors including NFқB and AP1 [293].  The upregulation of 
CD69 mRNA observed in Ramos cells following SAHA treatment suggests 
that NFқB is being activated resulting in transcriptional upregulation of this B 
cell activation marker.  This effect was also observed with RT-Q-PCR in 
Ramos cells [Figure 6-9].  To investigate this effect further RT-Q-PCR was 
performed in SU-DHL-4 cells, this analysis was performed with summer 
student Alison Donlevy.  There was robust induction of CD69 mRNA 
expression following six hours incubation with SAHA with significant further 
upregulation seen with combination treatment.  The effect of HDI on CD69 
mRNA expression was also confirmed in the HBL cell line and in human 
PBMC treated ex vivo (data not shown).   
It seemed plausible that this could be used as a pharmacodynamic endpoint 
to establish a transcriptional target effect of HDI.  To further examine this the 
regulation of cell surface CD69 was examined using flow cytometry initially in 
B cell NHL cell lines and subsequently in peripheral blood mononuclear cells 
(PBMC) treated ex vivo.  Measurement of the regulation of other B cell 
activation markers was investigated to establish whether this effect was as 
part of a generalised B cell activation.    
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Figure 6-10 CD69 upregulation in SU-DHL-4 cell line 
SU-DHL-4 cells at 0.5x10
6 cells/ml were plated in duplicate in 6 well plates 
and treated with SAHA (2.8μM), Rituximab (3μg/ml) or the combination. 
Control samples were left untreated. At the timepoints indicated cells were 
harvested and RNA was extracted usingTRIzol reagent, and purified using 
qiagen RNA columns.  Oligo dT primed cDNA was prepared from 1μg RNA 
and duplicate wells were loaded with 5µl cDNA , 15µl PCR master mix and 
appropriate taqman gene expression assay.  Q-RT-PCR was performed as 
previously described.  Data shown are mean (±range) from two independent 
experiments.      
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6.7  Up regulation of surface CD69 expression 
Microarray analysis and RT-Q-PCR had demonstrated upregulation of CD69 
mRNA expression. A flow cytometry assay was developed to investigate 
whether this resulted in upregulation of cell surface protein expression.  This 
assay was initially performed in human peripheral blood lymphocytes 
(PBMC) treated ex vivo.  Following 16 hours incubation with SAHA or 
Rituximab alone or in combination the percentage of CD69 positive, CD19 
positive  PBMC was determined [Figure 6-11].  There was a low but 
detectible level of CD69 positive B lymphocytes in control samples compared 
to an isotope matched antibody.  Consistent with the changes observed in 
mRNA expression in cell lines, there was reproducible up regulation of CD69 
cell surface expression with both SAHA and combination treatment.  The 
effect of SAHA was also investigated in primary NHL samples.  There was 
upregulation of surface CD69 expression observed in 3 NHL primary 
samples examined.  Cells were again treated overnight and CD19 was used 
to identify B cells within the population.  There was modest but reproducible 
upregulation of CD69 with the 2 concentrations of SAHA utilised [Figure 
6-12].      
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Figure 6-11 cell surface upregulation of CD69 in CD19 positive PBMC 
PBMC were extracted from whole blood by centrifugation using lymphoprep 
reagent.  After washing cells were resuspended in complete media with 
SAHA (1μM) or Rituximab (10μg/ml) alone or in combination, control samples 
were treated with DMSO alone. (A.) shows a representative dot plot 
demonstrating CD19 staining.  (B.) shows a representative histogram for PE 
labelled IgG1 isotype control antibody. (C.) and (D.) show representative 
histograms for control and SAHA treated cells respectively. (E.) shows mean 
percentage CD69 positive cells (±range) from 3 independent experiments.  
Independent student’s ttest was performed comparing untreated cells with 
the other conditions.     
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Figure 6-12 CD69 upregulation in primary cells: 
Primary B cell NHL cells from the Southampton University tumour bank were 
resuspended in complete media and incubated overnight (16 Hrs) with the 
concentration of SAHA indicated.  Control samples were left untreated or 
incubated with DMSO.  Cells were harvested by centrifugation and 
resuspended in FACS buffer with APC conjugated CD19 and PE conjugated 
CD69 antibodies.  Control samples were incubated with CD19 and an IgG1 
isotype control antibody.   Data shown are mean percentage of CD69 
positive cells (±range) from two separate experiments for (A., B.) Follicular 
NHL and (C.) DLBCL.   
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These experiments established that SAHA could induce upregulation of 
CD69 expression at both an mRNA and protein level.  The effect of HDI was 
investigated further by repeating the same assay with a range of 
concentrations of SAHA and FK228 [Figure 6-13].  Both these HDI resulted 
in dose dependent upregulation of CD69 expression, confirming that this 
effect was dose dependent.  These data also demonstrate that the effect is 
not due to inhibition of class 2 HDACs only.    
- 168 - 
 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5 20.0
0
5
10
15
20
25
30
35
40
45
50
55
FK228 Conc. (nM)
%
 
C
D
6
9
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
0 1 2 3 4 5 6 7 8 9 10
0
5
10
15
20
25
30
35
40
45
50
55
SAHA Conc. (μM)
%
 
C
D
6
9
 
p
o
s
i
t
i
v
e
 
c
e
l
l
s
FL4-H
S
S
C
-
H
10
0
10
1
10
2
10
3
10
4 10
0
10
1
10
2
10
3
10
4
FL2-H
C
o
u
n
t
10
0
10
1
10
2
10
3
10
4
0
17
33
50
66
1%
FL2-H
C
o
u
n
t
10
0
10
1
10
2
10
3
10
4
0
15
29
44
58
4%
FL2-H
C
o
u
n
t
10
0
10
1
10
2
10
3
10
4
0
15
30
45
60
1% 1%
FL2-H
C
o
u
n
t
10
0
10
1
10
2
10
3
10
4
0
12
24
36
48
50%
FL2-H
C
o
u
n
t
10
0
10
1
10
2
10
3
10
4
0
12
23
35
46
42%
CD19
A. B.
C
.
D.
E. F.
G.
 
Figure 6-13 Induction of CD69 in a dose dependent manner by HDI 
PBMC were extracted from whole blood by centrifugation using lymphoprep 
reagent.  After washing cells were resuspended in complete media and 
incubated for 16 hours with a range of concentrations of SAHA (0.07-10μM) 
or FK228 (1.25-20nM), control samples were treated with DMSO alone. (A.) 
shows a representative dot plot demonstrating CD19 staining.  (B.) and (C.) 
show representative histograms of untreated and SAHA (10μM) treated cells 
stained with PE labelled IgG1 isotype control. (D.) shows a representative 
histogram of CD69 expression in untreated cells, with percentage of positive 
cells shown. (E.) and (F.) show representative histograms of  CD69 
expression in SAHA (5μM) and FK228 (10nM) treated cells. (G.) shows dose 
response curves for mean percentage (±range) of CD69 positive cells 
against concentration for SAHA and FK228 respectively.  Data shown are 
from 3 independent experiments.     
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Having confirmed that incubation of PBMC with HDI resulted in dose 
dependent upregulation of CD69 expression, cells were incubated in the 
presence or absence of an NFқB inhibitor to examine whether this effect 
occurred as a result of activation of the NFқB pathway.  Co-incubation with 
the IKβ inhibitor, Bay 11-7082, resulted in inhibition of this upregulation 
confirming that this effect may be NFқB mediated [Figure 6-14]. 
To investigate whether this was the result of a specific transcriptional effect of 
HDIs, rather than as part of a generalised B cell activation the effect of SAHA 
on another B cell activation marker was investigated. Incubation with CPG 
resulted in upregulation of CD69 and CD23, however SAHA only induced 
upregulation of CD69.     
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Figure 6-14 Effect of NFқB inhibition on CD69 upregulation: 
PBMC were extracted from whole blood by centrifugation using lymphoprep 
reagent.  After washing cells were resuspended in complete media and 
incubated for 16 hours in the presence (▲) or absence (■) of the IKβ kinase 
inhibitor Bay11-7082 (1.25μM) and a range of concentrations of SAHA (0.07-
10μM), control samples were treated with DMSO alone or DMSO plus Bay 
11-7082.  data shown are mean percentage of CD69 positive cells (±range) 
from 3 independent experiments.     
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Figure 6-15 specific upregulation of CD69: 
PBMC were extracted from whole blood by centrifugation using lymphoprep 
reagent.  After washing cells were resuspended in complete media with 
SAHA (1μM) or CpG, control samples were treated with DMSO. (A.) shows a 
representative dot plot demonstrating CD19 staining.  (B.) shows a 
representative histograms for CD69 expression in control (-), SAHA  
(-) or CpG (-) treated cells (C.) shows a representative histograms for CD23 
expression in control (-), SAHA (-) or CpG (-) treated cells.  (D.) shows mean 
percentage CD69 positive cells (±range) for control (□), SAHA (■) or 
CpG(■),treated samples from 3 independent experiments.    
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6.8  Discussion  
Microarray gene expression analysis allows for the analysis of genome wide 
changes and provides a unique platform for evaluating the transcriptional 
response to anticancer therapies. 
Transcriptional effect of Rituximab 
There is little published data surrounding the transcriptional consequences of 
ligation by CD20 mAb.  Cittera et al treated DHL-4 and BJAB cells with 
10μg/ml Rituximab (without cross linking) for 2, 4 and 8 hours [284].   They 
observed little transcriptional activity with only 16 genes in DHL4 and 12 
genes in BJAB upregulated greater than two fold, and no genes 
downregulated. The u133 plus2.0 chip used for the experiments presented 
here has a much higher number of probes than this earlier array, was 
conducted in the presence of crosslinking and analysed using a different 
FDR (p≤0.05) which may explain the higher number of differentially 
expressed genes.  Despite these differences 7 genes (CD83, CCL3, CCL4, 
SGK, RGS2, FOS, ZFP36L) were identified which were differentially 
expressed across both experiments, including CCL3 which was the top 
ranked gene from our dataset.     
It has been well documented that in some circumstances CD20 mAb can 
induce intracellular signalling [294].  Data from earlier experiments has also 
shown that in this cell line cross linked Rituximab results in Ca
2+ flux and 
phosphorylation of ERK1/2, with published data showing this effect appears 
to be through utilization of the B cell receptor (BCR) signalling pathway [99].  
The timepoint utilised in the microarray experiment was not likely to show 
these early events which do not occur at a transcriptional level.   
The ability of Rituximab to inhibit NFқB activation is controversial with the 
only published data confirming this from Professor Bonavida’s group [68, 
102, 269, 270, 294].  The majority of these data were generated without 
crosslinking making comparison difficult.  Using a single representative target 
gene such as BclXL to establish ‘inhibition of NFқB’, then the data presented 
in this chapter is entirely consistent with this.     
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However, modulation of this pathway cannot be understood by assessment 
of a solitary gene.  The gene expression profile of NFқB target genes 
following Rituximab does not show down regulation of other anti apoptotic 
Bcl-2 family members.  This is consistent with the observation that caspase 
processing is not necessary to induce Annexin V positivity and that Bcl-2 
overexpression does not block the cell death seen.  Based on the hypothesis 
that Rituximab induces intracellular signalling through BCR it is not surprising 
that there was upregulation of a number of targets associated with 
lymphocyte activation (CD83, CD69) and intracellular signalling (TRAF, TNF) 
 
Transcriptional effect of SAHA 
In contrast to this the transcriptional effects of HDAC inhibitors are well 
described with differential regulation of between 2 and 10% of genes 
observed [207-209].  A number of groups have investigated the gene 
expression profiles of structurally different HDI across different cell lines [210, 
211].  It seems clear that although different experimental conditions result in 
regulation of distinct genes, there is a subset of ‘core genes’ which can be 
used to define an HDI transcriptional response. For example differential 
expression of TOB1, MXI1, and p21
cipi with downregulation of MYC were 
observed in all these studies and also in this experiment.  This factor allowed 
the use of the connectivity map to validate the gene expression signature 
observed in the microarray experiment presented in this thesis.  Peart et al 
observed that SAHA and FK228 modulated the expression of Bcl-2 family 
proteins in a complex fashion and argued that the overall effect coupled with 
upregulation of Apaf-1 was to induce activation of the intrinsic apoptotic 
pathway [211].  I observed that following 6 hours treatment with SAHA in 
Ramos cells there was also upregulation of Apaf-1 (4.4 fold) as well as 
significant changes in pro and anti apoptotic Bcl-2 proteins, however down 
regulation of BclXL was not seen.  This, coupled with the effects of over 
expressing Bcl-2 in Ramos cells suggest that the apoptosis seen in Ramos 
cells and the other B cell NHL cell lines is occurring via transcriptional 
modulation of the intrinsic apoptotic pathway.  Modulation of other well 
described pathways were also observed including cell proliferation regulating 
genes (TOB1, BTG1, MYC, and GADD45β).  In contrast to these studies the    
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use of a B lymphocyte cell line allowed insight into effects on B cell activation 
and localisation genes.  A striking feature of the functional annotation 
clustering analysis was that there appeared to be evidence B cell activation 
and immune modulation.  The role of HDI in immune modulation is becoming 
increasingly well described with both pro and anti inflammatory effects 
observed [295, 296].  One of the key regulators of inflammatory responses 
and the intrinsic apoptotic pathway is the NFқB transcription factor family.   
As discussed earlier HDI exert their transcriptional effects through; 
accumulation of acetylated core histones resulting in access of transcription 
factors to previously inaccessible promoter regions of genes [157, 297, 298]; 
and by directly influencing the acetylation of DNA binding proteins [146, 162, 
163].  Both these mechanisms are pertinent to the HDI mediated regulation 
of NFқB which is extremely complex with many gene specific interactions.  
HDAC3 promotes deacetylation of RelA and TSA promotes its DNA binding 
through acetylation [55], Chen et al have also shown that acetylation of K221 
promotes DNA binding whilst acetylation of K310 is required for full 
transcriptional activity.  In contrast to this there are also data suggesting that 
HDI can inhibit proteasome dependent NFқB activation [299].  To try and 
understand the effect of SAHA on NFқB targets in Ramos cells, the effect on 
well recognised targets was examined.  SAHA induced both up and down 
regulation of targets with almost equal frequency.  There was up regulation of 
pro apoptotic and down regulation of antiapoptotic Bcl-2 family members.  
However upregulation of Bcl-2 antiapoptotic transcripts (Bcl-2, Bcl2A1) with 
very low level downregulation of proapoptotic genes (BFLAR) was also seen.  
Despite this there was strong evidence of a transcriptional effect on many 
target genes important for regulation of apoptosis and lymphocyte activation 
and signalling.  
 
Transcriptional effect of combination 
The combination treatment effect is dominated by the SAHA transcriptional 
response.  The small subset of genes differentially expressed with 
combination treatment compared to SAHA, predominantly with upregulation 
allowed insight into combination effects.  Geneset enrichment analysis of this 
data set confirms that there is enrichment for NFқB target genes (CD69,    
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Bcl2A1, CD83, CCL3, CCR7, BLR1, TRAF1) suggesting the importance of 
this transcription factor family in cooperative activity.  The differential 
regulation of NFқB target genes following combination treatment is again 
dominated by the effect of SAHA.  However there are clear examples of gene 
expression changes in the combination resulting from Rituximab.  For 
example CCL3 is up regulated 14.9 fold by Rituximab and 16.2 fold following 
combination, but unaffected by SAHA alone. CD69 and CD83 are both 
associated with activation of B cells and demonstrate that both agents may 
be acting together to induce B cell activation at a transcriptional level via 
NFқB activation.  The effect on Bcl2A1 in contrast to this demonstrates how 
SAHA can reduce the upregulation of an anti apoptotic Bcl-2 family member.  
Although this effect in isolation may not be important, it is occurring in 
combination with modulation of other apoptotic regulatory molecules and may 
be part of an alteration of the balance of pro and anti apoptotic signalling.  If 
this effect is combined with the downregulation of BclXL observed following 
Rituximab and combination treatments, a plausible hypothesis that 
‘modulation of Bcl-2 family proteins could enhance the induction of apoptosis 
through the intrinsic pathway’ develops.  Data already presented in earlier 
chapters has shown that induction of intrinsic apoptotic pathways is 
necessary for co operative effect, and this genomic level data is consistent 
with this.   
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7  Discussion and future work 
 
The work presented here has specifically addressed the three main aims of 
the project. 
The first aim was to investigate the ability of different HDI and CD20 mAb to 
induce cell death and apoptosis in a panel of CD20 positive B cell NHL cell 
lines, with the primary aim of establishing whether a synergistic effect was 
apparent and whether this was cell line or investigational agent specific.  
Using Annexin V/PI staining and flow cytometric analysis synergistic 
induction of apoptosis has been shown in a panel of CD20 positive B cell 
NHL cell lines.  This synergistic killing appears to be specific to CD20 mAb, 
with a panel of other mAb not demonstrating this effect.  It appears that to a 
degree synergy is dependent on levels of Bcl-2 expression, and can be 
blocked by pharmacological caspase inhibition.  This effect has been 
recapitulated in a Ramos cell xenograft model, with significantly prolonged 
survival and reduced subcutaneous tumour growth. 
The second aim was to identify the underlying mechanism for this effect.  
Two approaches were used to do this.  Initially simple drug interactions were 
investigated prior to trying to elicit the effects of combination treatment on the 
intrinsic and extrinsic apoptotic pathways.  Some of the underlying 
mechanisms have been demonstrated.  Importantly it appears that the 
synergy observed is not simply due to changes in the early biochemical 
responses to HDI or CD20 mAb.  Western blotting has shown that HDI 
require caspase processing for their activity in these cells.  This does not 
seem to be the case with CD20 mAb.  Synergy requires caspase processing 
and for type I mAb can be overcome by high levels of Bcl-2 expression.  The 
synergy seen with type II mAb does not seem to depend on levels of Bcl-2 
expression.  This implies that the mechanism of this interaction occurs 
downstream of Bcl-2 in the apoptotic pathway, and may be subtly different for 
type I and II mAb.   
The third aim was to utilise gene expression analysis to try to identify a 
cooperative transcriptional effect on previously described common survival    
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pathways and to investigate novel interactions for further investigation.  This 
technique was also utilised to try and identify a biomarker of HDI 
transcriptional effect.  Gene expression analysis has demonstrated that 
SAHA induces a robustly reproducible gene expression profile.  Despite the 
very modest transcriptional effects of Rituximab, combination treatment 
results in significant changes in a number of genes compared to SAHA 
alone.  This in itself demonstrates that the combination results in changes in 
gene expression that are independent of either agent alone.  Gene set 
enrichment analysis and RT-Q-PCR analyses have demonstrated differential 
regulation of NFқB target genes and in particular members of the Bcl-2 
family.  These changes may be responsible for the synergistic apoptotic 
effects seen, but are extremely complex in nature.  Alongside this we have 
identified the activation marker CD69 as a specific transcriptional target of 
SAHA in B cell NHL cell lines, and have demonstrated upregulation of cell 
membrane protein expression in human B cells treated ex vivo.  This novel 
biomarker is potentially exploitable as an endpoint in clinical trials of HDI to 
demonstrate biological effect. 
 
Taken together these observations provide compelling evidence for the 
potential of combining these agents as a novel treatment of B cell NHL.  
However they also demonstrate the complexity of this interaction raising 
many potential new avenues for investigation.         
 
The logical future direction for this combination would be in an early phase 
clinical trial.  A protocol for this has been developed and funding for this 
clinical trial is currently being sought. 
This study is planned as an initial dose escalation phase I study and an 
expanded phase II cohort treated at a dose defined in the phase I study.  It is 
proposed that patients will receive vorinostat (SAHA) orally starting at a dose 
of 200mg.  After 14 days this will be given in combination with Rituximab at a 
standard dose of 375mg/m
2 weekly for 4 weeks.  This will be followed by a 
further 4 weeks of SAHA to maximise the exposure to the combination.  
SAHA will be dose escalated up to the expected MTD derived from previous 
phase I studies as a single agent.  The primary endpoint of the phase I study    
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will be to establish a safe and biologically effective dose for the phase II 
study.  The primary end point of the phase II study will be to determine anti-
tumour at a BED, the secondary endpoint will be toxicity.  We have proposed 
using a flow cytometry assay of CD69 expression in B lymphocytes, 
alongside western blotting for histone acetylation to confirm biological effect.   
 
In trying to further understand the interactions in vitro it would be important to 
explore the effects of HDI and the combination on gene specific promoters, 
particularly of NFқB target genes.  It has already been described how 
epigenetic regulation of NFқB subunits can influence the gene expression 
patterns of NFқB target genes, without altering its DNA binding properties 
[55, 300].  It is possible that this mechanism could account for some of the 
gene expression changes described earlier.  The NFқB promoter binding 
regions for a number of the differentially expressed genes have already been 
described [293, 301].  Using chromatin immunoprecipitation assay (ChIP) it 
would be possible to identify whether HDI or the combination resulted in 
alterations in the promoter occupation of these genes.  This would help to 
demonstrate a link between HDI mediated modulation of NFқB activity and 
consequently the expression of target genes implicated in the initiation and 
regulation of the intrinsic apoptotic pathway.   
 
The importance of the tumour microenvironment in developing and 
maintaining tumourigenesis has been well described [23].  This has not been 
exploited by conventional cytotoxic treatments, but may be a potential target 
for novel therapies.  As discussed earlier the ability of Rituximab to recruit 
effector cells through Fc receptor interactions, is likely to be very important 
for its clinical efficacy [84].  This mechanism has not been investigated in the 
data presented.  All in vitro assays were performed in the absence of these 
cells.  It is interesting that in the xenograft studies, where macrophages were 
present, Rituximab appeared more effective than in the in vitro assays.  This 
suggests that potentiation of Fc receptor interactions may be another 
important mechanism for the combination effect.  Recent data defining the 
epigenetic regulation of macrophage activation further strengthens this 
hypothesis [302].  Ishii et al have shown that alternatively activated    
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macrophage (M2) are characterised by a number of marker genes and that 
these are epigenetically regulated.  This provides another potential avenue 
for future investigations. 
 
In summary the data presented from this project have demonstrated how the 
combination of HDI and CD20 mAb result in synergistic induction of 
apoptosis in B cell NHL cells.  The mechanism of interaction between type I 
and type II mAb appear to be different consistent with their known 
mechanisms of action as single agents.  The gene expression analaysis has 
demonstrated how a complex effect on NFқB target genes occurs, which may 
be acting to influence the apoptotic response to this combination.  It will be 
interesting to see whether clinical trials of this combination can recapitulate 
this pre clinical data.     
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